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Summary of results
Cellular distributions o f ai-adrenoceptors (ARs) were assessed using visualisation 
and radioligand binding techniques in Rat-1 fibroblasts stably expressing the bovine 
aia“AR. Competitive radioligand binding (RLB) was compai’ed in whole cell and 
isolated membrane preparations using both classical and updated RLB protocols. A 
range o f agonists and antagonists displayed their known characteristics in membranes. 
Whole cell competitive RLB for most ligands displayed a high affinity binding site, 
consistent with a population o f -25%  o f the sites that had affinity > in membranes, 
whereas the other 75% had affinity variably lower than in membranes according to 
the competitor. Results suggest the high affinity component represents displacement 
o f  ^ H-prazosin from cell surface receptors and the low affinity component that follows 
a slow sustained plateau phase represents a displacement from intracellular binding 
sites. Displacement by competing ligands occurred in a time-dependent, temperature- 
independent manner.
An early hypothesis that ligands penetrated the cell and accessed intracellular 
compartments via an extraneuronal monoamine transporter (EMT) was dispelled 
following the inability o f corticosterone to block the uptake o f ligands entering cells.
A more likely method o f how ligands access intracellular compartments is by 
endocytosis via clathi’in-coated pits. Concanavalin A is an endocytotic blocker and 
exerted an inhibiting effect that could be overcome once a certain concentration of 
antagonist (QAPB) had been applied. It did, however, exert little effect on the ability 
o f an agonist (adrenaline) to displace radiolabelled prazosin from intracellular binding 
sites.
The possibility o f an endocytotic pathway for cellular penetration was supported by 
direct visualisation studies. Following a sustained period of time, the fluorescent a i- 
AR antagonist BODIPY-FL prazosin (QAPB) was detected in high fluorescent 
intensity “hot spots” thi'oughout the cytosol. The intensity of the fluorescent signal 
steadily decreased following cumulative applications of the ai-A R  agonist 
phenylephrine and was also reversible upon phenylephrine removal. This indicates
that not only can antagonists penetrate cells and bind to intracellular compartments, 
but also agonists can penetrate cells and subsequently displace antagonist from these 
intracellular binding sites. The ability o f antagonists to selectively compete at the cell 
surface and intracellular regions was validated by results showing the a-A R  
antagonist phentolamine displacing QAPB from both cell surface and intracellular 
binding sites. Colocalisation with fluorescent dyes that can identify subcellular 
compartments (Transferrin Alexa Fluor^"^^) indicated partial localisation with the early 
and recycling endosomes. This strongly suggests that aia-AR ligand complexes 
follow the endocytotic recycling pathway, via early and recycling endosomes.
Using microspectrofluorimetry teclmiques, phenylephrine-activated Ca^^ signals were 
recorded from single Rat-1 fibroblasts stably expressing the bovine aia-AR and used 
to analyse functional agonist-antagonist interactions. The results demonstrate that the 
dominant Ca^^ entry pathway evoked by the bovine aia-AR is store-operated, in 
which the Ca^ "^  content of agonist-sensitive intracellular Ca^^ stores governs Ca '^  ^
influx. Beyond the concentration o f phenylephrine that produced the maximum 
response (>3xlO'^M), the concentration-response relationships displayed fade, which 
could be explained by agonist-dependent depletion o f Ca^^ stores. Antagonism 
exhibited by QAPB produced concentration-dependent, nonparallel, rightward 
displacements in the control concentration-Ca^^ response curve to phenylephrine with 
a decrease in maximal response. This represents an example of insurmountable 
antagonism, where the antagonist dissociates very slowly (or not at all) from the 
receptor. It is demonstrated by a rightward shift as the antagonist concentration 
increases and also by a decrease in maximal response.
1.0 INTRODUCTION
1.1 Historical Perspective
Adrenoceptors (ARs) mediate the central and peripheral actions o f the primary 
sympathetic neurotransmitter, noradrenaline, and the primary adrenal medullary 
hormone (and central neurotransmitter) adrenaline. Adrenoceptors are found in 
nearly all peripheral tissues and on many neuronal populations within the central 
nervous system. Adrenoceptors mediate a variety o f functions and have been o f 
major interest for many years as targets for drug action (Bylund et al  ^ 1994).
It was as far back as 1895 that Oliver and Schaffer showed that in vivo injections of 
adrenal gland caused a rise in arterial blood pressure (Oliver & Schaffer, 1895). After 
the subsequent isolation o f adrenaline as the active principle, it was as shown by Dale 
in 1913 that adrenaline causes two distinct kinds o f effect, namely vasoconstriction 
(which predominates and causes the rise in arterial pressure) and vasodilation. 
Following the disappearance o f the vasoconstrictor component. Dale noticed that 
adrenaline caused a fall instead o f a rise in arterial pressure, when an animal was first 
injected with an ergot derivative (Rang et al, 1995). Dale had a disagreement with JN 
Langley in relation to these results, refusing to interpret them in terms o f a difference 
between categories o f receptor. This variation in effect was subsequently believed to 
have arisen from the release of different endogenous catecholamines called 
sympathins (sympathin I for inhibitory and sympathin E for excitatory), with each one 
producing a different effect at the same receptor (Cannon & Rosenbleuth, 1933).
In 1948, Ahlquist used a quantitative approach to propose the existence o f two AR 
subtypes, based on different rank orders o f potency. He found that the potencies o f 
various catecholamines including adrenaline, noradrenaline and isoprenaline, fell into 
two distinct patterns, depending on what response was being measured. Ahlquist 
designated the two types o f ARs as a  and p, and defined them in terms o f agonist 
potencies as follows (Rang et al, 1995):
a  Noradrenaline > Adrenaline > Isoprenaline 
P Isoprenaline > Adrenaline > Noradrenaline
Following Ahlquist’s findings, it was recognised that certain ergot alkoloids studied 
by Dale, act as selective a-A R  antagonists, and that Dale’s adrenaline reversal 
experiment reflected the unmasking o f the p effects o f adrenaline by a-A R  blockade. 
Final proof o f Ahlquist’s subclassification scheme came in 1957 with the discovery o f 
a compound that could block p-ARs (Moran & Perkins, 1958; Powell & Slater, 1958).
In 1967, Lands and colleagues, comparing rank orders o f potency o f agonists, in a 
manner similar to that o f Ahlquist, concluded that there were two subtypes o f the P- 
AR. The pi-AR, the dominant receptor in heart and adipose tissue, was equally 
sensitive to noradrenaline and adrenaline, whereas the P2-AR, responsible for 
relaxation o f vascular, uterine, and airway smooth muscle, was much less sensitive to 
noradrenaline compared to adrenaline (Bylund et al, 1994).
In the early 1970s, after prejunctional a-A Rs had been identified, it became apparent 
that pre- and postjunctional a-A Rs had different pharmacological characteristics. 
Langer proposed that postsynaptic a-adreiiergic receptors be referred to as a i, and 
presynaptic receptors be referred to as a 2 (Langer, 1974). Soon after, it was suggested 
that otz-adrenergic receptors may have several nonneuronal effects and that these 
receptors also be classified pharmacologically (Berthelsen & Pettinger, 1977).
Finally, with the discovery of potent and highly selective a ,- and a^-AR agonists and 
antagonists, the subdivision o f a ,-  and az-ARs, along with further divisions o f each o f 
these a-A R  subtypes, has come to rely on a pharmacological subclassification as 
opposed to the anatomical or functional subdivisions used previously.
1.2 Pharmacological Subclassification
It is clear that as-ARs are heterogeneous, although the number o f discrete subtypes 
remains controversial. All the a,-ARs subtypes are activated by the sympathetic 
neurotransmitters, noradrenaline and adrenaline and there remains no evidence for 
selective affinity o f either o f these catecholamines for any o f the a;-A R subtypes.
The first evidence o f two oCrAR subtypes came in 1982 when McGrath discovered 
that phenylethanolamines produced dose-response curves with a “shoulder” indicating 
two components, in both the rabbit basilar artery and the rat anococcygeus. However, 
the “non-phenylethanolamine” agonists produced virtually no response in the rabbit 
basilar artery, but a monophasic curve in rat anococcygeus. The “low concentration” 
component o f the response to “non-phenylethanolamines” in the anococcygeus was 
mediated by one type o f ai-A R  (ajA). The response to high concentrations o f 
phenylethanolamines was mediated by a second type (aio), at which “non- 
phenylethanolamines” were relatively poor agonists. The rat basilar artery had a “low 
dose component” of the response to noradrenaline which corresponded more closely 
to the “a is” than “Œia” ARs, i.e. “non-phenylethanolamines” have little agonist 
activity (McGrath, 1982).
Following McGrath’s discoveries, Hoick and colleagues (1983) showed differential 
interactions of non-selective a ,- and Oz-AR agonists at postjunctional apA R s of the 
rabbit pulmonary artery, which again led to suggestions of multiple subtypes o f the 
ctpAR (Hoick et al, 1983). A number o f other breakthrough findings followed suit, 
with Medgett and hanger’s (1984) work with the superfused tail artery displaying two 
populations o f apA R , one with low and one with high affinity for the non-selective 
a-A R  agonist prazosin. Drew (1985), expanded this idea by compiling pAj values for 
prazosin and discovering that the pAj values spanned more than 2  log units, and 
hypothesised that this variation was due to interaction at more than one type of a p  
AR.
In 1986, Morrow and Creese were the first to produced clear evidence for two 
subtypes of apA R. Using radioligand-binding techniques, they studied the ability of 
a series o f ligands to displace [^H] prazosin in rat brain membranes. Several ligands 
exhibited biphasic displacement curves, indicating low- and high-affinity binding 
sites, similar to the results obtained by Medgett and Langer. The two subtypes of [^H] 
prazosin binding had veiy different rank orders o f antagonist affinities: half of the 
sites showed the pharmacological profile o f W B4101 > prazosin > phentolamine > 
indoramine > dihydroergocryptine. That site was termed aiA. In contrast, the a,B 
subtype demonstrated the rank order o f prazosin > indoramine > dihydroergocryptine 
> WB4101 > phentolamine (Morrow & Creese, 1986).
Shortly after this, Johnson and Minneman (1987) showed that an alkylating analogue 
o f clonidine, chloroethylclonidine (CEC), reduced, but did not eliminate the a,-A R  
population in rat brain membranes. Since phenoxybenzamine and other alkylating 
agents were able to eliminate all apA R s, they concluded that there were two 
populations o f apA R s, one sensitive and the other insensitive to CEC. Minneman 
and colleagues later showed that the estimated dissociation constant for the CEC- 
sensitive and -insensitive otpAR populations matched the dissociation constants for 
the aiA and a,B-ARs respectively (Gaurino et al, 1996).
Han and colleagues (1987) performed a similar work. With the knowledge that CEC 
inactivated a subpopulation o f the apadrenergic receptor binding sites in rat brain, 
Han compared ocpadrenergic receptors in different tissues to determine whether such 
selective inactivation might reveal the presence of distinct receptor subtypes. He 
concluded that there are at least two subtypes o f apadrenergic receptors with different 
pharmacological properties in mammalian tissues, only one o f which is inactivated by 
CEC (Han et al, 1987). Later studies on COS-7 cells showed that CEC preferentially 
inactivates apA R s on the cell surface irrespective of their subtype and that the 
subtype-specific subcellular localisation rather than the receptor structure is a major 
determinant for CEC inactivation o f apA R s (Hirasawa et al, 1997).
Functional responses have also been attributed to each of the a,~AR subtypes and this 
has arisen by the identification o f selective a , A-AR antagonists 5-methylurapidil 
(Gross et al, 1988) and (+)-niguldipine (Boer et al, 1989). Structural modification o f 
the calcium channel antagonist (+)-niguldipine has led to an analogue, SNAP5089 
having no activity as a calcium channel antagonist, but enhanced ( 1 0 0 -fold) 
selectivity for the a t A-AR versus the other two ai-A R subtypes (Gluchowski et al, 
1994). 5-methylurapidil has 30- to 100-fold higher affinity for aiA- than for aia- and 
a t D-AR when the commonly available animal receptors (a,A, bovine; aiB, hamster or 
rat; a,D, rat) are used. However, various other studies that compared the affinity of 
this antagonist for the rat with human ai-A R  subtypes have shown the a , d-AR to have 
affinity for 5-methylurapidil that is intermediate between the ajA- and a^-A R s 
(Hieble et al, 1995).
1.2.1 ai H-, and aurAdrenoceptors
It was noted that there was a wide affinity range for prazosin as an antagonist of a r  
ARs. Flavahan and Vanhoutte (1986) differentiated aj-ARs into two groups, 
designated and a,L, with high (am) and low (a^ ) affinity for prazosin and 
yohimbine. Muramatsu and colleagues (1990) extended the am- and a^-A R  
classification o f Flavahan and Vanhoutte. They modified the a ^  group by 
subdividing it into a ^  and am. The a ^  group was defined as having low affinity for 
yohimbine and the novel a,-A R  competitive antagonist HY732. The am group had a 
moderate affinity for yohimbine and a high affinity for HV732. Prazosin has a higher 
affinity for the am-AR subtype than for the a ^  and am-AR subtypes (Muramatsu,
1994). Support for this subclassification system came from further radioligand 
binding studies (Oshita et al, 1993; Ohmura et al, 1993).
The proposal o f further subtypes has yet to be supported by molecular biological 
evidence. It has been suggested existing cloned subtypes may account for 
observations which led to the a,H versus a,L subdivision, in as much as cells 
expressing the human cloned aiA-AR have been shown to display an am-like 
pharmacology (Williams et al, 1996; Ford et al, 1997; Daniels et al, 1999).
1.3 Molecular Cloning
The cDNAs encoding three ai-A R  subtypes (aia, an,, and am) have been cloned and 
pharmacologically characterised (Michelotti et al, 2000). O f note, a rA R  
nomenclature has changed within the last 8 yeai's, with the International Union of 
Pharmacology adopting a^ , a ^ , and a ^  in 1995 (Hieble et al, 1995); the a,a used to 
be called a^ , the a ^  name has not changed, and the a ^  used to be called a^ , am, or 
aia/d). The lower case letters, a, b, c, and d refer to the cloned receptor subtypes 
whereas the upper case letters A, B, and D describe pharmacologically defined 
receptor subtypes present in tissue.
1.3.1 aui-adrenoceptoFs
The ttib-AR subtype was the first o f the a rA R  family to be cloned. This clone was 
isolated from a hamster vas deferens cell line (DD 1MF2) and encoded a protein o f 515 
amino acid residues, which was predicted to have the 7 membrane-spanning domains 
characteristic o f a G-protein-coupled receptor (Cotecchia et al, 1988). Expression o f 
this clone in COS-7 cells resulted in a protein with radioligand binding properties 
similar to that o f the native aie subtype, with a high affinity for prazosin and a low 
affinity for phentolamine, 5-methylurapidil, and yohimbine. Also consistent with the 
a,B subtype was a high sensitivity to irreversible inactivation by CEC. Northern 
analysis showed mRNA expression for this clone in a variety o f tissues expected to 
express the a^-A R , including liver, spleen, heart, and cerebral cortex. It is now 
generally agreed that this cDNA encodes the hamster a ^  subtype and rat (Voigt et al, 
1990; Lomansey et al, 1991), dog (Libert et al, 1989) and human (Ramarao et al,
1992) homologues have been isolated.
1.3.2 aiA-adrenoceptors
An additional cDNA that encoded a 466-residue polypeptide was isolated from a 
bovine cerebral cortex library (Schwinn et al, 1990). The protein expressed by the 
clone was different from the a^-A R , with 65% amino acid identity in the membrane 
spanning domains. The pharmacological profile was also distinct from either the am­
or ain/d-ARs, with a relatively high affinity for 5-methylurapidil, a high affinity for 
WB4101, and a high sensitivity to irreversible inactivation by CEC. Northern 
analysis experiments showed no am-mRNA in any rat tissue examined, with 
noticeable quantities found only in rabbit liver and human hippocampus. With the 
knowledge o f its unique pharmacology and limited tissue distribution, it was 
concluded that this clone encoded a novel subtype, which was designated a ic  
(Schwinn et al, 1991). Despite the lack of mRNA transcription. Southern 
hybridisation suggested the existence of the a ^  gene in the rat and later, a rat 
homologue o f the bovine a^-A R  was cloned by Laz and colleague (1993).
Later reports from several laboratories clearly showed that affinities o f an extensive 
series o f competitive antagonists for inliibition o f radioligand binding o f [^H]prazosin 
to the expressed (Xm-AR correlated highly with their affinities for binding sites in 
native tissues that were known to possess a,A-ARs (Testa et al, 1995; Ford et al, 
1994; Saussy et al, 1994; Faure et al, 1994; Langer et al, 1994). These results 
strongly suggested that the recombinant a^-A R  did in fact represent the native aiA- 
AR (Ford et al, 1994). There was, however, one major inconsistency that had to be 
explained between the a^-A R  clone identified by Schwinn and colleagues (1990) and 
the native «ia-AR and that was the difference in the sensitivity o f the recombinant 
receptor to alkylation by CEC. It was concluded that the difference in sensitivity was 
due to varying experimental conditions, the character o f the membrane in which the 
receptor is expressed and/or to species differences in CEC sensitivity o f the 
recombinant a^-A R  (Hieble et al, 1995). Because o f the initial confusion in 
nomenclature, the a,c designation is no longer recommended to describe the 
characteristics o f any recombinant o f native oti-AR.
1.3.3 air,~(idrenoceptors
A  third ai-AR, cloned by Lomansey and colleagues (1991), used homology screening 
from rat cerebral cortex library. The cDNA encoded a single polypeptide chain with a 
deuced sequence o f 560 amino acids. Lomansey designated the clone aja because it 
shared some characteristics of the pharmacological cx,A-AR including a higher affinity 
for WB4101 than the cloned a^-A R, resistance to inactivation by CEC and the 
presence of its mRNA in tissues laiown to contain large amounts o f the ŒiA-AR. 
However, Perez and colleagues (1991), studying an almost identical clone (98% 
homologous) that was also isolated from rat brain, found low affinity for the more 
selective aiA-AR antagonists, 5-methylurapidil and (+)-niguldipine. For a time, this 
single recombinant receptor was referred to as either the ai„-AR or the otw-AR. This 
suggestion caused a great deal o f confusion in the field. The suggestion in the 
consensus report o f the lUPHAR to refer to this receptor as the a,„/d-AR did little to 
clarify the issue (Gaurino et al, 1996). With the exception o f two codons within the 
sequence o f the aia-AR and the aid-AR, it was soon thought that these were in fact
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encoding the same receptor, generally known to be the a,d-AR (Minneman & 
Esbenshade, 1994). An updated consensus report by the lUPHAR suggested the am/d- 
AR be replaced by the designation o f a^-A R  for the cloned receptor and the « id-AR 
for the pharmacological homologue found in tissue.
1.3.4 Splice Variants
The cCrAR subtypes are unusual among GPCRs in that they have an intron in their 
protein coding regions at the end o f the putative 6 *^’ transmembrane domain (Ramai*ao 
et al, 1992; Chang et al, 1998). Three splice variants o f the human otiA-AR have been 
cloned («lA-i, cXia-2 and aiA-s) which differ in length and sequence of their C-terminal 
domains (Hirasawa et al, 1995). A fourth, novel isoform (a,A_4) has also been 
reported, which predominates in human prostate, liver, heart and bladder based upon 
mRNA determinations (Chang et al, 1998). Daniels and colleagues (1999) reported 
that all four isoforms display apparently identical pharmacological properties using 
functional analysis and that this pharmacology closely correlates with that o f the a,L- 
AR. Hence, no individual isoform represents the distinct pharmacological phenotype 
o f the rtiA- or a,L-AR (Daniels et al, 1999; Suzuki et al, 2000).
1.4 Signal Transduction Mechanisms
The adrenoceptors are divided into three families, the apA R s, the 0C2-ARs and the p- 
ARs. This subdivision is suggested by the observation that each o f the three receptor 
groups is associated with a specific second messenger system. The apA R s increase 
intracellular calcium concentrations, whereas ota-ARs and p-ARs inhibit and stimulate 
adenylyl cyclase, respectively (Byiimd et al, 1994).
The three cloned apA R s couple predominately to pertussis toxin-insensitive G 
Proteins o f the Gq/n family, and there is evidence of selectivity among the various a , 
subtypes (Wu et al, 1992). In intact tissue (Nebigil & Malik, 1992), as with cloned 
receptors (Perez et al, 1993), it has been shown that ot; subtypes can activate multiple
effectors via distinct pertussis toxin-sensitive (Gi or Go family) and -insensitive G 
Proteins (Gaurino et al, 1996).
Stimulation o f a,-ARs results in the activation o f various effector enzymes including 
PLC, PA2 and PLD, as well as activation o f Ca^ "^  channels, Na^-H'*' and Na'^-Ca^^ 
exchange and activation or inhibition of channels. In most cells, the primary 
functional response to activation of all a ,-A R  subtypes is an increase in intracellular 
Ca^ "^ . Activation or inhibition o f the receptor-coupled effectors involves coupling via 
G Proteins (Graham et al, 1996).
In 1975, Michell proposed that all receptors that increase Ca^^ levels also increase 
turnover o f phosphatidylinositol (PI), and proposed that this effect might be involved 
in the opening of Ca^^ gates. This hypothesis was strongly supported by Fain and 
Berridge (1979) whose results made it clear that breakdown o f PI was probably an 
important pathway for the formation o f second messengers involved in the control o f 
cytosolic Ca^^ levels (Minneman, 1988). Fain and Garcia-Sainz (1980) postulated 
that this was the major mechanism o f signal transduction for otpadrenergic receptors.
ŒpARs are one o f the many types o f cell surface receptors that produce changes in 
cellular activity by increasing intracellular level o f free Ca^^ (Summers & McMartin,
1993). Activation of apA R s stimulates PLC-p via Gq/u, which hydrolyses PIP2 to 
yield DAG and IP3. IP3 then interacts with specific receptors on intracellular 
organelles, such as the sarcoplasmic reticulum, to release stored Ca^^ (Graham et al, 
1996). DAG is a highly lipophillic substance which remains in the membrane and 
stimulates PKC in the presence o f Ca^ "^  ions and phospholipids. PKC is located in the 
eytosol and in the membrane fractions o f the cell, but only the membrane bound pool 
o f the enzyme is active (Szmigielski et al, 1997). PKC then phosphorlyates a variety 
o f cellular substrates, including Ca^ "^  chamiels, that may regulate intracellular Ca^^ or 
activate transcription o f various genes (Graham et al, 1996).
1,4.1 Calcium Influx
Activation o f a,-A Rs can increase Ca^ "^  influx via voltage-dependant (Ljung & 
Kjellstedt, 1987) as well as voltage-independent Ca^ "^  channels (Han et al, 1992).
Initially this was believed to be a discriminating criterion for classification o f the Œp 
AR subtypes. Han and colleagues (1987) worked with isolated smooth muscle and 
reported evidence for two types o f otpARs, which caused contractile responses 
through different mechanisms. They proposed the a,b-AR stimulated IP3 formation 
and caused contractions independent o f extracellular Ca^’*’ and that the ŒipAR did not 
stimulate IP3 formation and caused contractions, which required the influx of 
extracellular Ca^ "^  tlirough dihydropyridine-sensitive channels (Han et al, 1987). With 
the cloning o f receptors and the use o f many other cell types, there are now numerous 
exceptions to proposals such as Han’s. For example, the aib-ARs are linked to Ca^^ 
influx in rat vena cava (Sayet et al, 1993) and in M DCK-Dl cells (Klijn et al, 1991). 
Expressed receptors in COS-1 cells demonstrate that all thiee otpAR subtypes can 
mobilise intracellular calcium and increase Ca^ "^  influx via voltage-operated Ca^^ 
channels (Perez et al, 1993; Lomansey et al, 1993).
Extracellular Ca^ "^  can enter animal cells via three main pathways. These are VOCCs 
(Putney Jnr & Bird, 1993; Berridge, 1995; Clapham, 1995), LGCCs (Berridge, 1997) 
and RACCs (Catterall, 1995; Dunlap et al, 1995; Fasolato et al, 1994). The broad 
physiological functions o f these channels are to provide extracellular Ca^ "^  for 
increases in [Ca^^]c in given regions o f the cytoplasmic space, and to replenish Ca^^ 
stores in the sarcoplasmic reticulum and ER by replacing Ca^^ which is released from 
these stores and subsequently pumped out o f the cell (Barritt, 1999). The members of 
all o f these families o f plasma-membrane channels exhibit the electrophysiological 
properties usually attributed to a cation channel (Hille, 1992). That is, when induced 
to open, the channel remains open for a short period o f time (usually microseconds) 
before closing as the result o f an inactivation mechanism.
The subgroups o f RACCs that have been o f interest in recent years are the SOCCs 
(capacitative Ca^^ channels) (Putney Jm’ & Bird, 1993; Berridge, 1995; Clapham,
1995). These are defined as plasma-membrane Ca^^ channels that are opened in 
response to a decrease in the concentration o f Ca^ "^  in the lumen of the ER ([Ca^^jer) 
(Putney Jm* & Bird, 1993). Under physiological conditions, the decrease in [Ca '^^Jer 
that leads to channel opening is caused by the binding of IP3 to IP3-receptor Ca^^ 
channels and possibly also by the binding o f Ca^^ to ryanodine-receptor Ca^ "^  chamiels
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(Wayman et al, 1998; Bennett et al, 1998). The key event that initiates the opening o f 
SOCCs is the decrease in [Ca^’^ Jer (Barritt, 1999).
1.4.2 cyclicAMP
Stimulation o f a,-A R s has been reported to increase cAMP accumulation and to 
potentiate cAMP levels elicited through other receptors (Schultz & Daly, 1973; 
Johnson & Minneman, 1986). Activation o f rtiA-ARs in COS-7 and He La cells 
(Schwinn et al, 1991) or a ,g-ARs or otm-ARs in COS-1 and CHO cells was also 
shown to increase cAMP levels (Perez et al, 1993). The cAMP accumulation most 
likely occurs via a PKC-mediated potentiation o f adenylyl cyclase activity, although 
there is also evidence for at-AR-mediated inhibition o f cAMP degradation (Buxton et 
al, 1985).
Studies by Ruan and colleagues (1998) showed that all a rA R  subtypes are coupled to 
PLD and that activation o f these receptors increases AA release and cAMP levels in 
rat-1 fibroblasts. The aiA-ARs seemed to be coupled more effectively to AA release, 
PLD activity and cAMP system than either am- or am-ARs. This conclusion arose 
after the finding that the a rA R  agonist phenylephrine produced a much greater 
increase in AA release, PLD activity and cAMP accumulation in rat-1 fibroblasts 
stably expressing the a^ -A R  than in those expressing the am- or a^-A R . 
Furthermore, cAMP generated by a,A-AR stimulation acted as an inhibitory 
modulator of PLD activity and AA release via PKC (Ruan et al, 1998).
1.4.3 Arachidonic Acid
It was Burch and colleagues in 1986 that showed that stimulation of a,-A Rs in a rat 
thyroid cell line increased release o f AA, which in turn mediated a noradrenaline- 
stimulated cell replication. Other studies have shown that stimulation o f a;-A Rs can 
cause AA release in many cells (Kanterman et al, 1990; Blue et al, 1994), either 
through activation o f PA] (Kanterman et al, 1990; Nishio et al, 1996) or PLD (Ruan 
et al, 1998). Some evidence suggests that such increases in AA release require
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extracellular Ca^^, but are independent of increases in intracellular Ca^^, suggesting a 
role for PA2 (Zhong & Minneman, 1999). The involvement o f a pertussis toxin 
sensitive G Protein have been supported by studies in rabbit aortic smooth muscle 
(Nishio et al, 1996), while other studies provide evidence for the involvement o f PKC 
or MAPK pathways.
In more recent years, activation o f AA release has been shown to be downstream of 
MAPK pathways (Xing & Insel, 1996). In MDCK cells, immunoprécipitation studies 
combined with specific inhibitor showed that an 85-kD cytosolic PA2 was activated 
by a rA R  stimulation. PD 98059, a specific inhibitor o f MAPK pathways, blocked 
this activation and also inhibited adrenaline-promoted AA release. Down-regulation 
or inhibition of PKC also blocked MAPK activation and AA release, hence a^-AR 
appear to regulate AA release tlii'ough phosphorylation-dependant activation o f PA2 
by MAPK, subsequent to activation o f PKC in these cells (Zhong & Minneman, 
1999).
1.4,4 Phospholipase D
Activation o f PLD also appears to be involved in the action of aj-ARs (Llahi & Fain, 
1992; Balboa & Insel, 1998; Ruan et al, 1998). Such activation seems to be 
secondary to the initial signalling, i.e., it may be induced by increases in Ca^ "^  or PKC 
activation. Balboa and Insel (1998) studied activation o f PLD stimulated by 
adrenaline in MDCK cells. They discovered that even though adrenaline stimulated 
PKC a  and PKC e, this was not related to PLD activation. Furthermore, blocking 
PLC with neomycin did not significantly decrease adrenaline-stimulated PLD activity. 
A role for Ca^^ in PLD activation by ai-A Rs was suggested after chelation of 
extracellular Ca^^ noticeably inhibited PLD activation. All three a rA R  subtypes 
appear to be able to activate PLD, although the mechanisms may differ in different 
cell types (Ruan et al, 1998; Zhong & Minneman, 1999).
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1.4,5 Mitogenic Responses
Signalling to the nucleus has become a major area o f research in recent years. It is 
clear that a rA R  activation may result in mitogenesis and that constitutively active 
mutants are tumorigenic (Allen et al, 1991), that is, a ,-A R  genes could be considered 
as protooncogenes. Mitogenic responses are caused by a conserved cascade o f events 
including receptor phosphorylation, binding o f adaptor proteins, such as She and 
Grb2, and eventually recruitment and activation o f the small molecular weight G 
Proteins Ras. R af is then activated by Ras and this activates downstream MAPK 
cascades (Davis, 1993). It is now clear that GPCRs can rapidly activate MAPK 
pathways and this activation is an important factor in the regulation o f cell 
proliferation and growth (Zhong & Minneman, 1999).
a rA R  stimulated DNA synthesis and activation o f MAPK involves activation o f 
phosphatidylinositol 3-kinase via a pertussis toxin-sensitive G Protein (Hu et al,
1996). Differences in the signalling pathways o f aiA- and am-ARs have been 
observed involving phosphatidylinositol 3-kinase, p2K^^ and MAPK (Hu et al, 1999). 
Neither Ca^ "^  nor PKC appears to mediate a,A-AR activation o f MAPK in transfected 
PC12 cells (Berts et al, 1999; Garcia-Sainz et al, 1999).
1.5 G-protein coupled receptors
Adrenoceptors are part o f the superfamily o f receptors that exert their physiological 
effects by coupling to guanine nucleotide-binding proteins (G Proteins). The G- 
protein coupled receptor (GPCR) family comprises many o f the receptors that are 
familiar to pharmacologists, such as muscarinic Ach receptors, adrenoceptors, opiate 
receptors and receptors for many peptides. A large number o f these receptors have 
been isolated and purified, and some have been cloned, revealing a remarkably 
coherent pattern o f their molecular structure (Rang et al, 1995).
G Proteins contain three subunits, the p and y subunits o f 35-37 and 8 -lOkDa and a  
subunits of 45-52kDa. The P and y subunits ai*e tightly associated with each other and 
do not differ greatly among the G Proteins. In the basal state, G Proteins have GDP 
bound to the catalytic state o f GTPase on the a  subunit, and interaction o f agonists
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with a coupled receptor induces release o f GDP and its replacement by GTP. The 
dissociated G TP-a and p/y subunits, interact with effector proteins to modulate 
cellular responses including second messenger metabolism and ion channel function 
(Freissmuth et al, 1989; Ikeda, 1996; Clapham & Neer, 1993). The a  subunit is 
reassociated with the p/y subunit by the hydrolysis o f GTP to GDP due to the activity 
o f the a  subunit GTPase. The spontaneous GDP release rate corresponds to a tonic 
activation rate in the absence o f activated receptors (Remmers et al, 1999).
G protein activity is regulated both by receptor-catalysed GTP binding to the a  
subunit and by the rate o f GTP hydrolysis. Regulators of G protein signalling (RGS) 
proteins are a recently identified family on intracellular GTPase-activating proteins 
(GAPs) (Dolman & Thorner, 1997; Berman & Gilman, 1998) that accelerate GTP 
hydrolysis by G a  subunits (Berman et al, 1996; Hunt et al, 1996; Heximer et al,
1997), thus limiting the duration o f G protein activation. RGS proteins can regulate 
signalling by uncoupling the cycle o f GTP binding and hydrolysis from effector 
protein activation by the G a  subunit, even in the presence o f persistent agonist 
stimulation (Xu et al, 1999).
G Protein subtypes are cun'ently defined by their a  subunits, o f which 23 (including 
splice variants) are Icnown, and up to 5 different (3 and 11 different y subunits have 
been identified (Neer, 1995). This means that a greater number of heterotrimers 
composed o f specific a , |3 and y subunits may exist and be involved in signal 
transduction pathways. In many cases, the coupling between receptor and G Protein 
may seem unselective since one receptor may activate more than one G Protein and 
thus initiate more than one signal transduction pathway (Macrez-Lepretre et al, 1997). 
However, there are many examples showing that different receptors activate the same 
effector system (Offermamis & Schultz, 1994; Gudermann et al, 1996).
Despite their diverse biological functions, GPCRs share many common 
characteristics. They possess seven domains o f 20-25 hydrophobic residues in the 
form o f a  helixes, which span the plasma membrane (Grady et al, 1997). They have 
an extracellular NH2 terminus, thi'ee intracellular loops, and an intracellular COOH 
terminus. The tliree intracellular loops have been shown to bind and activate the G 
Proteins (Franke et al, 1990). It is thought that upon agonist binding, these loops
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either become more exposed or undergo conformational changes transduced through 
transmembrane movements. The aminergic binding receptors, such as the a,-A R 
family, appear to bind ligands within the membrane-spanning domain (Strader et al, 
1987).
The structui'e o f a,-ARs is very similar to that o f rhodopsin, the light-activated retinal 
receptor involved in visual transduction; bacteriorhodopsin, the light-activated proton 
pump o f Halobacteriiim halobium, and (3-ARs (Riek et al, 1995). However, there is 
little amino acid identity between ai-A Rs and either rhodopsin or bacteriorhodopsin 
and only a low degree o f identity (20%-30%) with the |3-AR, even though both otr 
ARs and p-ARs are activated by the catecholamines, adrenaline and noradrenaline 
(Graham et al, 1996). All models for adrenergic structure are based on the structure 
o f bacteriorhodopsin and as a result, a great deal o f data for mammalian adrenoceptors 
has come from mutational studies that alter critical amino acids involved in receptor 
function (Gaurino et al, 1996; Piascik et al, 1996; Michelotti et al, 2000).
Like other members o f the GPCR family, ai-A Rs are single polypeptide chains, 
ranging from 355 to 511 amino acids that fold into a highly conserved structure of 
seven predicted membrane-spanning regions, TM l-7 (Michelotti et al, 2000). The 
seven TM regions fold into a conformation that creates a hydrophilic ligand-binding 
pocket surrounded by a hydrophobic core for the physiological agonists adrenaline 
and noradrenaline (Piascik et al, 1996). The TM regions are most likely arranged in a 
juxtaposed, counter-clockwise cluster that forms the binding pocket (Gaurino et al, 
1996). However, the ligand-binding pocket is distinct in each of the different 
subtypes, since they can discriminate between a wide variety of synthetic agonists and 
antagonists (Hwa et al, 1995).
The amino termini of ai-ARs are located extracellularly and possess several 
consensus sites for modification by N-linked glycosylation. The amino termini vary 
significantly in length, with the terminus for the a^ -A R  being much longer (-90 
amino acids) than the terminus for the a,A-AR (25 amino acids) or the a^ -A R  (42 
amino acids). The longer amino terminus o f the aio-AR may limit efficient 
translation or membrane insertion as this subtype is more poorly expressed in the
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plasma membrane than the other two subtypes, despite abundant production o f 
mRNA (Graham et al, 1996).
The carboxy termini are located intracellularly and possess consensus sites for 
phosphorylation by serine/threonine protein kinases and modification o f protein at 
these sites is involved in receptor desensitisation (Garcia-Sainz, 1993). The carboxy 
temiini contain a conserved cysteine residue, approximately 16 amino acids after the 
end o f TM-7 that is most likely post-translationally modified by thioesterification 
with palmitic acid.
L 5.1 ai-AR Agonist Binding
The binding of catecholamines to the a,-A R s seems to occur in a different manner 
than with the P2-AR, where an aspartic acid residue (Asp^*^) in TM-3 is involved in 
forming a salt bridge with the protonated amine o f the catecholamine (Strader et al, 
1987). In the P2-AR, two serine residues, Ser^ "^^  and Ser^^^, have been shown to be 
involved in hydrogen-bond interactions with the hydroxyl groups on the catechol ring 
and both residues are required for the high affinity binding o f agonists and for full 
activation o f the receptor. Two serine residues in TM-5 o f the ai^-AR, Ser^ ^® and 
Ser*^^, are partly responsible for the agonist binding affinity o f this receptor subtype 
(Hwa & Perez, 1996). Unlike the P2-AR, the catechol hydroxyl groups are not 
located an equal distance from their respective serine residues. Both hydroxyl groups 
appear closer to Ser^^^, with the me/a-hydroxyl group forming the closest interaction. 
It is only the Ser^^^ that is required for full agonist action upon receptor activation. 
The aib and aia-ARs have an extra serine located at the analogous position to residue 
189 in the ai„-AR, and a Ser^°^ Ala mutation in the a,b-AR was found to have no 
effect on the binding affinity, or functional responsiveness o f this receptor (Hwa et al,
1995). This showed that the two key serine residues involved in catecholamine 
binding to the (Xi-AR are located tliree amino acid residues apart in the helix, while 
the P2-AR serines are located two residues apart.
The aromatic interactions o f the phenyl ring of the agonist and the phenylalanine 
residue in TM -6  are also different in the a r  than the P2-AR. In the P2-AR, Phe^^^
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(equivalent to Phe^^' in the a rA R ) was suggested to be involved in an aromatic 
interaction with the agonist (Strader et al, 1989). In contrast, a study in the aja-AR 
using various teclmiques showed that only Phe^'^ (equivalent to Phe^^^ in the P2-AR) 
is critically involved in both binding and activation (Chen et al, 1999; Piascik & 
Perez, 2001).
Waugh and colleagues (2000) unexpectedly discovered two additional phenylalanine 
residues involved in the binding o f agonists. Phe^^^ in TM-4 and Phe'^^ in TM-5 of 
the aiA-AR are involved in agonist-specific binding interactions. Mutation o f both of 
these residues contributes to a 150-fold loss o f affinity for the endogenous agonist. 
An interesting observation is that the P2-AR does not conserve these aromatic 
residues, further highlighting differences in the agonist binding pocket between these 
two receptors.
The ajA-AR shows a 10- to 100-fold higher binding affinity for nonselective agonists 
compared with the a,B-AR subtype. There are two residues responsible for this 
selectivity, Aia™"* in TM-5 and Met^'^ in TM -6  o f the a.e-AR AR (Hwa et al, 1995). 
Although the interactions were direct, the mechanism o f this selectivity was due to the 
specific packing interactions of these two residues as mismatched combinations of the 
aiB- and aiA-AR residues resulted in constitutive activity.
1.5.2 Antagonist Binding
There is a limited knowledge o f how antagonists bind to the a,-ARs. Piascik and 
colleagues (2 0 0 1 ) have shown using mutagenesis studies that the subtype-selectivity 
o f two aiA-AR-selective antagonists phentolamine and WB4101 are conferred by 
interactions with three consecutive residues (Gln'^^, Ile*^ ,^ Asn*^^) o f the second 
extracellular loop (Zhao et al, 1996; Piascik & Perez, 2001). A phenylalanine residue 
(Phe^*") at the surface o f TM-2 in the aiA-AR accounts for the a,A- versus am- 
selectivity o f dihydropyridine antagonists such as niguldipine, although the studies 
mentioned here involve residues involved in selectivity and with a limited set of 
antagonists. Waugh and colleagues (2001) reported that two conserved phenylalanine 
residues near the extracellular surface o f TM-7 are involved in nonselective binding
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for nearly all ai-antagonists. This indicates the first case o f a common site o f 
antagonist binding for members o f the adrenergic receptor family. W augh’s study 
supported the hypothesis that imidazoline agonists bind in a different manner than 
phenethylamine agonists after discovering the two residues also altered imidazoline 
binding such as cirazoline. It seems imidazolines bind similarly to antagonists, which 
may explain their partial agonist properties.
1.5.3 Inverse Agonism and Neutral Antagonism
When GPCRs exist in a spontaneously active form in the absence of an agonist, the 
term used is ligand-independent or constitutive receptor activation. This has been 
observed in cell lines in which receptors are overexpressed or mutated (Barker et al, 
1994; Bond et al, 1995; N e wman-T ancredi et al, 1997). A two-state receptor model 
may explain this where GPCRs exist in equilibrium between two conformations, an 
active form (R*) and an inactive form (R) (Leflcowitz et al, 1993; Samama et al,
1993). Based on this model, agonists shift the equilibrium to the active conformation 
(R*), hence increasing receptor activity, whereas some antagonists, called inverse 
agonists, lead preferentially to the inactive conformational state (R), resulting in 
reduced basal receptor activity (Leff, 1995; Zhu et al, 2000). There is also another 
type o f antagonist called a neutral antagonist, which is believed to bind equally to 
both R'  ^ and R without affecting the equilibrium. In such a case, the neutral 
antagonist can inhibit the effects o f both agonists (reducing the receptor signal) and 
inverse agonists (thereby increasing receptor signalling in the simultaneous presence 
o f an inverse agonist) (Zhu et al, 2000).
It was reported that Recordati compounds such as REG 15/3039, REG 15/2739 and 
REG 15/3011, act as neutral antagonists at the wild-type a^-A R, but as inverse 
agonists at the wild-type a,b-AR in GOS-7 cells (Rossier et al, 1999). Using the same 
cell type, Zhu and colleagues (2000) constructed a constitutively active mutant of the 
aia“AR by changing the Ala^^' to Tin* in TM-3 and found prazosin to act as an inverse 
agonist and KMD-3213 behaving as a neutral antagonist. Their results found that a 
neutral antagonist can reverse the action o f an inverse agonist at the receptor site (Zhu 
et al, 2 0 0 0 ).
18
i. 6 Subtype-Selective Drugs
The affinities and selectivities of drugs for ai-A R  subtypes have been determined 
mostly by competition for radioligand binding to heteroiogously expressed 
recombinant subtypes. The majority o f antagonists, including the prototype ai-A R 
selective antagonist prazosin, display little or no selectivity between the tlii'ee a rA R  
subtypes (Hancock, 1996). However, a wide range o f drugs with varying degrees o f 
selectivity has been identified. A significant effort in drug design that is directed at 
obtaining selective compoimds will be advantageous in studying the interactions and 
functional roles o f these subtypes and may have potential therapeutic applications.
1.6.1 aiA-AR Antagonists
The development of a,A-AR selective antagonists has proved to be the most fruitful. 
The first a,A-AR antagonist to be identified was WB4101, which displays a 20-fold 
higher affinity for the aiA than a,B subtype (Morrow & Creese, 1986). Along with an 
intermediate affinity for the a ^  subtype, this limited selectivity confines its use in 
differentiating between subtypes.
Following the discovery o f this property o f WB4101 came the identification of 5- 
methylurapidil (Gross et al, 1988) and (+)-niguldipine (Boer et al, 1989) as selective 
aiA-AR antagonists. Both o f these antagonists had a greater selectivity (80-500-fold) 
between aiA and am subtype and a low affinity for the a ^  subtype, making them 
useful as tools for distinguishing subtypes in radioligand binding assays (Han & 
Minneman, 1991). A problem with both these antagonists is that 5-methylurapidil is a 
partial agonist at serotonin 5-HT[a receptors, while (+)-niguldipine is a 
dihydropyridine Ca^^ channel antagonist. These actions do not complicate 
radioligand binding studies, but limit their use in functional experiments. This is 
especially true in smooth muscle, in which both serotonin receptors and 
dihydropyridine sensitive Ca^^ channels play major functional roles, and where 
defining the functional roles o f a rA R  subtypes is o f significant interest (Minneman 
& Esbenshade, 1994). The (+)-niguldipine derivative, SNAP5089 has been
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developed and is highly aiA- selective, but has a much lower affinity for voltage-gated 
Ca^ "^  channels (Wetzel et al, 1995).
Interest in aiA-AR selective antagonists has been strong as it has been postulated that 
these antagonists may have significant therapeutic advantages over non-subtype 
selective apA R  antagonists in the treatment o f BPH. The a,A-AR subtype 
predominates in the urethia and prostate o f man (Price et al, 1993; Faure et al, 1994) 
and has been claimed to be the receptor mediating noradrenaline induced smooth 
muscle contraction in these tissues (Hatano et al, 1994; Marshall et al, 1995). The 
moderately a,A-AR selective antagonist tamsulosin has been introduced for treatment 
o f BPH (Foglar et al, 1995). Studies by Blue and colleagues (1997) have assessed the 
in vitro and in vivo pharmacology o f tamsulosin and dismissed the proposal that the 
compound is uroselective based on a degree o f ajA-subtype selectivity.
Williams and colleagues (1999) reported the profiles of two novel a^ -A R  selective 
antagonists, Ro 70-0004 and a structurally related compound, R S-100329 (for 
chemical structure, see Fig. 1.3). They found both compounds to be high affinity 
antagonists at the rttA-AR, with a considerable selectivity over the am- and am- 
subtypes. They both potently inliibit in vitro and in vivo Œia-AR mediated 
contractions of lower urinary tract tissue and appear to exhibit only weak 
cardiovascular effects when compared to standai'd non-selective a ,-A R  antagonists 
such as prazosin (for chemical structure, see Fig. 1.2) and tamsulosin. The clinical 
use o f Ro 70-0004 in the symptomatic treatment o f BPH is currently being assessed 
(Williams et al, 1999)
Another compound that has potential use in the treatment of BPH is RWJ-38063. 
Pulito and colleagues (2000) compared the in vitro and in vivo uro selective properties 
o f four novel arylpiperazine compounds with those of tamsulosin. The binding 
activities o f RWJ-38063, RWJ-68141, RWJ-68157, RWJ-69736 and tamsulosin were 
examined at each of the three cloned ai-A R  subtypes to determine their affinities and 
receptor subtype selectivities. All the RWJ compounds showed significantly higher 
binding affinities for the rti^-AR subtype than either the aib- or a^-A R  subtype. 
Although tamsulosin had the highest affinity for the aia-AR subtype o f all the
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compounds tested, it showed the lowest level of selectivity for this subtype (Pulito et 
al, 2 0 0 0 )
1.6.2 aurAR Antagonists
Finding selective antagonists for a , a and am-ARs has been more difficult. CEC was 
originally thought o f as an a^ -A R  selective alkylating agent (Han et al, 1987), but 
complications in the use o f site directed alkylating agents and controversies over its 
selectivity in inactivating the recombinant a ,-A R  subtypes have pushed it into 
disfavour (Hirasawa et al, 1997). There have been some cases o f competitive 
antagonists being moderately a^ -A R  selective, such as spiperone and cyclazosin or 
its (-f-)-enantiomer (Giardina et al, 1996), but the extremely limited selectivity o f these 
compounds has hindered their use in subclassifying receptors (Eltze et al, 2001).
Patane and colleagues (1998) reported the discovery o f a potent and selective am-AR 
antagonist, L-765,314. The group had intended to incorporate new structural 
elements into the prazosin piperazine subunit. The effects induced by the modest 
structural changes to the 2-#-piperazinyl-4-aminoquinazoline containing a , 
antagonist suggested a potential strategy for introducing subtype selectivity in other 
series o f nonselective or less-selective a rA R  antagonists (Patane et al, 1998).
A novel am-AR-selective compound with no direct chemical resemblance to other a ,- 
AR antagonists was characterised thi'ough binding experiments with native or cloned 
a ,-A R  subtypes in different animal and human tissues (King et al, 1994). This 
compound, named A H l 11 lOA, displayed an approximately 10- and 20-fold 
selectivity to subtype B relative to A and D, respectively, and an affinity rank order at 
these subtypes o f B > A > D (King et al, 1994; Giardina et al, 1996; Saussy et al, 
1996). The case for A H l lllO A  being listed as the only recommended am-AR- 
selective antagonist (Alexander & Peters, 2000) was dismissed by Eltze and 
colleagues (2001). The group characterised A H l 11 lOA as a low affinity, unselective 
and in most cases non-competitive antagonist with respect to the a ^ - ,  am- and am- 
AR subtypes. They also found A H l 1 IlOA to be almost equipotent at a ,-  and oCa-ARs,
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hence the claimed usefulness o f A Hl 11 lOA for Œm-AR subtype characterisation, at 
least by means o f functional experiments, seems to be unjustified (Eltze ei al, 2001).
1.6.3 aiD-AR Antagonists
The partial serotonin 5-EITia receptor agonist BMY 7378 (for chemical structure, see 
Fig. 1.3), has been shown to be a selective antagonist at the subtype with 
approximately 100-fold higher affinity for the a^o than the aiA or a,B subtype. Goetz 
and colleagues (1995) compared the binding affinities in the tlri'ee recombinant 
subtypes expressed in fibroblast cells rather than nonhomogeneous subtypes in 
tissues. BMY 7378 is more selective than (-)-discretamine, which Ko and colleagues
(1994) described as a selective am-AR antagonist (15- to 25-fold). The cystamlne- 
bearing quinazoline cystazosin, displayed a high affinity for the am-AR subtype and 
when compared with BMY 7378, cystazosin had a much better specificity profile 
since it has lower affinity for Dz and 5-HTia receptors (Minarini et al, 1998). 
Buspirone, a close structural analogue o f BMY 7378 has been reported as another 
compound with the ability to functionally discriminate the am-AR from the other 
known a rA R  subtypes in various tissues (Eltze et al, 1999). Another substituted 8 - 
azapiro[4,5]decane-7,9-dione, MDL 73005EF was also found to have significant 
selectivity for the am-AR (Saussy et al, 1996).
1.6.4 a,-AR Agonists
Little is known about the subtype selectivity of a,-A R  agonists. Comparing the 
affinities o f agonists for receptors is much more difficult than comparing the affinities 
of antagonists due to problems in determining agonist affinities in both radioligand 
binding and functional studies. There is some information available on the 
comparative potencies and efficacies o f agonists at the cloned a rA R  subtypes. 
Oxymetazoline is a partial agonist that displays selectivity in radioligand binding 
assays, with an approximately 2 0 -fold higher apparent affinity for the aiA than a ^ o r  
am subtypes (Minneman et al, 1988; Hancock, 1996; Zhong & Minneman, 1999).
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Tsujimoto and colleagues (1989) reported that methoxamine is selective for the 
subtype in both affinity and efficacy.
Using hepatocytes from guinea pigs, rats and rabbits, which express am-, am and aiA- 
ARs respectively, Garcia-Sainz and colleagues (1993) investigated the agonist 
pharmacology o f these subtypes. After the labelling o f phosphatidylinositol, they 
discovered that methoxamine had a high intrinsic activity in guinea pig liver (am-) but 
not in rat or rabbit liver, whilst oxymetazoline displayed a high intrinsic activity in 
rabbit liver (aiA-) but not in guinea pig or rat liver (Garcia-Sainz et al, 1993). These 
results suggested methoxamine as a possible am-seiective agonist and oxymetazoline 
as a possible aiA-selective agonist. The results were interpreted with caution 
however, as the receptor reserves o f the different subtypes in the various liver 
preparations were unlcnown and efficacy camiot be obtained directly from intrinsic 
activity. Nevertheless, these results did suggest that commonly used agonists could 
show different efficacies at different ai-A R  subtypes (Minneman & Esbenshade,
1994).
Minneman and colleagues (1994) studied the potencies o f a range o f full and partial 
agonists at the recombinant subtypes. Using radioligand binding studies, the group 
confirmed that full agonists such as adrenaline and noradrenaline showed about a 2 0 - 
fold higher apparent affinity for the am subtype compared to the other two. This 
potency difference was not apparent when receptor-mediated second messenger 
responses were measured in intact cells, which was o f some surprise. Noradrenaline, 
adrenaline, 6 -fluoronoradrenaline and phenylepluine had similar potencies and 
apparent intrinsic activities for stimulating inositol phosphate formation mediated by 
all three recombinant a ,-A R  subtypes in human embryonic kidney (HEK) 293 cells 
(Minneman et al, 1994). Methoxamine was most potent at the a^A-AR subtype, but 
had a significant intrinsic activity at all tlii'ee subtypes, while various imidazolines, 
including cirazoline, displayed a significantly higher intrinsic activity at the a,A-AR 
subtype compared to the other two.
There have been other aiA-AR selective agonists reported. Knepper and colleagues
(1995) reported that A-61603 is a member o f the tetrahydro-1 -naphthyl imidazoline
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agonists and is a potent agonist at apA R s. A-61603 is 35-fold more potent at human 
cloned a^ - than at aib- or a  id-ARs in radioligand binding studies and 100- to 300-fold 
more potent than noradrenaline and phenylephrine in isolated canine prostate strips 
and rat vas deferens (aiA-ARs). In contrast, A-61603 is only 40-fold more potent than 
phenylephrine at a^-A R s (rat spleen) and 35-fold less potent at a^ -A R s (rat aorta) 
(Knepper et al, 1995; Meyer et al, 1996; Willems et al, 2001). Even though A-61603 
shows a low affinity for other receptors, it displays a reasonable affinity and agonist 
property at a^-AR subtypes (Willems et al, 2001). Chemical structures for adrenaline, 
noradrenaline, phenylephrine and A-61603 are shown in Figure 1.1.
More recently, O ’Neill and colleagues (2001) described the pharmacological 
properties o f a potent and selective aiA-AR agonist, A-204176. Following functional 
studies using rabbit urethra, the group reported that A-204176 shows selectivity for 
aiA in vitro and enhanced urethral selectivity in comparison to the non-selective 
adrenergic agonist PPA. However, despite its selectivity for a,A versus a ^  and am- 
subtypes, A-204176 did not show the degree o f urethral selectivity in vivo that would 
have been expected from its in vitro functional profile (O’Neill et al, 2001). These 
results were in contrast to the development o f selective a,a antagonists for the 
treatment o f BPH where compounds lacking a ^  activity produce little cardiovascular 
effect (Kirkby, 1999; Takeda et al, 1999). The data indicates that A-204176 may be a 
useful pharmacological tool to investigate the functional role o f the aiA adrenergic 
subtype in the urethra.
It is clear that there is a need for more selective agonists and antagonists, especially 
for the aiB and aio subtypes. The discovery o f such compoimds would help by 
allowing quantitative assessment of subtype distribution by radioligand binding 
studies and in defining their functional roles. This remains unlikely, however, due to 
the lack of clearly defined potential therapeutic applications for such compounds.
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1.7 Desensitisation
Adrenoceptors are subject to regulation by a variety of mechanisms including 
phosphorylation, protein-protein interactions, protein trafficking and transcription.
One of the most intensively studied o f these mechanisms is desensitisation, a general 
phenomenon where the intensity o f a biological response diminishes over a period o f 
time, despite continued stimulus (Michelotti et al, 2000). The concept of 
desensitisation is based mainly on exhaustive studies performed with the Gs-coupled 
P2-ARS (Leflcowitz et al, 1998; Pitcher et al, 1998; Krupnick & Benovic, 1998; 
Goodman et al, 1996; Krueger et al, 1997). Desensitisation can be homologous, 
where receptor response wanes upon continuous exposure to its agonist or 
heterologous, where the activation o f one receptor can result in reduced responses to 
activation of other unrelated receptors, particularly when there is activation of 
signalling pathways or effectors common to the receptor types (Freedman & 
Leflcowitz, 1996; Bunemann et al, 1999). Both phosphorylation o f agonist-occupied 
receptor and uncoupling o f the phosphorylated receptor from G Protein by p-arrestins 
are involved in the mechanism o f desensitisation. Two distinct arrestin like genes 
have been cloned, termed ^-arrestin  1 and ^-arrestin 2  (Lohse et al, 1990; Attramadal 
et al, 1992).
1.7.1 Homologous Desensitisation
The process of receptor desensitisation has been most extensively characterised for 
the p2-adrenergic receptor, although many o f the mechanisms operative for P2- 
receptor desensitisation are being observed for other GPCRs (Hein & Kobilka, 1997). 
It is generally accepted that homologous de sensitisation involves receptor 
phosphorylation by GRKs (Ferguson et al, 1997; Krupnick & Benovic, 1998; Garcia- 
Sainz et al, 2000). The sites for GRK phosphorylation seem to be in the carboxyl 
terminus for the p-adrenergic receptors (Bouvier et al, 1988) or in the third 
intracellular loop of (X2-ARs (Eason et al, 1995). GRKs are a family o f at least six 
serine/tlii'eonine protein kinases that phosphorylate GPCRs only in the agonist bound 
state. Receptors with bound agonist activate heterotrimeric G-Proteins, releasing GPy
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complexes. These membrane-bound Gpy heterodimers and PIP2 bind to the carboxyl 
terminal domain o f soluble GRKs that targets the kinase to the receptor (Pitcher et al,
1998).
There are hundreds to thousands o f GPCRs and only a limited number o f GRKs, 
suggesting that different GRKs recognise different subsets of GPCRs as substrates in 
vivo (Bunemann et al, 1999). Six GRKs have been identified from mammalian 
cDNA libraries: GRKl (rhodopsin kinase), GRK2 and GRK3 (formerly referred to as 
the p-adrenergic receptor kinases p-A RKl and p-ARK2), GRK4, GRK5 and GRK6 
(Chuang et al, 1996). GRKl and GRK4 are localised in a tissue-specific manner, 
restricting their interaction with many types of GPCR, whereas the other GRKs are 
widely distributed, and in the cardiovascular system, GRK2, 3 and 5 have been 
suggested to regulate a number o f GPCRs (Chuang et al, 1996; Bunermami et al,
1999).
Evidence has recently suggested that GRKs may also inhibit receptor signalling via 
phosphorylation-independent mechanisms. Using kinase-negative mutants o f GRKs 
and truncated receptors, it has been shown that binding o f GRKs to the receptors 
inhibits signalling (Dicker et al, 1999). Muldierjee and colleagues (1999) also 
provided evidence that arrestins may bind and desensitise some GPCRs in the absence 
o f receptor phosphorylation and that receptor activation seems to start these processes 
(Garcia-Sainz et al, 2000).
/. 7.2 Heterologous Desensitisation
Many GPCRs are desensitised via feedback regulation by second messenger- 
stimulated kinases, such as PKA and PKC. This is an example o f heterologous 
desensitisation since, in principle, any stimulant that can increase cAMP or DAG has 
the potential to induce the phosphorylation and desensitisation o f any GPCR 
containing the consensus phosphorylation sites for PKA or PKC (Garcia-Sainz et al,
2000). Other proteins involved in signalling and possessing such consensus sites can 
also be phosphorylated and their function can be modified as a result o f this.
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Similarly, a single receptor type is susceptible to phosphorylation and desensitisation 
by multiple protein kinases (Nambi et al, 1985).
There is evidence that PKA-dependant phosphorylation o f the P2-AR can strengthen 
the coupling o f the receptor to the inhibitory G Protein Gj (Daaka et al, 1997) and 
promote activation o f the MAP kinase pathway via a process that has been suggested 
to be pertussis toxin sensitive and to require receptor endocytosis (Daaka et al, 1998). 
This shows that even though PKA-mediated phosphorylation o f the pi-AR can switch 
off signalling via the receptor’s normal partner, Gs, at the same time it helps to couple 
the receptor to an inhibitory G Protein (Bunermami et al, 1999).
1.7.3 Phosphorylation o f ai-ARs
The information on ai-A R s phosphorylation/desensitisation is more limited than that 
available for a j-  and P-ARs. There is information available on am -A R 
phosphorylation/desensitisation, but more infoimation is needed on the possible 
phosphorylation o f other subtypes. There appears to be little, if  no information on the 
possible phosphorylation of aio-ARs. When transfected into Rat-1 fibroblasts, a i-  
ARs are differentially regulated by activation o f PKC. Activation o f PKC with 
phorbol esters clearly inhibited the actions mediated through a ie - and am -ARs, 
whereas those mediated thi’ough a  1 a-ARs were unaltered (Vazquez-Prado & Garcia- 
Sainz, 1996).
Studies on aiA-ARs stably expressed in Rat-1 fibroblasts show that these receptors are 
phosphorylated in response to noradrenaline and when PKC is activated by phorbol 
esters (Vazquez-Prado et al, 2000; Garcia-Sainz et al, 2000). This was something of 
a surprising result as there is very little effect of active phorbol esters on the 
adrenergic modulation of cellular parameters (aiA-AR-mediated increases in 
intracellular Ca^^ concentration or phosphoinositide hydrolysis). There was however, 
a small effect o f active phorbol esters on noradrenaline-stimulated [^^SjGTPyS 
binding (Vazquez-Prado et al, 2000). It must also be noted however, that a  1 A-ARs 
are much less sensitive (or more resistant) to desensitisation and are phosphorylated to
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a lesser extent than am -ARs. A major future Issue is the identification o f the 
isoforms o f PKC and phosphatidylinositol 3-kinase that play important roles in 
heterologous desensitisation. These kinases are now extremely important in the 
regulation of reeeptor function and unfortunately there are no pharmacological agents 
with sufficient selectivity to address these aspects. Molecular biological techniques 
will probably be used and once these aspects have been clarified, there will be a 
window for drug design, which may be o f therapeutic potential (Garcia-Sainz et al, 
2000).
1.8 Endocytosis
Mammalian cells have evolved a variety o f mechanisms to internalise small 
molecules, macromolecules and particles and target them to specific sealed organelles 
within the cytoplasm. Together, these processes are known as “endocytosis”, a term 
proposed by de Duve in 1963. Under its broad definition, endocytosis includes 
various methods o f uptake o f extracellular material by cells, including phagocytosis 
(or “cell eating”), pinocytosis (or “cell drinking”), clathrin-dependent receptor- 
mediated endocytosis and clathrin-independent endocytosis (Mukherjee et al, 1997).
Receptor-mediated endocytosis via clathrin-coated pits is a shared pathway used for 
the internalisation o f a variety o f ligand-receptor complexes. Roth and Porter (1964) 
were the first to describe these coated pits and vesicles in mosquito oocytes and 
proposed that these structures help in yolk formation by taking up absorbed proteins 
from the extracellular fluid. Kanaseki and Kadota (1969) first reported the fact that 
the coat actually corresponds to a baselike structure. Receptor-mediated endocytosis 
of molecules that concentrate in the coated pits leads to their extremely efficient 
clearance from the cell surface.
1.8.1 Clathrin-Coated Vesicles
Clathi’in-coated pits are ~150nm invaginated structures on the plasma membrane 
(Willingham et al, 1981) that occupy approximately 2% of the plasma membrane
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surface on human fibroblasts (Anderson et al, 1977). These pits assemble on the 
cytoplasmic face o f the plasma membrane by the recruitment o f the adaptor complex 
AP-2, a heterotetramer comprising two large subunits, a  and |32 (each of ~100kDa), 
and two smaller chains, |i2 (50kDa) and a2  (20kDa). The function o f such adaptors is 
to link clathrin to the membrane and to organise the structural assembly o f the coat 
with the selection o f cargo proteins and lipids (Takei & Haucke, 2001).
Endocytosis o f plasma membrane or synaptic vesicle components is affected by the 
gathering o f clatlirin-coated vesicles that serve to concentrate cargo proteins and 
lipids into the emerging vesicle and provide a mechanical means to deform the 
membrane into a vesicular bud (Takei & Haucke, 2001). This bud then matures and 
subsequently pinches off, forming a free clathrin-coated vesicle. Energy-dependant 
uncoating restores a vesicle (Braell et al, 1984), which can either fuse with 
endosomes and be routed to lysosomes for degradation or, in the case o f a synaptic 
vesicle, be refilled with neurotransmitter and recycled back to the cell surface for 
another round o f delivery (Gruenberg & Maxfield, 1995; Brodin et al, 2000). 
Ciatlu'in-coated vesicles formed at the plasma membrane fuse with early, but not late 
endosomes, even though there are late endosomes present next to early endosomes. 
This specificity must reflect the presence o f a specific receptor on the early endosome 
membrane (Gruenberg & Maxfield, 1995).
1.8.2 Caveolae
The definition of caveolae has expanded in recent years to include vesicles detached 
from the plasma membrane proper, associated in groups as grape-like clusters or 
rosettes or even in fused form as elongated tubules or /^ra/î^-cellular channels (Razani 
et al, 2002). Since their discovery in the 1950s, caveolae were given the exclusive 
electron microscope description o f membrane invaginated “smooth” vesicles of 
approximately 50 to lOOnm in size (as opposed to the more dense clathrin-coated 
pits). As more is learned about these structures, caveolae can no longer be classed as 
static in-pocketings o f the plasma membrane, but can take on disparate shapes and 
forms by conglomerating and/or fusing with one another (Razani et al, 2002).
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Caveolae have also been implicated in endocytotic processes. Clatlirin-coated 
vesicular transport has been almost entirely associated with endocytosis (Take! & 
Haucke, 2001), but it has become apparent that certain receptors and extracellular 
macromolecules are exclusively transported via caveolae rather than the clathiin­
coated pits. The first example o f this came when caveolae bound and internalised 
cholera and tetanus toxins (Montesano et al, 1982). Biochemical evidence supported 
these findings when it was shown that treatment o f cell with cholestrol binding agents 
(nystatin or f lip  in) cancelled the endocytosis o f certain macromolecules (e.g., 
albumin) without affecting the uptake o f  clathrin-dependent ones (Schnitzer et al, 
1994; Razani et al, 2002).
It is unclear where the endocytosed caveolar vesicle targets in the cell. Among the 
possibilities is direct transport to endosomes with or without further trafficking to 
other intracellular compartments. For example, in the case o f cholera toxin, it is 
believed that caveolar endocytosis on the apical membrane Is followed by retrograde 
transport to endosomes, the Golgi apparatus, the ER and finally resorting to the 
basolateral membrane (Lencer et al, 1999). However, this trafficking scheme does 
not apply to all caveolae-mediated endocytosis. The budded caveolae containing the 
simian virus 40 (SV40) eventually merges with larger, non-endosomal, non-lysosomal 
caveolin-1 containing organelles that target to the ER (Pelkmans et al, 2001). These 
organelles were named “caveosomes” and provide the first evidence o f distinct 
compartments formed from internalised caveolae. This correlates with earlier work, 
which stated that under specific conditions, caveolins can either directly traffic from 
the plasma membrane to Golgi/ER compartments or localise to non-endosomal 
vesicles (Conrad et al, 1996; Roy et al, 1999).
1.8.3 Endocytotic Rate
In unstimulated cells, there is a relatively slow endocytosis o f receptors from the cell 
surface into endosomes, but in the presence o f agonist, the rate o f endocytosis is 
increased dramatically (Koenig & Edwardson, 1997). It seems that when agonist 
binds, the receptor is activated and becomes liable to endocytosis. If the ligand 
dissociates, the receptor can still be associated with the endocytotic machinery and be
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endocytosed minus the ligand. This means that when the agonist is present, it 
enhances the rate o f receptor endocytosis, but the amount o f agonist endocytosed 
depends on both its dissociation rate and the receptor endocytosis rate. For the lower 
affinity ligands, such as the muscarinic acetylcholine receptor agonists, it appears 
unlikely that they are internalised at all (Koenig & Edwardson, 1997).
1.8.4 Inhibiting Endocytosis
Endocytosis and recycling o f GPCRs are both extremely temperature and energy 
dependent with both these processes almost completely prevented below 16°C (Von 
Zastrow & Kobilka, 1994). Other ways to inhibit receptor endocytosis include 
increased extracellular hyperosmolarity (normally achieved with 0.45M sucrose), 
depletion o f intracellular K^ and acidification o f the cytosol (Roettger et al, 1995). 
Treatment with phenylarsine oxide also inhibits endocytosis (Hunyady et al 1991), 
although it is known to have many effects on cellular function through interactions 
with sulphydryl groups. These properties described are characteristic o f endocytosis 
via clathi'in-coated pits, and in some cases agonist-stimulated accumulation of GPCRs 
in these pits. Their budding from the cell surface to form clatlnin-coated vesicles were 
directly visualised by Koenig and Edwardson (1997). There have also been reports o f 
endocytosis via uncoated pits (Roettger et al, 1995).
1.8.5 Receptor Degradation
Receptor degradation is also important when modelling intracellular movement, 
especially since the rate of degradation increases dramatically in the presence of 
agonist (Koenig and Edwardson, 1997). It is common for receptor density to decrease 
after agonist concentrations have been elevated for a considerable time and this 
change shows an important component o f the response to chronic drug treatment 
(Sleight et al, 1995).
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Following endocytosis, receptors enter a tubulo-vesicular endosomal compartment 
(Tooze & Hollinshead, 1991). As mentioned previously, once in the endosome, 
GPCRs can either be recycled to the plasma membrane or directed to other 
destinations on the endocytotic pathway, such as the lysosome. The different extents 
o f recycling and degradation for different GPCRs suggest that signals operate in early 
endosomes to determine the later fate of the endocytosed receptor, with recycling to 
the plasma membrane being the default pathway (Koenig and Edwardson, 1997). It is 
possible that the activation state o f the receptor once it reaches the endosome plays 
some part in its fate. Evidence for this was proved using the tlirombin receptor, which 
was directly activated by a unique proteolytic mechanism (Hein et al, 1994). 
Tluombin cleaves the receptor’s amino terminus to expose a new tenninus, which 
then acts as a tethered peptide ligand.
For GPCRs where agonists are o f low affinity (i.e. micromolar), such as the p-AR and 
the muscarinic receptor, it is unlikely that sufficient agonist will be endocytosed to 
cause significant receptor activation in endosomes (Sorensen et al, 1997). On the 
other hand, peptides often have higher affinity for their respective GPCRs (i.e. 
nanomolar to picomolar) and it is possible that the agonist concentration in the 
endosome’s lumen could be high enough to cause receptor activation. If constant 
activation does target GPCRs to lysosomes, it would be expected that the receptors’ 
fates depend on the affinity of the agonist (Koenig and Edwardson, 1997).
1.8.6 Receptor Trafficking
Michelotti and colleagues (2000) reported that a green fluorescent protein-tagged aia- 
AR undergoes constitutive (agonist-independent) cycling between the cell surface and 
nonlysosomal intracellular compartments. This finding o f agonist-independent 
cellular trafficking may provide a potential means for continuous aia-AR signalling, 
which could possibly contribute to the development of myocardial hypertrophy (Price 
& Schwinn, 1998). This was supported by earlier findings where transiently 
expressed, green fluorescent protein- or FLAG-tagged aia-AR and aib-AR subtypes 
displayed differential sensitivity to CEC as a result o f differences in subcellular
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localisation and not differences in structural determinants (Hirasawa et al, 1997).
This should increase the chance o f pharmacologic manipulation of ai-A R s as 
differences in subtype-specific trafficking are clarified.
The aia-AR is unique in that agonist exposure in a rat neonatal myocyte model results 
in continued signalling, while aib- and aid-ARs undergo desensitisation (Rokosh et 
al, 1996). All three ai-A R s are expressed in neonatal rat cardiac myocytes and these 
myocytes maintain full a i-A R  responsiveness to noradrenaline exposure, even 
following 24-72 hour continuous stimulation, suggesting that persistent ai-A R  
signalling results from aia-AR expression and signalling (Rokosh et al, 1996; 
Michelotti et al, 2000). Signalling differences between subtypes do not dictate these 
results as ai-A R s mainly couple to the same second messenger cascade, albeit with 
otia = ocib> aid efficacy (Schwinn et al, 1995).
1.9 Fluorescent Ligand Binding
1.9.1 GPCRs and GFP
Cell surface GPCRs are extremely difficult to localise accurately, even in fixed tissue, 
due to the nonspecificity o f antibodies, in turn due to the high degree o f conservation 
of sequence, and to the inherent low resolution o f autoradiography (Daly et al, 1998). 
The gene encoding green fluorescent protein (GFP) from the jellyfish worm 
victoria was first isolated in 1992 (Prasher et al, 1992) and has quickly become a 
popular reporter molecule for monitoring protein expression and localisation (Kallal 
& Benovic, 2000). The introduction of GFP for use as an autofluorescent epitope tag 
(Cubit et al, 1995) has allowed the visualisation of GPCRs and their regulatory 
proteins in real-time with a precision not afforded by fluorescent antibody staining o f 
fixed cells (Ferguson, 1998).
GFP is a 238 amino acid protein that emits green light with an emission maximum of 
509mn upon fluorescent excitation at 488nm. GFP fluorescence is stable and has 
been measured non-invasively in living cells of many species including mammals,
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drosophila, C.elegans, yeast and E.coli (Milligan, 1999). GFP fluorescence can be 
detected by fluorimetry, by fluorescence activated cell sorting (FACS) and by 
microscopy. No cofactors or substrates are required, making the attractiveness of 
GFP as a reporter protein apparent (Chalfie & Kain, 1998).
There have been various attempts at conjugating fluorescent molecules to receptor 
ligands in the hope o f identifying their binding sites. The reason was to study the 
localisation o f the receptors rather than studying their properties. The aim was to 
produce a fluorescent compound that would remain fluorescent when bound to the 
receptor and would remain bound when the free drug was washed away (McGrath et 
al, 1996). Problems seemed likely to occur with the latter, as washing would 
probably cause the ligand to dissociate and diffuse away, unless it has very high 
affinity.
The fluorescent ligand-receptor complex can be studied particularly effectively with 
confocal microscopy. This allows localisation o f the receptive site within a cell, 
tissue or organ giving much higher spatial resolution than autoradiography and offers 
high resolution and quantitative analysis in three dimensions. Also, temporal 
resolution is achievable: binding can be followed in real-time in live tissue with the 
consequent advantages of studying the kinetic properties o f the receptors and their 
relationship to cellular activation processes (Daly et al, 1998).
Not all GPCRs are effectively delivered to the plasma membrane o f cells. Hirasawa 
and colleagues (1997) examined the subcellular localisation o f native a,*- and 
ARs and compared it with CEC sensitivity o f each subtype. Flow cytometry analysis 
and immunocytochemical and GFP-fluorescent localisation analysis by confocal 
microscopy showed that aiA-ARs predominately localise intracellularly, whereas most 
o f (XiB-ARs localise on the cell surface, and that CEC preferentially inactivates the cell 
surface a,-A R  irrespective o f the subtype (Hirasawa et al, 1997). Recent work has 
confirmed these cellular localisation findings by use o f flow cytometry and confocal 
microscopy techniques (Sugawara et al, 2002; Koshimizu et al, 2002). The long held 
suggestion that CEC can be used as a selective pharmacological discriminator for the 
aiB-AR was re-examined. Inactivation o f the two GPCR subtypes by CEC was
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equivalent in membrane preparations, but displayed selective inactivation o f the am - 
AR in intact cell studies. It was concluded that CEC Is not essentially a selective 
alkylating agent between these two closely related GPCRs if  provided with equal 
access, but that the observed differential effects o f CEC might instead relate to uneven 
subcellular distribution of the two GPCRs (Hirasawa et aï, 1997; Milligan, 1999).
1.9.2 QAPB and Subcellular Localisation
An example of a fluorescent ligand for otrARs is BODIPY FL-prazosin, alternatively 
Imown as QAPB (McGrath & Daly, 1995). This compound is related to the Œi-AR 
antagonists doxazosin, prazosin and terazosin (Ruffolo et al, 1995). QAPB has been 
used to visualise a-ARs on live cells and intact pieces o f tissue. The punctate 
fluorescence found confirms the punctate nature o f a-A R  distribution reported by 
Uhlen and colleagues (1995) in MDCK cells. This is an example o f the ligand- 
receptor complex being more fluorescent than the unbound ligand (McGrath et al,
1996). The chemical structure o f QAPB is shown in Figure 1.2.
Daly and colleagues (1998) visualised QAPB at concentrations equivalent to those 
used for radioligand binding, in real time, at kinetic equilibrium, with a defined 
receptor subtype on live cells. The cells used were rat-1 fibroblasts expressing the 
recombinant a^-AR. QAPB was validated as a competitive antagonist against the a ,- 
AR agonist phenylephrine’s production of inositol phosphates and as a competitive 
ligand against [^H] prazosin, confirming that it is a ligand for functional aid-ARs.
The binding and functional antagonism data showed that despite the modification of 
the molecule to incorporate the fluorescent tag, it retains the properties required o f a 
high affinity pharmacological “antagonist” ligand. QAPB entered live cells and hence 
reported spatial distribution o f binding sites thioughout the cell, not only at the 
expected functional locations on the plasma membrane. It was assumed that QAPB 
entered the cells because it is lipophilic. It showed no fluorescence in the aqueous 
phase and so could be employed at equilibrium. It was, however, fluorescent when 
bound to the receptor, allowing estimation o f receptor occupation under equilibrium 
conditions (Daly et al, 1998; MacKenzie et al, 2000).
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Following Daly’s studies, MacKenzie and colleagues (2000) confirmed QAPB as a 
high affinity nonsubtype-selective competitive antagonist at ai-AR-binding sites. 
QAPB bound to the cell membrane and intracellular perinuclear sites in all three 
recombinant a rA R  subtypes expressed in rat-1 fibroblasts, although it was more 
prominent around the perinuclear area o f the cell in the a,b-AR subtype (MacKenzie 
et al, 2000). This is an example o f different subtypes adopting different locations in 
the same host cell. Previous work by Hrometz and colleagues (1999) had reported 
that in fibroblasts expressing each o f the receptors, ai-ARs are expressed not only on 
the cell surface, but also in intracellular compartments. Immunostaining in these 
fibroblasts was noted on the cell surface and also in the perinuclear region (Flrometz 
et al, 1999). MacKenzie’s group also reported that quantitative three-dimensional 
mapping o f QAPB-associated fluorescence binding in native human cells showed that 
40% of high affinity binding sites were found in intracellular compartments. The 
binding in these pro static smooth muscle cells was found particularly around the 
nucleus, which could represent binding in the Golgi and may include both newly 
synthesised and recycling stores o f receptors. This demonstrates that the vast quantity 
o f intracellular binding sites previously shown in recombinant cells is not an artifact 
o f artificial systems, but a natural phenomenon (MacKenzie et al, 2000).
L9.3 Extraneuronal Monoamine Transporter
The discovery by MacKenzie and colleagues (2000) that ai-A R subtypes bind ligands 
at intracellular sites raises the possibility that this may be a general property of 
heptahelical receptors and this has important implications for drug action. If 
intracellular receptors transduce signals, then activators or blockers might act at these 
differentially with regard to whether they can penetrate the cells, by means of 
diffusion/lipophilicity or whether they are substrates for membrane carriers.
The catecholamine noradrenaline, is taken up and accumulated by smooth muscle 
cells that express a rA R s  (Avakian & Gillespie, 1968). The transporter responsible, 
known as the extraneuronal monoamine transporter (EMT), has been cloned 
(Grundemann et al, 1998). This transporter was previously known as Uptake,.
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Iversen (1965) had concluded that Uptake2 lacked stereoselectivity based on the 
comparison o f (-)- with (+)-noradrenaline and (-)- with (±)-adrenaline in the isolated 
rat heart. It was soon discovered that the naturally secreted glucocorticoid in the rat, 
corticosterone, was a potent inhibitor of Uptakcz (Iversen & Salt, 1970). When the 
transporter is blocked, the metabolism o f noradrenaline is attenuated which implies 
that the purpose o f the carrier is to eliminate noradrenaline from the extracellular 
space (Eisenliofer et al, 1996; MacKenzie et al, 2000). The presence o f intracellular 
Ki-ARs with the ability to bind ligands, raises the possibility that a function o f the 
transporter is to deliver catecholamines to intracellular receptors.
Extraneuronal uptake, like metabolism o f catecholamines by COMT, exists almost 
exclusively in non-neuronal cells (Karhunen et al, 1994), and monamine oxidases 
(MAO-A and MAO-B). Grundemann and colleagues (1998) cloned the EMT and 
reported its use as a widely distributed second line o f defence, inactivating the 
fraction o f released monoamine transmitters that escape neuronal uptake and hence 
stopping uncontrolled spreading of the signal (Grundemann et al, 1998). Amino acid 
sequence analysis identified EMT as a new member o f the recently defined family of 
amphiphilic solute facilitators (ASF) (Schomig et al, 1998). The cloning o f EMT 
provides a new candidate not just for diseases based on autonomic dysfunction, but 
also for neuropsychiatrie disorders.
37
HO
Phenylephrine
HO H \ CCH2NHCH3 HCI
Noradrenaline
% / “ I
CH— CH2 — NHg
Adrenaline
CH— CH2 — NH XCH3
A61603
HN" Me
HO
NH
.HBr
Figure 1.1 Agonist chemical structures: a i-A R  agonist phenylephrine, a  1 a-AR 
agonist A61603 and catecholamines; noradrenaline and adrenaline.
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Figure 1.2 Prazosin and QAPB structures. Chemical structure o f the ai-A R  
antagonist prazosin and a fluorescent derivative o f prazosin, BODIPY FL-prazosin 
(QAPB).
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Figure 1.3 BMY7378 and R S100329 structures: Chemical structures o f the aid-AR 
antagonist BMY7378 and the ocia-AR antagonist RS 100329.
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2.0 Aims & objectives
The lab has been using fluorescent ligands such as BODIPY FL-prazosin (QAPB) to 
visualise a subset o f receptors (ai-A Rs) that belong to the GPCR family. Initial 
expectations were that ai-A R s are exclusively membrane bound receptors. 
Subsequent experiments presented in Chapter 3 o f the present study revealed a high 
proportion of fluorescent ligand could be found inside cells. Other antagonists can 
displace these fluorescent ligands; hence competitive binding takes place inside cells.
Using classical and updated radioligand binding teclmiques (for detailed diagrams of 
protocols, see Figures 2.1 & 2.2), we could make a comparison o f binding to isolated 
cell membranes and whole cells. Any differences would indicate differences in 
intracellular binding or issues related to penetration o f cells by ligands. A number of 
questions were addressed.
1. Is binding inside eell similar or different from binding at the cell surface?
2. Do antagonists bind similarly inside cells and is this influenced by their ability 
to penetrate cells?
3. Are there ways to selectively block receptors on the cell membrane or inside 
the cell?
4. Can a-A R  agonists eross cell membranes and act on intracellular sites?
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Figure 2.1 Radioligand binding protocols. A, shows the “elassical” radioligand 
binding protocol and B, shows a new radioligand binding protocol.
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Figure 2.2 Updated radioligand binding protocol. Diagram shows a new “cold’ 
radioligand binding protocol.
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2.1 METHODS
2.1.1 Cell Culture.
Rat-1 Fibroblasts stably expressing the bovine aia-AR and human a^ -A R  were used. 
Cells were grown in monolayers in DMEM containing 10% (v/v) foetal bovine serum, 
100 I.U./ml penicillin, lOOpg/ml streptomycin and Im M  L-glutamine in a 95% air 
and 5% CO2 atmosphere at 37°C. Selection was maintained by adding genetic in 
(G418) (400jig/ml) to the growth media.
2.1.1.1 Freezing cells.
Cells are grown to confluence in 75 cm^ tissue culture flasks, growth media removed 
and replaced with fresh growth media eontaining 10% DMSO. Cells are removed 
from the base o f the flask by gentle agitation and aliquoted into 1.5ml cryovials. The 
cryovials are stored at -70°C for 24 hours, then labelled in cryocanes and frozen down 
in liquid nitrogen.
2.1.1.2 Growing cells
Single cryovials containing the cells were removed from cryocanes and left in the 
incubator at 37°C for 5-7 minutes. Once defrosted, cells were earefully triturated 
twice and added to a 25cm^ tissue culture flask. 1 Omis of DMEM was slowly added 
to the flask, the flask cap was loosened and the suspension left in the incubator for 40 
minutes to allow cells to adhere to the base o f the flask. The media was then 
removed, replaced with 5mis fresh media and flask placed in incubator to be 
maintained as normal.
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2.1.1.3 Cell splitting
Cells were maintained using a “splitting” process. Once cells reached confluence, 
growth media was removed and cells washed with 2mls 0.25% trypsin/EDTA 
solution. The wash solution was removed, replaced with 2.5mls fresh trypsin/EDTA 
and 2.5mis fresh DMEM, then transferred to a 13ml centrifuge tube and centrifuged at 
4000rpm for 3 minutes at 22°C. The solution was discarded, leaving a pellet. Using a 
Pasteur pipette, 1ml DMEM was added and carefully triturated 15-20 times before 
adding a further 9mls DMEM. After resuspending, 1ml o f the cell suspension was 
added to a 25cm^ tissue culture flask along with 4mls fresh DMEM. The cells were 
then placed in the incubator and maintained as normal.
2.1.2 Membrane Preparation
Cells were grown to confluence and harvested using a rubber policeman followed by 
centrifugation at 4000rpm for 3 minutes at 22°C. The cell pellet was resuspended in 
5ml o f Tris-HCl assay buffer (150mM NaCl, 50mM Tris-HCl, lOmM M gCb, 5mM 
EDTA, pH 7.4) then stored for 24 hours at -80°C . After defrosting on ice, the cells 
were homogenised using a pre-chilled Teflon-in-glass homogeniser. The homogenate 
was centrifuged at 4000rpm for 5 minutes at 4°C, the supernatant recovered and 
centrifuged at 26000rpm for 30 minutes at 4°C. The resulting membrane pellet was 
re suspended in 1ml o f iee-eold Tris-HCl assay buffer and sheared by passage through 
a 26-gauge needle. The homogenate was processed for protein estimation using a 
BCA’^ '^  Protein Assay Kit (Pierce) using bovine serum albumin as the standard. 
Aliquots not used immediately for ligand binding studies were stored at -80°C.
2.1.3 Whole Cell Preparation
Similar to membrane preparations, cells were grown to confluenee and harvested 
using a rubber policeman followed by centrifugation at 4000rpm for 3 minutes at 
22°C. The resulting pellets were pooled, supernatant discarded and replaced with 
8mls ice-cold Tris-assay buffer. After a brief resuspension, cells were drawn through
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a 26-gauge needle into a universal tube 10-12 times. A small amount o f cell 
suspension was administered into the haemocytometer channel beneath a coverslip to 
determine the cell number. Cells were viewed under a microscope and a counter used 
to count cells in the 25(5x5) grid. Cells were then immediately ready for use in ligand 
binding studies.
21.4 Radioligand binding studies
2.1.4.1 Competition binding experiments
Estimates of binding affinity (pKi) for [% ]-prazosin (0.2nM) in the presence of a 
range o f increasing concentrations o f competing ligands were made using rat-1 
fibroblast membranes (0.05mg/ml) or whole cells (6.5 x 10  ^cells/tube) in a total 
volume o f 0.5ml Tris-HCl assay buffer. All equilibrations were carried out for 30 
minutes at 22°C, or at 37°C in a heated water bath, and reactions terminated by rapid 
cold vacuum filtration. Non-specific binding was defined as the concentration of 
bound ligand in the presence o f lOjiM phentolamine. Throughout all competition 
binding experiments, the amount o f radioactivity bound remained consistent.
2.1.4.2 Displacement binding experiments
These experiments employed slightly different protocols to those used for standard 
competition experiments. [^H]-prazosin (0.2nM) was incubated with rat-1 fibroblast 
membranes (0.05mg/ml) or whole cells (6.5 x W  cells/tube) for 15, 30 or 60 minutes 
at 22°C or at 37°C in a heated water bath. A range o f increasing concentrations of 
competing ligands were then added and left to incubate for 15, 30, 60 and 120 
minutes at 22°C or at 37°C in a heated water bath or at 4°C in a cold room. Reactions 
were terminated by rapid cold vacuum filtration as described previously. Non-specific 
binding was defined as the concentration o f bound ligand in the presence o f lOjiM 
phentolamine. Ligands used in competition and displacement binding studies 
included prazosin, QAPB, adrenaline, noradrenaline, BMY7378, L-765314,
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phenyleplil'ine HCI, (R)-A-61603 and R S I00329. Throughout all displacement 
binding experiments, the amount o f radioactivity bound remained consistent.
2.1.4.3 Data analysis
Competition and displacement binding experiments were carried out in duplicate, 
repeated a minimum of thr ee times and the results from each pooled and expressed as 
mean ± s.e.m. Non-specific binding (determined in the presence o f lOfxM 
phentolamine) was defined as 0 % and total binding (in the absence o f any competitor) 
was defined as 100%. Specific binding is then calculated accordingly and expressed 
as % specific binding o f maximum.
Competitive and displacement binding curves can be described by the equation:
Y= NSB + (T o ta l-N S B l
|^ ]^ Q ( lo B [ O ] - lo g [ I C 5 0 ] )
Y = total binding in the presence o f the competitor
Log[D] = logarithm of the concentration o f  competitor
NSB = non-specific binding in the presence o f  a saturating concentration o f D
Total = binding in the absence o f competitor
[loglCso] = logarithm to the base 10 o f the concentration o f the competitor which 
inhibits the binding of the radioligand by 50%
The above equation describes a situation in whieh the radiolabel and the competing 
ligand eompete for only 1 receptor type. However, in many tissues there are 2 classes 
o f binding sites, which may represent 2 subtypes o f receptor. This can be described 
by a more complicated equation:
Y= NSB + (T otal-N SB ). ( F__________ + 1 - F  )
J  J  q (Io îî[D]-1o b [IC 50]) I  Q (lo g [D ]-lo g [IC 5 0 ])
Y, NSB, Total and [D] are the same as for the previous equation and F = the fraction 
o f binding to receptors o f the first type o f receptor.
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Data from competition and displacement experiments were analysed using both the 
one-site and two-site models. Results of these were compared to determine which 
gave the more accui'ate fit. This was achieved in a number of ways. Firstly, the 
graphs were compared visually to assess which equation appeared to be fitting the 
data better, after which a number o f statistical parameters were determined, which are 
provided by GraphPad when performing nonlinear regression. The curve-fitting 
program Prism version 3.0 (GraphPad Software, San Diego, CA) was used 
throughout. (All definitions taken from GraphPad guide to Nonlinear Regression by 
Dr. Flarvey Motulsky, 1996).
95% Confidence Intervals; if all the assumptions o f non-linear regression are true, 
then there is a 95% chance that the true value o f the variable lies within the interval. 
Therefore the naiTower the confidence interval, the better the fit.
Sura of Squares (SS): the sum of squares is defined as the sum of the square o f the 
vertical distances o f the points from the curve. So the smaller the value o f SS, then 
the closer the points are to the curve and the more accurate the fit.
rh a measure o f the goodness o f the fit. It is a fraction between 0 and 1 and has no 
units. When r^  ^  0 the best-fit curve fits the data no better than a horizontal line going 
tlirough the mean o f all the y values, i.e. Icnowing x does not help you predict y.
When r^  =1, all points lie exactly on the curve with no scatter i.e. if you know x, you 
can predict y.
GraphPad Prism also performs a test ealled the F test that directly compares the fits of 
2 equations and reports which is statistically better suited to the data. The results are 
presented in the form o f an F Ratio that is calculated as follows:
F = (SS1 -SS2V SS2 
(DFl -  DF2)/DF2
SS = sum o f squares 
DF = degrees o f freedom
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If  the simpler equation (i.e. the one-site model) is correct, then F ~ 1 because the 
relative increase in the sum o f squares is approximately equal to the relative increase 
in the degrees o f freedom. Ho^vever, if  F is much greater than 1, then the more 
complicated equation is correct because the relative increase in the sum o f squares 
(going fi'om the complicated to the simpler model) is greater than the relative increase 
in the degrees o f freedom. For the purposes o f the present study, a two-site model 
was accepted only when the F Ratio was much greater than 1 and produced a p value 
o f < 0.05.
The Ki or inhibition constant is defined as the concentration of unlabelled drug that 
will bind half the receptors at equilibrium, in the absence of radioligand or any other 
competitors and can be calculated using the Cheng-Prusoff equation (Cheng & 
Prusoff, 1973). For each competition and displacement experiment, a Ki was 
calculated and then converted to a pK, value, which is the negative logarithm to the 
base 10  o f the IQ.
Nonlinear regression was also cairied out using the Hill equation in order to 
determine the Hill slope, which allows for the quantification o f the slope steepness.
Y =  NSB 4-(T o ta l-N S B )
1 + 1 0  (1OSÏC50 - factor
A one-site competitive binding curve that follows the law o f mass action will have a 
slope o f -1  (it is negative because the curves go downhill). I f  the slope differs 
significantly from -1  then the binding does not follow the law o f mass action. One 
possible explanation may be that there is a heterogeneous population o f receptors for 
which the competing drug has different affinities or it could be a result o f 
heterogeneity in the receptor coupling to other molecules such as G proteins. A Hill 
slope was calculated for each competition and displacement experiment in order to 
provide further information about the nature o f the binding.
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2.L5 Materials and Chemicals
Cell culture plastics were supplied by Falcon. DMEM with sodium pyruvate, foetal 
bovine serum, L-glutamine, penicillin, streptomycin and trypsin/EDTA were 
purchased from Gibco Life Technologies (Paisley, Scotland); Phenylephrine FICl, 
adrenaline, noradrenaline, HEPES and EDTA were purchased from Sigma (Dorset, 
UK); The (R)-enantiomer o f A-61603 was a gift from Dr Michael Meyer (Abbott 
Laboratories, Abbott Park, IL); L-765314 was a gift from Dr Michael Patane (Merck 
& Co. Inc, NJ); R S I00329 (Dr. Michelson, Roche Bioscience, Palo Alto, CA); 
Phentolamine, QAPB, prazosin HCI, BMY7378 dihydrochloride from Research 
Biochemicals Inc. (Natick, MA); [^H]Prazosin (0.2nM; specific activity, 76 Ci/mmol) 
was ordered from Amersham Corp. (Arlington Heights, IL)
Stock solutions for each chemical were prepared in distilled water or dimethyl 
sulfoxide and subsequently aliquoted and stored at -20°C. These stock solutions were 
diluted to working concentrations in the physiological salt solution on each 
experimental day.
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2,2 RESULTS
2.2.1 Competitive Inhibition o f Radioligand Binding.
2.2.1.1 Membranes.
The binding affinities (pÆ;) of various ligands for the bovine ai„-AR were first 
assessed in standard membrane preparation assays versus prazosin (Table 2.1). 
This is the common method used to determine a rA R  affinity (Kenny et al, 1996).
All incubation times were a standard 30 minutes at room temperature (22°C) unless 
stated otherwise. Non-specific binding was determined in the presence o f 
phentolamine (10 pM)
Binding affinities for the non-subtype selective a,-A R  agonist phenylephiine were 
determined in the presence and absence o f the non-hydrolysable GTP analogue GTP- 
y-S (0.25mM). In the presence o f GTP-y-S, the curve was monophasie with one low 
affinity component (pK. = 5.6) and a Hill coefficient close to unity. In the absence of 
GTP-y-S, the curve was biphasic with a high (pKi = 7.9) and low (pK{ = 5.2) affinity 
component (Fig. 2.22). This biphasic behaviour is generally observed for agonist 
binding on isolated membranes in the absence o f GTP due to a complex two-stage 
binding process (Bockaert et al, 1997).
The specific a ,rA R  agonist (i?)-A-61603 displayed a higher affinity for the a,a-ARs 
compared with phenylephrine in the presence and absence o f GTP-y-S (0.25mM). In 
the presence of GTP-y-S, the curve was monophasie with one low affinity component 
(pT^ i = 6.85) and in the absence o f GTP-y-S, the curve was biphasic with a high {pK\ = 
10.26) and low {pKi = 6.82) affinity component (Fig. 2.23) consistent with (7?)-A- 
61603 being a high affinity agonist at a;,-A R binding sites.
The catecholamines noradrenaline and adrenaline displayed similar agonist profiles 
on membrane preparations (Fig. 2.24 & 2.25). For these two ligands, the incubation 
temperature was changed to 37°C in anticipation o f subsequent experiments on 
binding to whole cells. The experiments were performed in the absence o f GTP-y-S.
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Both showed similar low affinity components with adrenaline displaying a slightly 
higher affinity (pKj = 5.80) than noradrenaline (pK, = 5.05).
The subtype selective ai^-AR antagonist R S I00329 showed a high affinity by 
displacing specific [^HJprazosin binding to oCia-AR membranes with a pK[ value of 
9.63 (Fig. 2.5) and also displayed a small low affinity component (pKi = 8.16). The 
non-selective a-A R antagonist prazosin displayed a lower affinity to a,a-AR 
membranes than RS 100329 as shown previously (Fig. 2.3), with a pK\ value o f 8.57 
and a Hill coefficient close to unity. The fluorescent analogue o f prazosin, BODIPY- 
FL prazosin (QAPB), is a non-subtype selective competitive antagonist at a,-A R  
binding sites. As expected, QAPB displayed a similar antagonist profile to prazosin 
(Fig. 2.4) with a slightly lower affinity (pT i^ = 8.37) and a Hill coefficient of unity. 
The subtype selective aib-AR antagonist L-765314 displayed a lower affinity for ai„- 
AR membranes (Fig. 2.6) with a pATj value o f 6.29.
2.2.L2 Whole Cells.
The binding affinities for [^H]prazosin sites o f various agonist and antagonists were 
then assessed on whole-cell preparations (Table 2.2) harbouring the recombinant 
bovine a^-A R  as this is the modality in which visualisation of Ugand-ligand 
competition is assessed. A specific group o f binding experiments was also performed 
using the recombinant human a^-A R.
Similarly to the membrane experiments, binding affinities for phenylephrine were 
determined in the presence and absence o f GTP-y-S (0.25mM). In whole-cell 
preparations, curves should appear monophasie. As the high affinity binding state is 
not observed in the presence o f GTP, all receptors in whole cells containing natural 
levels o f GTP should be under the low affinity binding state. This was confirmed 
using phenylephrine (Fig. 2.26), which displayed a single low affinity component in 
the absence (pKi = 4.97) and presence (pifj = 4.88) o f the GTP analogue. A 
comparison o f phenylephrine membrane and whole-cell curves in the presence o f 
GTP-y-S is shown in Figure 2.27.
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In the absence o f GTP-y-S, (R)-A-61603 displayed a biphasic curve (Fig. 2.28) with a 
high (pÆi = 8.25) and low (pKi = 5.85) component. Interestingly, there was not a full 
displacement by (i?)-A-61603 and approximately 25% of binding sites were not 
displaced from. To increase the probability of maximum displacement, the 
experiment was repeated with a longer incubation period of 2  hours at room 
temperature (Fig. 2.28). This longer incubation resulted in a full displacement and 
curve showing high {pK\ = 6.82) and low (pK, = 5.63) components. Similarly to 
membrane experiments, these results showed (7?)-A~61603 to be a specific agonist at 
a  I a-AR. binding sites. As the previous results had hinted at a time-dependant 
displacement, the next set o f experiments using (7?)-A-61603 in the presence o f GTP- 
y-S were performed using various incubation times of 15, 30 and 120 minutes (Fig. 
2.29). Contrary to the expected monophasie curves, each curve for separate 
incubations displayed both high and low affinity components and in a manner similar 
to previous results, there were approximately 25% o f binding sites that had not been 
accessed.
Experiments using noradrenaline as the eompeting ligand were carried out for the 
standard incubation time o f 30 minutes, but the temperature was changed to 37*^0.
Our early hypothesis regarding cell penetration by catecholamines was that it 
occun'ed via the extraneuronal monoamine transporter (EMT) (Grundemann et al, 
1998). The EMT could deliver catecholamines to intracellular receptors. This 
transporter reportedly functions optimally at temperature 37°C. A eomparison of 
incubation temperatures (22°C and 37°C) was the focus o f an initial binding 
experiment using noradrenaline as the competing ligand (Fig. 2.30). Both curves 
were biphasic, displaying high and low affinity binding sites and pÆ; values o f similar 
value (Table 2.3). A comparison o f noradrenaline binding profiles in membranes and 
whole-cells at incubation temperature 37°C is shown in Figure 2.31. To test the 
hypothesis that noradrenaline and other ligands may penetrate the cells via the EMT, 
binding experiments were performed (Fig. 2.32) in the presence o f the Uptake] 
inhibitor corticosterone (1 pM ) (Iversen & Salt, 1970). The result was a high (pÆj = 
7.72) and low (pK, = 4.24) affinity component, but still almost a full displacement 
(Table 2.3). Although in the absence o f corticosterone, the results presented a two- 
site binding curve, the curve did not appear as biphasic as the curve in the presence of
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corticosterone. The initial high affinity component (25% o f binding sites) was 
followed by a small plateau phase before the low affinity component (75% of binding 
sites). This could suggest an initial displacement from cell membranes and the 
plateau phase may represent a difficulty o f the ligand to penetrate the cell. The low 
affinity phase would therefore represent the ability o f ligands to displace the 
radiolabel from intracellular binding sites. This suggested corticosterone had little, if 
any effect. However, the biphasic effect o f noradrenaline was particularly clear in the 
presence o f corticosterone, so this deserves further investigation (see discussion).
In pursuit o f the concept that the uptake o f the ligand into the cell may occur in a 
time-dependant mamier, the binding affinities for noradrenaline were determined by 
comparing an incubation time of 15 minutes with a 30-minute period (Fig. 2.33).
This showed that a greater displacement occurred following the 30-minute ineubation. 
The 30-minute incubation produced higher affinity values (pKj = 6.71 & 4.42) than 
those observed with a 15-minute incubation (pA7, = 5.81 & 3.94) (Table 2.3).
Adrenaline displayed a low affinity by displacing specific [^HJprazosin binding to ai^- 
AR whole cells with a pÆ, value o f 4.96 (Fig. 2.34 & Table 2.2). Interestingly, 
adrenaline produced a monophasie, one-site cuiwe and a lower affinity value 
compared with noradrenaline. RS 100329 again demonstrated a high affinity to aia- 
AR whole cells with a pK\ value of 10.99 and also a low affinity value o f 7.35 (Fig.
2.8 & Table 2.2). Similar to the phenomenon observed with the noradrenaline 
experiment in the presence of corticosterone, RSI 00329 high affinity component 
(approx. 2 0 % of binding sites) was followed by a slow sustained plateau phase before 
the low affinity component (approx. 80% o f binding sites), which again raised the 
possibility of a difficulty o f cellular penetration.
Prazosin and QAPB were expected to display a similar binding profile for the 
displacement of [^H]prazosin, but prazosin displayed a one-site affinity with a pK{ 
value o f 8.72 (Fig. 2.7 & Table 2.2). The curve shows that prazosin has a similar 
profile in cells and in membrane preparations. This suggests that prazosin itself has no 
apparent difficulty penetrating the cell. QAPB is a light-sensitive compound and 
therefore a series o f experiments were carried out under light and dark conditions to
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test the effect o f light on QAPB binding (Fig. 2.9). The binding affinity was almost 
identical under both circumstances, but a higher affinity value was observed under 
normal light conditions (p^i = 9.94) than in darkness (pÆ; = 9.26). Subsequent 
experiments with QAPB would be carried out under normal light conditions. A 
comparison o f QAPB membrane and whole-cell curves under light conditions is 
shown in Figure 2.10. QAPB continued the trend o f a high affinity component 
preceding a slow sustained plateau and low affinity component. A difficulty in 
cellular penetration for QAPB and not for prazosin could be caused by the size or 
chemical properties o f the fluorescent component o f the compound. The antagonist 
L-765314 also displayed a high (pK\ = 7.27) and low affinity component (pÆ, = 4.72) 
separated by a plateau phase (Fig. 2.11 & Table 2.2). There was not full 
displacement, although the curve shows there would have been full displacement at 
higher concentrations o f the antagonist. L-765314 had a much lower affinity than the 
other antagonists to otnrAR whole cells consistent with its specificity for aib-ARs 
(Patane et al, 1998).
The binding affinities for prazosin sites o f the subtype selective a^-A R  
antagonist BMY7378 were then assessed on membrane and whole-cell preparations 
harbouring the recombinant bovine a^-A R  and also the recombinant human a^-A R  
(Fig. 2.12). BMY7378 displayed a lower affinity than prazosin, QAPB and 
R S I00329 at bovine ai„-AR whole cells with a pK[ value o f 6.36, but produced 
subnanomolar affinity (pi^i = 9.48) for the displacement o f prazosin at human a,d- 
AR whole cells (Table 2.4).
2.2.2 New Radioligand Binding Protocol 1.
A new series of protocols for competitive RLB experiments were devised that were 
slightly different from the ‘classical’ binding approach used for earlier experiments in 
the thesis. These earlier experiments allow competition between a test compound and 
[^H]prazosin in which the test compound is given a few minutes before [^H]prazosin 
and a period o f 30 minutes is then allowed for equilibrium to be established. This 
assumes that there is equal access o f test compound and [^H]prazosin and that the two
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compounds and the receptor come to equilibrium, with the extra few minutes for the 
test compound conferring no advantage. However, in whole cell experiments these 
conditions may not apply. Some receptors may be less accessible than others e.g. 
intracellular cf. cell surface and some ligands may penetrate cells more easily than 
others. Receptor location or other cell characteristics may be modified by the ligands. 
For those reasons, the timing and order o f addition o f competitive ligands may 
influence the final ‘equilibrium’. Furthermore, in our experiments to visualise 
fluorescence binding and verify its properties with competing ligands, the compounds 
are given sequentially to allow comparison with and without a competitor. A new 
displacement protocol was therefore devised that would recreate a more ‘real’ context 
o f visualisation experiments than in standard ligand-ligand competition. All non­
specific binding was still determined in the presence o f phentolamine (10 p.M).
Essentially cells are equilibrated with [^Hjprazosin and then competitors are added for 
a further period. This means that competitors must displace [^H]prazosin from its pre­
equilibrated location(s). The first set o f new experiments was performed with 
noradrenaline as the displacing ligand on bovine a^-A R  whole cells. The cells and 
[^H]prazosin were incubated together at room temperature (22°C) for varying time 
periods o f 15, 30 and 60 minutes before noradrenaline was added at a range of 
concentrations and left to incubate at 37°C for a fixed time period of 60 minutes 
before reaction termination. The hypothesis was that 60 minutes would provide 
sufficient time for [^HJprazosin equilibrium binding to whole cells as opposed to 15 
or 30 minutes (Fig. 2.35). There was a greater displacement by noradrenaline after 
cells have been left to incubate with the radiolabel for 60 minutes. The three time 
courses provided results with high and low affinity components and similar binding 
affinities (Table 2.5). A comparison of noradrenaline binding curves using the 
‘classical’ and new RLB approaches are shown in Figure 2.36. When prazosin 
binding was pre-established (new protocol), noradrenaline was less effective at 
displacing it.
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2.2.3 New Radioligand Binding Protocol 2.
After devising a new RLB displacement protocol as previously explained, this 
protocol was expanded to provide a more consistent comparison with visualisation 
studies. Previous imaging experiments demonstrated that 60 minutes was sufficient 
time for prazosin binding to reach equilibrium to bovine aia-AR whole cells both 
on cell surface and at intracellular binding sites. All subsequent experiments would 
now have a time course o f 60 minutes at room temperature for the radiolabel to 
equilibrate with the cells before the displacing ligand was added.
As R S I00329 had displayed a pronounced two-site biphasic response using the 
‘classical’ RLB protocol, it was the subject o f the first experiment using the updated 
displacement protocol. After a 60-minute equilibration between cells and radiolabel, 
R S I00329 was applied for 30 minutes at a temperature o f 22°C or 37°C. This was a 
test to determine if the incubation temperature had a direct effect on the ability o f the 
ligand to displace the radiolabel. Altering the temperature had no effect on the total 
amount o f  ^ H-prazosin bound. Figure 2.13 shows that altering the temperature had 
very little effect on the ability o f RSI 00329 to displace radiolabel. Subsequent 
experiments would be performed at 37°C as there was a marginally greater 
displacement at this temperature and since it was considered that any transport 
processes that might be involved would be more likely to be active at this 
temperature. Both curves were monophasic with a low affinity component (Table 
2.6). The same experiment was repeated using QAPB as the competing ligand (Fig. 
2.14 & Table 2.6). Similar to R S100329, there was a greater displacement at 37°C at 
the biphasic concentrations o f ligand. Both curves were biphasic with a very high 
affinity site followed by a sustained plateau phase until lO'^M QAPB where a low 
affinity component was observed, reinforcing the concept that QAPB has difficulty 
penetrating the cells.
As equilibration between cells and radiolabel and incubation temperature for 
maximum displacement had been resolved, the next series of experiments was to 
determine if  the displacement was time-dependant once the displacing ligand had 
been added.
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The new protocol was first performed on bovine ain-AR membranes, as the 
differences in incubation times should have made no difference to the displacement 
from the cell surface. Following incubation with adrenaline for 15, 30 and 60 minutes 
at 37°C, the three curves were almost superimposed and displayed similar one-site 
binding affinities (Fig. 2.37 & Table 2.7a). The same experiments were performed, 
but this time on bovine ai^-AR whole cells. There was a greater displacement at 30 
minutes than after 15 minutes and a greater displacement than both these times after 
60 minutes (Fig. 2.38). The displacement curves were biphasic with both high and 
low affinity p7f, values (Table 2.7a). This indicated a time-dependant implement to 
displacement o f [^Hjprazosin by adrenaline.
To test the hypothesis that ligands may be entering cells and accessing intracellular 
binding sites via an EMT, a series o f experiments was performed using the new 
displacement protocol in the presence o f 1 |iM  corticosterone. In the first set o f 
experiments, corticosterone was present only after pre-equilibrium with [^H]prazosin 
(Fig. 2.39). This would show if  the corticosterone had a direct single effect on the 
ability o f adrenaline to penetrate the cells. Adrenaline was used rather than 
noradrenaline, as the former is believed to be a better substrate for the EMT 
(Grundemann et al, 1998). Both 15 and 30-minute incubation curves were 
monophasic with similar binding affinity values (Table 2.8), but the 60-minute 
incubation displacement curve showed both high and low affinity components, 
suggesting that corticosterone may have a small effect after a certain period of time, 
but there was still a near maximum displacement. To determine if  corticosterone had 
any effect on the uptake of [^HJprazosin into cells, the experiment was repeated where 
the whole experiment was carried out in the presence of corticosterone (Fig. 2.40).
All displacement curves were monophasic, demonstrating a near maximum 
displacement and similar pÆ, binding values (Table 2.8). This confirmed that 
corticosterone had no effect on the ability o f adrenaline to displace from intracellular 
binding sites. Data also showed that ^Fl-prazosin uptake was not reduced by 
corticosterone.
A second hypothesised mechanism by which ligands might penetrate cells is via an 
endocytotic pathway. This was tested using an endocytotic blocker concanavalin A.
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In a series o f experiments similar to the first set performed with corticosterone, the 
equilibrium between cells and [^Hjprazosin was established in the absence of 
concanavalin A, Con A (0.25 mg/ml) was added at the same time as adrenaline and 
left for 30 minutes at 37°C to determine whether endocytosis was directly responsible 
for adrenaline uptake into the cell (Fig. 2.41). To determine if  concanavalin A had 
any effect on the uptake o f [^HJprazosin into cells, the experiment was repeated where 
the whole experiment was caiTied out in the presence of concanavalin A (Fig. 2.41). 
Both sets o f experiments produced biphasic displacement curves with high and low 
affinity pK[ values (Table 2.9) and a near maximum displacement. This confirmed 
that concanavalin A was having little or no effect. The same experiment was 
performed with QAPB as the displacing ligand. The whole experiment was 
performed in the presence of concanavalin A. The binding curve was monophasic 
with a pK\ value o f 7.71 (Table 2.12). Surprisingly, there was a full displacement by 
QAPB (Fig. 2.17). There appears to be difficulty o f  cellular penetration until lO'^M 
QAPB when there was a pronounced fall in the binding curve. Using GraphPad 
Prism statistical analysis, an F test showed the binding curve changed from biphasic 
in the absence of concanavalin A to monopahsic in the presence o f concanavalin A.
In the absence of concanavalin A, the F ratio was 12.98 and had a p value o f 0.0002.
In the presence o f cocanavalin A, the F ratio was 0.43 and had a p value o f 0.66.
Using the F-test (as described in the data analysis section), a two-site model is only 
accepted when the F ratio is much greater than 1 and produces a p value o f <0.05.
This suggests that concanavalin A may be exerting an inhibiting effect that can be 
overcome once a certain concentration o f QAPB is applied. Comparing the amount of 
radiolabel bound for both protocols, there is more ^Fl-prazosin bound when half the 
experiment is performed in the presence o f concanavalin A, as opposed to the whole 
experiment in concanavalin A. This would be expected, as it shows that concanavalin 
A is exerting a small inhibiting effect on the uptake o f  ^ H-prazosin.
An identical series o f experiments to those using adrenaline (Figs. 2.37 & 2.38) was 
performed on bovine ai^-AR membranes and whole cells using noradrenaline as the 
displacing ligand. As with adrenaline, the noradrenaline displacement curves were 
monophasic and superimposed on top o f each other in membrane preparations (Fig. 
2.42 & Table 2.7a). In whole cells, the curves displayed both high and low affinity
59
components (Fig. 2.43 & Table 2.7a). There was a greater displacement at 30 minutes 
than after 15 minutes and a greater displacement than both these times after 60 
minutes. A similar protocol was followed with a series of other displacing ligands on 
whole cells. Phenylephrine displayed an unusual set o f results in that a 15-minute 
incubation provided the greatest displacement. The most clearly biphasic curve was 
observed after 30 minutes (Fig. 2.44 & Table 2.7b). A biphasic displacement curve 
was also observed with (i?)-A-61603 (Fig. 2.45). The phenomenon o f approximately 
20-25% of binding sites being inaccessible to (i?)-A-61603 was similar to that found 
with previous experiments (Fig. 2.28). Inspection of the curve shows that a maximum 
displacement might have been achieved given higher concentrations o f the agonist. 
After a 30-minute displacement period, (7?)-A-61603 again displayed a high affinity 
for the aii,-AR (Table 2.7b). Both phenylephrine and (i?)-A-61603 had displayed a 
difficulty in penetrating the cell. The earlier trend continued where the initial high 
affinity component may represent a displacement from the cell surface and the plateau 
phase represents a difficulty o f the ligand to penetrate the cell.
Prazosin was used as the displacing ligand using the new displacement protocol on 
both bovine a,a-AR membranes and whole cells (Fig. 2.15). After 30 minutes 
displacement, prazosin had penetrated the cell and displayed a monophasic binding 
curve and pJ i^ value o f 7.18 (Table 2.7a). Both L-765314 (Fig. 2.20) and BMY7378 
(Fig. 2.21) displayed a much lower affinity at aia-ARs compared with the other 
antagonists as expected, but after 30-minute displacement periods, both the 
antagonists showed single site components (Table 2.7b) with Hill coefficients close to 
unity. This demonstrated that both these antagonists had an apparent ease in 
penetrating the cell. BMY7378 did show a slightly higher affinity (p/fi = 6.39) than 
L-765314 (pÆi = 5.48).
The next set o f experiments involved altering the incubation time between the a,a-AR 
cells and [^H]prazosin. Figure 2.16 shows two sets o f experiments where one 
protocol had the cells incubating with the radiolabel at room temperature for 60 
minutes and the other for 90 minutes. QAPB was the displacing ligand and was left 
for 60 minutes at room temperature before terminating the reaction. The curve with a 
first incubation time o f 60 minutes was more monophasic with a pÆ, of 6.63 (Table
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2.10) and there was not a full displacement with approximately 30% o f binding sites 
unaccounted for. The curve with a first incubation time o f 90 minutes was clearly 
biphasic with high (pÆj = 11.01) and low (pÆ| = 7.54) affinity components.
2.2.4 New Radioligand Binding Protocol 3.
The updated radioligand binding protocol was further expanded to determine the 
effect cold temperature had on displacement from whole cells and membranes. The 
ain-AR cells or membranes were pre-incubated with [^H]prazosin for one hour at 
room temperature. The displacing ligand was then added for 15 or 60 minutes at 4°C. 
If displacing ligands do penetrate cells and access intracellular compartments by 
endocytosis, they should fail to penetrate cells at 4°C as a result o f the endocytotic 
mechanism being halted by cold temperatures. In whole cells preparations, 
noradrenaline (Fig. 2.46) and QAPB (Fig. 2.18) displayed similar curves, with only 
approximately 25% of all sites displaced. There is a marginally greater displacement 
after 60 minutes using noradrenaline. This would suggest that the 25% of displaced 
sites might represent cell surface receptors. However, a full displacement by 
noradrenaline (Fig. 2.47) and QAPB (Fig. 2.19) was not observed in membranes. 
Following addition o f displacing ligand, an incubation time of 15 minutes (Fig. 2.19) 
or 60 minutes (Fig. 2.47) caused only an approximate 15% displacement. QAPB 
displayed a higher affinity at a,a“AR whole cells and membranes than noradrenaline 
(Table 2.11).
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Figure 2.3 Displacement of 0.2 nM prazosin binding to bovine a^ -A R  
membranes by increasing concentrations of prazosin. Non-specific binding was 
determined in the presence o f 10 |iM  phentoiamine. Values are the mean (± S.E.) of 
four experiments performed in duplicate.
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Figure 2.4 Displacement o f 0.2 nM prazosin binding to bovine aia-AR 
membranes by increasing coneentrations o f QAPB. Non-specific binding was 
determined in the presence of 10 p.M phentoiamine. Values are the mean (± S.E.) of 
four experiments performed in duplicate.
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Figure 2.5 Displacement o f 0.2 nM [^H]prazosin binding to bovine a^-AR  
membranes by increasing concentrations o f RS 100329. Non-specific binding was 
determined in the presence o f 10 pM phentoiamine. Values are the mean (± S.E.) of 
five experiments performed in duplicate.
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Figure 2.6 Displacement of 0.2 iiM [^Hjprazosin binding to bovine a^-AR  
membranes by increasing concentrations of L-765314. Non-specific binding was 
determined in the presence of 10 pM phentoiamine. Values are the mean (± S.E.) of 
four experiments performed in duplicate.
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Figure 2.7 Displacement o f 0.2 nM [ Hjprazosin binding to bovine a^ -A R  (1 )  
whole cells and (K) membranes by increasing concentrations o f prazosin. Non­
specific binding was determined in the presence o f 10 p,M phentoiamine. Values are 
the mean (± S.E.) o f (S ) four and (0 ) four experiments performed in duplicate.
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Figure 2.8 Displacement o f 0.2 nM [^Hjprazosin binding to bovine aia-AR (1 ) 
whole cells and (A) membranes by increasing concentrations o f RSÎ00329. Non­
specific binding was determined in the presence o f 10 pM  phentoiamine. Values are 
the mean (± S.E.) o f ( i )  four and (S) five experiments performed in duplicate.
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Figure 2.9 Displacement o f 0.2 nM [^Hjprazosin binding to bovine aia-AR whole 
cells by increasing concentrations o f QAPB in ( i )  light surroundings and (□) dark 
surroundings. Non-specific binding was determined in the presence of 10 jiM 
phentoiamine. Values are the mean (± S.E.) o f (■) four and (Cl) four experiments 
performed in duplicate.
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Figure 2.10 Displacement o f 0.2 nM prazosin binding to bovine aia~AR (H) 
whole cells and ( H )  membranes by increasing concentrations o f QAPB. Non-specific 
binding was determined in the presence o f 10 |iM  phentoiamine. Values are the mean 
(± S.E.) of (1 )  four and (k>J) four experiments performed in duplicate.
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Figure 2.11 Displacement o f 0.2 nM [^Hjprazosin binding to bovine aia-AR 
whole ceils and (@) membranes by increasing concentrations of L-765314. Non­
specific binding was determined in the presence o f 10 [iM phentoiamine. Values are 
the mean (± S.E.) o f ( Î )  five and (k%) four experiments performed in duplicate.
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Figure 2.12 Displacement of 0.2 nM [ Hjprazosin binding to bovine aia-AR 
whole cells, (S ) membranes and to human ajd-AR (□ ) whole cells and (W) 
membranes by increasing concentrations o f BMY7378. Non-specific binding was 
determined in the presence of 10 jiM phentoiamine. Values are the mean (± S.E.) o f 
( i )  four, (A) four, (□ ) four and (A) six experiments performed in duplicate.
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Figure 2.13 Comparison o f radioligand binding protocols using RSI 00329 as the 
competing/displacing ligand. Displacement o f 0.2 nM [^Hjprazosin binding to bovine 
aia~AR whole cells by increasing concentrations o f RSI 00329 using an updated 
radioligand binding protocol. Both second incubations were 30 minutes at a 
temperature of (H) 37°C and ( IS)  22°C. Also shown is the displacement o f 0.2 nM 
[^Hjprazosin binding to bovine au -A R  (S ) whole cells and ( I q I )  membranes by 
increasing concentrations o f RSI 00329 using the standard radioligand binding 
protocol. Non-specific binding was determined in the presence o f 10 ]xM 
phentoiamine. Values are the mean (± S.E.) o f (1 ) three, (A) three, (®) four and (ia) 
five experiments performed in duplicate.
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Figure 2.14 Comparison o f radioligand binding protocols using QAPB as the 
competing/displacing ligand. Displacement o f 0.2 nM [^Hjprazosin binding to bovine 
aia-AR whole cells by increasing concentrations o f QAPB using an updated 
radioligand binding protocol. Both second incubations were 30 minutes at a 
temperature of ( i )  37°C and (1ZÜ) 22°C. Also shown is the displacement of 0.2 nM 
[^Hjprazosin binding to bovine aia-AR (0 )  whole cells and (W) membranes by 
increasing concentrations o f QAPB using the standard radioligand binding protocol. 
Non-specific binding was determined in the presence of 10 pM  phentoiamine. Values 
are the mean (± S.E.) o f (■) four, (A) four, (0 )  four and (id) four experiments 
performed in duplicate.
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Figure 2.15 Comparison o f radioligand binding protocols using prazosin as the 
competing/displacing ligand. Displacement o f 0.2 nM [^Hjprazosin binding to bovine 
aia-AR whole cells by increasing concentrations o f prazosin using an ( 1 ) updated 
and ( 0 ) standard radioligand binding protocol and in membranes using an ( 1) 
updated and (o )  standard radioligand binding pro tocol. Both second incubations 
were 30 minutes at a temperature o f 37°C for the updated protocol. Non-specific 
binding was determined in the presence o f 10 |lM  phentoiamine. Values are the mean 
(± S.E.) of (■ ) four, (ii) two, ( 0 ) four and (d ) four experiments performed in 
duplicate.
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Figure 2.16 Displacement o f 0.2 nM [^H]prazosin binding to bovine aia-AR whole 
cells by increasing concentrations of QAPB using an updated radioligand binding 
protocol. First incubation time was (■) 60 and (A) 90 minutes at a temperatuie of 
22°C. Second incubation time was 60 minutes at a temperature o f 22°C. Non-specific 
binding was determined in the presence o f 10 jiiM phentoiamine. Values are the mean 
(± S.E.) o f (H) four and (A) two experiments performed in duplicate.
75
O )c
’tdc
ÛÛ
o 
"o
0 )o.
c o
125n
100 -
75-
50-
25-
-14 -13 -12 -11 -10 -9 -8
log [QAPB] (M)
-7 -6 -5
Figure 2.17 Displacement o f 0.2 nM [^Hjprazosin binding to bovine «la-AR whole 
cells by increasing concentrations o f QAPB using an updated radioligand binding 
protocol in the ( • )  presence and ( ! )  absence o f 0.25mg/ml concanavalin A. Second 
incubation time was 60 minutes at a temperature o f 22°C. Non-specific binding was 
determined in the presence o f 10 pM phentoiamine. Values are the mean (± S.E.) of 
four ( • )  and (■ ) four experiments performed in duplicate.
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Figure 2.18 Effect o f cold temperature on displacement o f 0.2 nM [^Hjprazosin 
binding to bovine aia-AR whole cells by increasing concentrations of QAPB using an 
updated radioligand binding protocol. Second incubation time was (1 )  15 and (*) 60 
minutes at a temperature o f 4°C. Non-specific binding was determined in the 
presence o f 10 |iM  phentoiamine. Values are the mean (± S.E.) o f (S ) four and (@) 
four experiments performed in duplicate.
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Figure 2.19 Effect o f cold temperature on displacement o f 0.2 nM [ Hjprazosin 
binding to bovine aia-AR membranes by increasing concentrations o f QAPB using an 
updated radioligand binding protocol. Second incubation time was 15 minutes at a 
temperature o f 4°C. Non-specific binding was determined in the presence of 10 |.iM 
phentoiamine. Values are the mean (± S.E.) of two experiments performed in 
duplicate.
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Figure 2.20 Displacement o f 0.2 nM [^Hjprazosin binding to bovine aia-AR whole 
cells by increasing concentrations o f L-765314 using a ( 0 ) standard and (1) updated 
radioligand binding protocol. Membrane data is also shown ( I d )  for standard binding 
protocol. Second incubation time was 30 minutes at a temperature o f 37°C for 
updated protocol. Non-specific binding was determined in the presence o f 10 p.M 
phentoiamine. Values are the mean (± S.E.) of (1) five, (S ) five and ('oi) four 
experiments performed in duplicate.
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Figure 2.21 Displacement o f 0.2 nM prazosin binding to bovine a^ -A R  whole 
cells by increasing concentrations o f BMY7378 using a (0 )  standard and (■ ) updated 
radioligand binding protocol. Membrane data is also shown (d )  for standard binding 
protocol. Second incubation time was 30 minutes at a temperature of 37°C for 
updated protocol. Non-specific binding was determined in the presence o f 10 pM 
phentolamine. Values are the mean (± S.E.) o f (S ) four, (0 )  four and ( 1^ ) four 
experiments performed in duplicate.
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Figure 2.22 Displacement of 0.2 nM [^Hjprazosin binding to bovine aia-AR 
membranes by increasing concentrations o f phenylephrine in the (iffi) presence o f and 
(n ) absence o f 0.25 mM GTP-y-S. Non-specific binding was determined in the 
presence o f 10 |iM  phentolamine. Values are the mean (± S.E.) o f (Ü) six 
experiments and (D) three experiments performed in duplicate.
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Figure 2.23 Displacement o f 0.2 nM prazosin binding to bovine aia-AR 
membranes by increasing concentrations o f A61603 in the (Z) presence o f and (In) 
absence o f  0,25 mM GTP-y-S. Non-specific binding was determined in the presence 
o f 10 pM phentolamine. Values are the mean (± S.E.) o f (ffl) two experiments and 
(□) thi’ee experiments performed in duplicate.
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Figure 2.24 Displacement o f 0.2 nM [^H]prazosin binding to bovine a^-A R  
membranes by increasing concentrations o f noradrenaline. Incubation temperature 
was 37°C. Non-specific binding was determined in the presence of 10 |iM 
phentolamine. Values are the mean (± S.E.) of four experiments performed in 
duplicate.
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Figure 2.25 Displacement o f 0.2 nM [^Hjprazosin binding to bovine aia-AR
membranes by increasing concentrations of adrenaline. Non-specific binding was 
determined in the presence o f 10 |aM phentolamine. Values are the mean (± S.E.) o f 
three experiments performed in duplicate.
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Figure 2.26 Displacement o f 0.2 nM [^HJprazosin binding to bovine aia-AR whole 
cells by increasing concentrations o f phenylephrine in the (A) presence of and ( i )  
absence o f 0.25 mM GTP-y-S. Non-specific binding was determined in the presence 
o f 10 jiiM phentolamine. Values are the mean (± S.E.) of (&) thi'ee and (1 ) thi*ee 
experiments performed in duplicate.
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Figure 2.27 Displacement o f 0.2 iiM prazosin binding to bovine aia-AR 
whole cells and (®) membranes by increasing concentrations of phenylephrine in the 
presence o f 0.25 mM GTP-y-S. Non-specific binding was determined in the presence 
o f 10 p,M phentolamine. Values are the mean (± S.E.) of (1:1) three and (QB) six 
experiments performed in duplicate.
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Figure 2.28 Displacement o f 0.2 iiM H]prazosin binding to bovine aia-AR whole 
cells by increasing concentrations o f A61603. Incubation times are (1 )  30 and (U) 
120 minutes.. Non-specific binding was determined in the presence o f 10 fxM 
phentolamine. Values are the mean (± S.E.) of (®) four and (A) two experiments 
performed in duplicate.
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Figure 2.29 Displacement o f 0.2 nM [ H]prazosin binding to bovine au-AR whole 
cells by increasing concentrations o f A61603 in the presence o f 0.25 mM GTP-y-S. 
Incubation times are (1 ) 15 minutes, (■ ) 30 minutes and (®) 120 minutes. Non­
specific binding was determined in the presence o f 10 |iM phentolamine. Values are 
for one single experiment performed in duplicate.
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Figure 2.30 Effect o f temperature on displacement of 0.2 nM prazosin binding to 
bovine aia-AR whole cells by increasing concentrations o f noradrenaline. Incubation 
temperatures were (1 ) 22“C and (l^ S) 37°C. Non-specific binding was determined in 
the presence of 10 |0,M phentolamine. Values are the mean (± S.E.) of ( i )  four and 
( a )  four experiments perfomied in duplicate.
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Figure 2.31 Displacement o f 0.2 nM [^H]prazosin binding to bovine aia-AR (TJ) 
whole cells and (ffl) membranes by increasing concentrations o f noradrenaline. Both 
incubation temperatures were 37“C. Non-specific binding was determined in the 
presence o f 10 p,M phentolamine. Values are the mean (± S.E.) o f ( 0 ) four and (Kl) 
four experiments performed in duplicate.
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Figure 2.32 Displacement o f 0.2 nM [^Hjprazosin binding to bovine au -A R  whole 
cells by increasing concentrations o f noradrenaline in the ( 0 ) absence and ( i 4 )  
presence o f IjiM  corticosterone. Incubation temperature for both sets o f experiments 
was 37°C. Non-specific binding was determined in the presence o f 10 [XM 
phentolamine. Values are the mean (± S.E.) o f (1 )  four and (A) four experiments 
performed in duplicate.
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Figure 2.33 Effect o f incubation time on displacement of 0.2 nM [^Hjprazosin 
binding to bovine aia-AR ’whole cells by increasing concentrations o f noradrenaline. 
Incubation times were (®) 30 minutes and ( ^ )  15 minutes. Incubation temperature 
for both sets o f experiments was 37®C. Non-specific binding was determined in the 
presence o f 10 pM  phentolamine. Values are the mean (± S.E.) o f (B) four and (iôl) 
four experiments performed in duplicate.
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Figure 2.34 Displacement o f 0.2 nM H]prazosin binding to bovine aia~AR (1 )  
whole cells and (kS) membranes by increasing concentrations o f adrenaline. Both 
incubation temperatures were 37“C. Non-specific binding was determined in the 
presence o f 10 ]LlM phentolamine. Values are the mean (± S.E.) of (1 )  four and (lâ) 
two experiments performed in duplicate.
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Figure 2.35 Displacement o f 0.2 nM [^H]prazosin binding to bovine a^-AR whole 
cells by increasing concentrations o f noradrenaline for 60 minutes at 22°C. First 
incubation times ([^HJprazosin alone) were (ü ) 15 minutes, (■) 30 minutes and (V) 
60 minutes at 22°C. Non-specific binding was determined in the presence o f 10 p.M 
phentolamine. Values are the mean (± S.E.) o f { At) four, (■) four and (1 )  four 
experiments performed in duplicate.
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Figure 2.36 Displacement o f 0.2 nM [^H]prazosin binding to bovine aia-AR whole 
ceils by increasing concentrations o f noradrenaline using a (fâ) new radioligand 
binding protocol and (B) standard radioligand binding protocol. Both incubations 
were 30 minutes at a temperature o f 37°C. Non-specific binding was determined in 
the presenee o f 10 fxM phentolamine. Values are the mean (± S.E.) o f (j^) four and 
(■ ) four experiments performed in duplicate.
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Figure 2.37 Displacement o f 0.2 nM [^H]prazosin binding to bovine aia-AR 
membranes by increasing concentrations o f adrenaline using an updated radioligand 
binding protocol. Second incubation times were (4) 15, (■) 30 and (M )60 minutes at 
a temperature o f 37°C. Non-specific binding was determined in the presence o f 10 
pM phentolamine. Values are the mean (± S.E.) o f (4) two, (■ ) four and (IT) four 
experiments performed in duplicate.
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Figure 2.38 Comparison o f radioligand binding protocols using adrenaline as the 
competing/displacing ligand. Displacement o f 0.2 nM [^H]prazosin binding to bovine 
ttia-AR whole cells by increasing concentrations o f adrenaline using an updated 
radioligand binding protocol. Second incubation times were (A) 15, (0)30 and (If!) 
60 minutes at a temperature o f 37°C. Also shown is the displacement o f 0.2 nM 
[^HJprazosin binding to bovine aia-AR (S ) whole cells and (d ) membranes by 
increasing concentrations o f adrenaline using a standard binding protocol. Non­
specific binding was determined in the presence o f 10 pM phentolamine. Values are 
the mean (± S.E.) o f (1 ) four, (■ ) six, ( f  ) four, (@) four and (d ) two experiments 
performed in duplicate.
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Figure 2.39 Effect o f corticosterone on displacement of 0.2 nM [^H]prazosin binding 
to bovine aia-AR whole cells by increasing concentrations o f adrenaline using an 
updated radioligand binding protocol. Second incubation times were (â ) 15, ( ! )  30 
and (Rl) 60 minutes at a temperature o f 37°C in the presence o f 1 p.M corticosterone. 
Non-specific binding was determined in the presence o f 10 pM phentolamine. Values 
are the mean (± S.E.) o f (A) four, (1 )  four and (W) three experiments performed in 
duplicate.
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Figure 2.40 Comparison o f the absence and presence o f corticosterone on the 
displacement o f 0.2 nM [^H]prazosin binding to bovine aia-AR whole cells by 
increasing concentrations o f adrenaline using an updated radioligand binding 
protocol. Second incubation times were ( i  ) 15, (■ ) 30 and (f!) 60 minutes at a 
temperature o f 37”C. The whole experiment performed in the presence o f 1 |liM 
corticosterone. Also shown are the control experiments in the absence o f 
corticosterone. Second incubations were (A) 15, (□ ) 30 and (V) 60 minutes at 37°C. 
Non-specific binding was determined in the presence o f 10 jiM phentolamine. Values 
are the mean (± S.E.) o f {A) two, (■ ) two, (®) two, (A) four, (□ ) six and (V) four 
experiments performed in duplicate.
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Figure 2.41 Effect o f concanavalin A on displacement o f 0.2 nM H]prazosin 
binding to bovine aia-AR whole cells by increasing concentrations o f adrenaline 
using an updated radioligand binding protocol. (■ ) Half and ( A )  whole experiment 
performed in presence o f 0.25mg/ml concanavalin A. Also shown is the (W) control 
experiment in the absence o f concanavalin A. Second incubation times were 30 
minutes at a temperature o f 37°C. Non-specific binding was determined in the 
presence o f 10 pM phentolamine. Values are the mean (± S.E.) o f (■ ) two, (i) two 
and (®) six experiments performed in duplicate.
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Figure 2.42 Displacement o f 0.2 nM [^H]prazosin binding to bovine «la-AR 
membranes by increasing concentrations o f noradrenaline using an updated 
radioligand binding protocol. Second incubation times were (à) 15, ( 0 ) 30  and (fi) 
60 minutes at a temperature o f 37°C. Non-specific binding was determined in the 
presence o f 10 |iM  phentolamine. Values are the mean (± S.E.) o f (là) four, ( i )  four 
and (If) four experiments performed in duplicate.
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Figure 2.43 Comparison o f radioligand binding protocols using noradrenaline as the 
competing/displacing ligand. Displacement o f 0.2 nM [^HJprazosin binding to bovine 
aia-AR whole cells by increasing concentrations of noradrenaline using an updated 
radioligand binding protocol. Second incubation times were (à )  15, (■ ) 30 and (!^) 
60 minutes at a temperature o f 37°C. Also shown is the displacement o f 0.2 nM 
[^HJprazosin binding to bovine au -A R  (S ) whole cells and (id) membranes by 
increasing concentrations o f noradrenaline using a standard binding protocol. Non­
specific binding was determined in the presence o f 10 pM phentolamine. Values are 
the mean (± S.E.) o f (ii) four, ( 1 ) four, (fl) four, (0 )  four and (loi) four experiments 
performed in duplicate.
102
o
O )c
?  E
ilQ .
e n
125-,
100 -
75-
50-
25-
11 -10 -9 8 7 6 5 4 3 2
log [Phenylephrine] (M)
Figure 2.44 Comparison o f radioligand binding protocols using phenylephrine as the 
competing/displacing ligand. Displacement o f 0.2 nM [^H]prazosin binding to bovine 
aia-AR whole cells by increasing concentrations o f phenylephrine using an updated 
radioligand binding protocol. Second incubation times were (1.) 15, (■ ) 30 and (f ) 
60 minutes at a temperature o f 37°C. Also shown is the displacement o f 0.2 nM 
[^HJprazosin binding to bovine aia-AR (0 )  whole cells and (f4) membranes by 
increasing concentrations o f phenylephrine using a standard binding protocol. Non­
specific binding was determined in the presence o f 10 fiM phentolamine. Values are 
the mean (± S.E.) of (4) four, (■ ) four, (!1) four, (S ) three and (IP) six experiments 
performed in duplicate.
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Figure 2.45 Comparison o f radioligand binding protocols using A61603 as the 
competing/displacing ligand. Displacement o f 0.2 nM prazosin binding to bovine 
aia-AR ( 1 ) whole cells by increasing concentrations o f A61603 using an updated 
radioligand binding protocol. Second incubation time was 30 minutes at a 
temperature o f 37°C. Also shown Is the displacement of 0.2 nM [^HJprazosin binding 
to bovine aia-AR (@) whole cells and (!oj) membranes by increasing concentrations 
o f A61603 using a standard binding protocol. Non-specific binding was determined 
in the presence of 10 p.M phentolamine. Values are the mean (± S.E.) o f ( i )  four,
(@) four and (@) three experiments performed in duplicate.
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Figure 2.46 Effect o f cold temperature on displacement o f 0.2 nM [^H]prazosin 
binding to bovine aia-AR whole cells by increasing concentrations o f noradrenaline 
using an updated radioligand binding protocol. Second incubation time was (1 )1 5  
and (f!) 60 minutes at a temperature o f 4°C. Non-specific binding was determined in 
the presence o f 10 p.M phentolamine. Values are the mean (± S.E.) o f ( 1 ) four and 
(!▼!) four experiments performed in duplicate.
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Figure 2.47 Effect of cold temperature on displacement o f 0.2 nM prazosin 
binding to bovine aia-AR membranes by increasing concentrations o f noradrenaline 
using an updated radioligand binding protocol. Second incubation time was 60 
minutes at a temperature of 4°C. Non-specific binding was deteitnined in the 
presence o f 10 jiM phentolamine. Values are the mean (± S.E.) o f four experiments 
performed in duplicate.
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TABLE 2.1
Classic Binding Protocol; Membranes
Comparison o f  affinity estimates from rat-1 fibroblasts expressing bovine aia-AR in membranes. 
Displacement o f f  H]prazosin (0.2nM) was determined with increasing concentrations o f  competing 
ligand from at least three experiments performed in duplicate (± S.E.M) in the presence or absence of 
0.25 mM GTP-y-S. All incubations were 30 minutes at temperature 22°C unless stated otherwise. 
Nonspecific binding was determined in the presence o f  10 |i.M phentolamine.
-GTP-y-S +GTP-y-S
Ligands pA7i Fig. p^i «H Fig.
Phenylephrine 7.9 ±0.6 
5.2+ 1.1
0.4 ±0.1 2.22 5.6 ± 1.6 0.9+ 0.1 2.22,2.27
(i?)-A-61603 10.26 ±0.58 
6.82 ± 1.0
0.2 ±0.1 2.23 6.85 ±0.99 0.6 ±0.3 2.23
Noradrenaline 5.05 ± 1.61 0.7 ± 0.1 2.24, 2.3 1
Adrenaline 5.80 ± 1.52 0.7±0.1 2.25,2.31
RS100329 9.63 ± 0.22 
8.16 ±0.77
0.7 ± 0.1 2.5, 2.8
Prazosin 8.57+ 1.68 0.9+ 0.1 2.3, 2.7
QAPB 8.37 ± 1.77 l.0±0.1 2.4, 2.10
L-765314 6.29 ± 1.70 1.0±0.1 2.6,2.11
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T A B L E  2.2
Classic Binding Protocol: Whole Cells
Comparison o f  affinity estimates from rat-1 fibroblasts expressing bovine aja-AR in whole cells. 
Displacement o f [^H]prazosin (0.2nM) was determined with increasing concentrations o f competing 
ligand from at least tlu'ee experiments performed in duplicate (± S.E.M) in the presence or absence o f  
0.25 mM GTP-y-S. Incubation times were altered for experiments with (/?)-A-61603 and experiments 
with QAPB were performed under light and dark conditions. Nonspecific binding was determined in 
the presence o f 10 pM phentolamine.
-GTP-y-S +GTP-Y-S
Ligand pA:i nn Fig. piCi wh Fig.
Phenylephrine
(Æ)-A-61603
4.97 ± 1.0 0.7 ±0.1 2.26 4.88 ±0.82 0.6 ±0.1
( !5 m in ) 8.07 ± 0.28 0.6 ±0.1 
5.91 ±0.85
2.26, 2.27 
2.29
8.25 ±0.05 
5.85 ±0.92
0.7 ±0.1 2.28 (30m in) 8.10 ± 0.66 0.5 ±0.1 
5.78 ± 1.0
2.29
6.82 ±0.92 
5.63 ±0.49
0.8 ±0.1 2.28 (120m in) 7.61 ±0.32 0.5 ±0.2 
5.45 ±0.66
2.29
Noradrenaline 6.44 ±0.31 
4.64 ±0.84
0.6 ±0.1 2.30,2.31
Adrenaline 4.96 ± 1.27 0.7 ±0.1 2.34
RSI 00329 10.99 ±0.27 
7.35 ±0.89
0.6 ± 0.2 2.8
Prazosin 8.72 ± 1.21 1.2 ±0.2 2.7
QAPB (dark) 9.26 ± 0.59 
7.38+ 1.10
0.7 ±0.1 2.9
(light) 9.94 ± 0.37 
7.37 ±0.94
0.6 ±0.1 2.9, 2.10
L-765314 7.27 ±0.33 
4.72 ± 0.92
0.5 ± 0.2 2.11
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TA BLE 2.3
Corticosterone influence on noradrenaline
Comparison o f  affinity estimates from rat-1 fibroblasts expressing bovine aia-AR in whole cells. 
Displacement o f [^H]prazosin (0.2nM) was determined with increasing concentrations o f noradrenaline 
from at least three experiments performed in duplicate (± S.E.M). Incubation times and temperatures 
were altered for specific experiments that were also performed in the presence or absence o f  1 pM 
corticosterone. Nonspecific binding was determined in the presence o f  10 pM phentolamine.
37°C 22°C
Noradrenaline
experiment
p i^ Wh Fig P i^ Uw Fig.
30 mins 6.71+0.44 
4.42 ±0.85
0.4 ±0.1 2.30 6.44 ±0.31 
4.64 ± 0.84
0.6 ±0.1 2.30
30 mins + IpM 
corticosterone
7.72 ± 0.25 
4.24 ± 0.98
0.5 ±0.1 2.32
15 mins 5.81 ±0.52 
3.94 ±0.77
0.5 ±0.1 2.33
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TABLE 2.4
BMY7378: Comparison o f otia and aid adrenoceptors.
Comparison o f affinity estimates fi om rat-1 fibroblasts expressing bovine ai^-AR and human a^-A R  
in membranes and whole cells. Displacement o f  [^Hjprazosin (0.2nM) was determined with increasing 
concentrations o f BMY7378 from at least four experiments performed in duplicate (+ S.E.M). 
Nonspecific binding was determined in the presence o f 10 pM phentolamine.
Whole cells Membranes
Subtype p i^ Fig p i^ ÎÎU Fig.
OCia"AR 6.36 ± 1.38 1.0 + 0.1 2.12 7.16+1.64 0.9+ 0.1 2.12
aid-AR 9.48+1.54 0.8+ 0.1 2.12 9.30 ± 1.20 1.0+ 0.2 2.12
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TA BLE 2.5
Effect o f pre-incubation time on displacement by noradrenaline; whole cells 
Comparison o f  affinity estimates from rat-1 fibroblasts expressing bovine «la-AR in whole cells. 
Displacement o f noradrenaline was determined using a different RLB binding protocol with increasing 
concentrations o f  noradrenaline from at least four experiments performed in duplicate (± S.E.M). Pre­
incubations with prazosin (0.2nM) were o f  varying times at 22°C, followed by second incubations 
o f 60 minutes at 37°C. Nonspecific binding was determined in the presence o f 10 pM phentolamine.
aia-AR whole cells
1 St incubation P^i «H Fig.
15 mins 7.51 ± 0 .0 9  
4.17 ± 0 .8 9
0.6 ±  0.1 2.35
30 mins 6.07 ± 0 .5 1  
3.93 ±  1.01
0.5 ± 0 .1 2.35
60 mins 6.58 ± 0 .2 9  
4.32 ±  1.01
0.6 ± 0 .1 2.35
I l l
TA BLE 2.6
Displacement at 37°C and 22°C: whole cells
Comparison o f affinity estimates from rat-1 fibroblasts expressing bovine «la-AR in whole cells. 
Displacement o f f  Hjprazosin (0.2nM) was determined using an updated RLB binding protocol with 
increasing concentrations o f  competing ligands from at least four experiments performed in duplicate 
(± S.E.M). First incubation o f  60 minutes at 22“C was followed by a second incubation o f  30 minutes 
at varying temperature. Nonspecific binding was determined in the presence o f 10 pM phentolamine.
37°C 22°C
Ligand pKi riH Fig pKi « H Fig.
RS100329 6.78+1.19 1 .0 ± 0.1 2.13 6.72 ± 1.08 0.9 ±0.1 2.13
QAPB 10.89 + 0.03 
6.33 ±0.71
0.6  ± 0.2 2.14 8.96±0.18 
6.39 ± 0.76
0.5 ±0.2 2.14
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TA BLE 2.7a
Displacement after [^ITJprazosin for 60 minutes: Membranes and whole cells 
Comparison o f affinity estimates from rat-1 fibroblasts expressing bovine a,a-AR in membranes and 
whole cells. Displacement o f f  HJprazosin (0.2nM) was determined using an updated RLB binding 
protocol with increasing concentrations o f competing ligands from at least four experiments performed 
in duplicate (+ S.E.M). First incubation o f 60 minutes at 22°C was followed by a second incubation o f  
varying time at 3TC. Nonspecific binding was determined in the presence o f 10 pM phentolamine.
Whole cells Membranes
Ligand + 
incubation
p^i Fig. pZi Fig.
Adrenal ine
15 mins 5.75 + 0.09 
3.84 + 0.82
0.6 ±0.2 2.38 5.51 + 1.51 0.8±0.1 2.37
30 mins 7.23 ± 0.03 
4.10+1.15
0.5 ±0.2 2.38 5.36 ± 1.48 0.9 ±0.1 2.37
60 mins 6.11 ±0.08 
4.37 ±0.58
0.6 ±0.2 2.38 5.44 ± 1.58 0.8 ±0.1 2.37
Noradrenaline
15 mins 7.90 ±0.32 
3.89± 1.15
0.5 ±0.2 2.43 5.26 ± 1.62 0.7 ±0.1 2.42
30 mins 6.97 ± 0.24 
3.96 ±0.89
0.5 ±0.1 2.43,2.36 5.09 ± 1.44 0.7 ±0.1 2.42
60 mins 7.86 ±0.06 
4.52 ± 1.30
0.6 ± 0.2 2.43 5.10± 1.54 0.8 ±0.1 2.42
Prazosin
30 mins 7.18± 1.57 1.4 ±0.1 2.15 9.12± 1.26 1.10±0.3 2.15
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TA BLE 2.7b
Displacement after prazosin for 60 minutes: Whole cells 
Comparison o f  affinity estimates from rat-1 fibroblasts expressing bovine ttta-AR in whole cells. 
Displacement o f [^H]prazosin (0.2nM) was determined using an updated RLB binding protocol with 
increasing concentrations o f  competing ligands from at least three experiments performed in duplicate 
(± S.E.M). First incubation o f  60 minutes at 22°C was followed by a second incubation o f  varying time 
at 37°C. Nonspecific binding was determined in the presence o f 10 pM phentolamine.
aia-AR whole cells
Ligand + 
incubation
P i^ nn Fig.
Phenylephrine
15 mins 7.12±0.37  
4.04± 1.15
0.6 ±0.2 2.44
30 mins 8.00 ± 0.29 
3.77 ±0.85
0.5 ±0.2 2.44
60 mins 4.06 ± 0.93 
4.32 ± 1.01
0.9 ± 0.3 2.44
(7?)-A-61603
30 mins 8.92 ±0.39 
4.59 ±0.77
0.3 ± 0.2 2.45
L-765314
30 mins 5.48± 1.12 1.0 ±0.2 2.20
BMY7378
30 mins 6.39 ± 1.36 0.9 ±0.1 2.21
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TA BLE 2.8
Corticosterone influence on adrenaline
Comparison o f  affinity estimates from rat-1 fibroblasts expressing bovine ai^-AR in whole cells. 
Displacement o f  [^Hjprazosin (0.2nM) was determined using an updated RLB binding protocol with 
increasing concentrations o f  adrenaline from at least three experiments performed in duplicate (± 
S.E.M). Experiments performed in the presence and part-presence o f IpM corticosterone. First 
incubation o f 60 minutes at 22°C was followed by a second incubation o f varying time at 37°C. 
Nonspecific binding was determined in the presence o f 10 pM phentolamine.
Ligand + 
incubation
Corticosterone Part-Corticosterone
pA7i nn Fig pKi Fig.
Adrenaline
15 mins 4.08 ± 1.36 0.710.1 2.40 4.06 ± 1.05 0.810.2 2.39
30 mins 4.23+ 1.40 0.8+ 0.1 2.40 4.36 ± 0.92 0.910.1 2.39
60 mins 4.00+ 1.21 1.0 ±0.2 2.40 6.95 ± 0.24 0.4 ± 0.2 2.39
4.01 ±0.74
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TABLE 2.9
Concanavalin A; influence on adrenaline
Comparison o f  affinity estimates from rat-1 fibroblasts expressing bovine aig-AR in whole cells. 
Displacement o f [^Hjprazosin (0.2nM) was determined using an updated RLB binding protocol with 
increasing concentrations o f adrenaline from at least three experiments performed in duplicate (± 
S.E.M). Experiments performed in the presence and part-presence o f 0.25 mg/ml concanavalin A. First 
incubation o f  60 minutes at 22°C was followed by a second incubation o f  30 minutes at 37°C. 
Nonspecific binding was determined in the presence o f 10 pM phentolamine.
Concanavalin A Part-Concanavalin A
Ligand + 
incubation
pifi nn Fig pATi n\\ Fig.
Adrenaline 
30 mins 8.37 + 0.07 
3.98 + 0.86
0.5 ±0.2 2.41 7.06 ± 0.63 
4.10± 1.14
0.4 ±0.1 2.41
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TA BLE 2.10
Effect o f  pre-incubation time on displacement by QAPB: whole cells 
Comparison o f  affinity estimates from rat-1 fibroblasts expressing bovine «la-AR in whole cells. 
Displacement o f  [^HJprazosin (0.2nM) was determined using an updated RLB binding protocol with 
increasing concentrations o f QAPB h orn at least tln ee experiments performed in duplicate (± S.E.M). 
First incubation o f  varying time at 22°C was followed by a second incubation o f  60 minutes at 22°C. 
Nonspecific binding was determined in the presence o f  10 pM phentolamine.
aia-AR whole cells
Ligand + 
incubation
p^i Wh Fig.
QAPB
60 mins 6.63 ± 0.96 0.5 ±0.2 2.16
90 mins 11.01 ±0.51 
7.54 ± 1.07
0.4 ±0.1 2.16
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TABLE 2.11
Displacement from whole cells and membranes at 4°C
Comparison o f affinity estimates from rat-1 fibroblasts expressing bovine ain-AR in membranes and 
whole cells. Displacement o f [^HJprazosin (0.2nM) was determined using an updated RLB binding 
protocol with increasing concentrations o f  competing ligands from at least three experiments 
performed in duplicate (± S.E.M). First incubation o f  60 minutes at 22°C was followed by a second 
incubation o f varying time at 4°C. Nonspecific binding was determined in the presence o f 10 pM 
phentolamine.
Whole cells Membranes
Ligand + 
incubation
pATi nn Fig. pTfi nn Fig.
Noradrenaline 
15 mins 
60 mins
5.96 ±0.70 
5.41 ±0.81
0.7 ±0.3 
0.4 ± 0.2
2.46
2.46 7.64 ±0.69 0.8 ±0.6 2.47
QAPB
15 mins 8.25 ±0.91 0.7 ±0.3 2.18 9.16 ±0.96 1.1 ±0.5 2.19
60 mins 7.90 ±0.64 0.6 ±0.3 2.18
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TA BLE 2.12
Concanavalin A; influence on QAPB; whole cells
Comparison o f  affinity estimates from rat-1 fibroblasts expressing bovine ai^-AR in whole cells. 
Displacement o f [^HJprazosin (0.2nM) was determined using an updated RLB binding protocol with 
increasing concentrations o f  QAPB from at least four experiments performed in duplicate (± S.E.M). 
Experiments performed in the presence and absence o f 0.25-mg/ml concanavalin A. Cells pre-treated 
with con A for 90 minutes at 22°C before first incubation o f 60 minutes at 22°C with prazosin.
This was followed by a second incubation o f 30 minutes at 37°C. Nonspecific binding was determined 
in the presence o f 10 pM phentolamine.
Concanavalin A No Concanavalin A
Ligand + 
incubation
nn Fig. P i^ Fig.
QAPB 
60 mins 7.71 ± 1.22 0.5 ±0.05 2.17 11.01 ±0.51 
7.54 ± 1.07
0.4 ±0.1 2.17
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2.3 DISCUSSION
2.3.1 Competitive inhibition o f radioligand binding
2.3.1.1 Agonists
Radioligand binding is now a standard teclmique used for analysis of the interactions 
o f ligands with their receptors. The technique is fast, simple and allows the 
investigation o f the pharmacological properties o f many drugs within a short time. 
Used in conjunction with modern analysis techniques (Uhlen & Wikberg, 1991; 
Wikberg et al, 1998), the results obtained are generally very accurate and highly 
reproducible. The most commonly used radioligand binding technique is the 
membrane filtration receptor assay. A variation on the membrane assay, the intact 
cell radioligand binding assay, has specific advantages in certain circumstances, such 
as screening large numbers o f small cell samples and studies o f receptor 
internalisation (Bylund & Toews, 1993).
The present study determined the binding affinities of various ligands in a series o f 
competition-binding experiments with the a[-AR-selective antagonist [^Hjprazosin as 
the radioligand. The binding affinities o f agonists and antagonists for the bovine aia- 
AR were first assessed in standard membrane preparation assays. This is the common 
method used to determine ai-A R  affinity (Kenny et al, 1996).
A well-studied example of agonist interaction with receptors linked to GPCRs is by 
comparing the competition o f agonists with radio labelled antagonist in the presence or 
absence o f GTP (or its analogues). When the competing ligand used is an agonist, the 
situation becomes more complex than using an antagonist, as an agonist will interact 
with its G protein. The first step in this interaction is a decrease in the affinity o f the 
nucleotide-binding site for GDP and the formation o f a ternary complex (agonist- 
receptor-a empty Py). When GTP is absent, the activated receptor is unable to 
dissociate from the a-subunit and so the receptor and G protein are essentially locked 
together or frozen (Bockaert et al, 1997). This frozen state increases the stability o f 
the agonist-receptor complex and so increase the agonist’s affinity for the receptor.
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hence a high affinity state. However, when GTP is present, this transient state 
disappears, the activated receptor is able to dissociate from the a-subunit and the 
GPCR cycle proceeds as normal, i.e. the activated a-GTP subunit interacts with the 
effector protein. This represents the low affinity state. When the G protein 
concentration is limiting or when some receptors camiot associate to G proteins, then 
a mixture of agonist-receptor and agonist-receptor-G protein complexes can 
accumulate to give rise to a heterogeneous binding curve. This behaviour is generally 
only observed for agonist binding on membranes in the absence o f  GTP. The 
heterogeneous binding curve will become homologous when GTP is present.
Binding affinities for the non-subtype selective ai-A R agonist phenylepludne were 
determined in the presence and absence o f the non-hydrolysable GTP analogue GTP- 
y-S in the present study. The results were consistent with the aforementioned GTP 
theory. In the absence of the GTP analogue, the binding curve was biphasic, 
displaying both high and low affinity components. When GTP-y-S was present, the 
binding curve was monophasic. This phenomenon was reproduced using the specific 
au-A R  agonist (R)-A-61603 as the competing ligand. (7?)-A-61603 displayed a 
higher affinity for the bovine ai^-AR than phenylephiine, which would be expected 
due to its specificity for a^-ARs. Knepper and colleagues (1995) had previously 
reported that (i?)-A-61603 was highly selective for the cloned bovine aj^-AR 
expressed in mouse fibroblasts.
As mentioned previously, the high affinity state is not observed in the presence of 
GTP; therefore in whole cells containing GTP, all receptors should be under the low 
affinity state. Binding is heterogeneous in membranes (high and low affinity states), 
but homogeneous in whole cells (low affinity state). The binding affinities for 
[^Hjprazosin sites of various agonists and antagonists were assessed on whole-cell 
preparations harbouring the recombinant bovine ai„-AR in the present study, as this is 
the modality in which visualisation o f ligand-ligand competition is assessed. With 
phenylephrine as the competing ligand in the presence and absence o f GTP-y-S, the 
whole cell binding curve was consistent with the literature. Both curves almost 
superimposed on top o f each other, displaying a monophasic nature and low affinity 
pKi values.
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The situation was slightly different when (i2)-A-61603 was used as the competitor in 
whole cell binding assays in the absence and presence o f GTP-y-S. In the absence of 
the GTP analogue, the curve was biphasic and there was only an approximate 75% of 
displacement. This suggested that there were binding sites inaccessible to (i?)-A- 
61603. A possible explanation was that the uptake o f the ligand into the cell was time 
dependant and subsequent experiments with a 2 -hour incubation period resulted in a 
full displacement. According to the literature, in the presence o f GTP-y-S, binding 
curves were expected to be monophasic. To investigate further the thought that {R)~ 
A-61603 might displace the radiolabel, a series o f experiments were performed with 
incubation times of 15, 30 and 120 minutes. All thi'ee binding curves were biphasic 
and repeated the phenomenon where 25% o f binding sites seemed inaccessible. The 
various incubation times had no real effect on the binding curves and it appears that 
(R)-A-61603 can cause full displacement after 2 hours in the absence o f GTP-y-S, but 
not in the presence of the analogue. Visualisation experiments where (R)-A-61603 
could displace QAPB from intracellular compartments may help resolve this issue.
Both noradrenaline and adrenaline displayed similar low affinity binding curves in 
membrane preparations. In whole eells, noradrenaline displayed both high and low 
affinity components whereas adrenaline displayed only a low affinity component.
Our early hypothesis was that catecholamines were delivered to intracellular receptors 
via an extraneuronal monoamine transporter (EMT) (Grundemann et al, 1998). The 
EMT (previously known as Uptake2) reportedly functions optimally at 37°C. The 
present study compared competition-binding experiments at 22°C and 37°C using 
noradrenaline as the competing ligand. Both curves were biphasic, displaying high 
and low affinity binding sites and similar pK\ values. Literature maintains that 
incubation temperature can be varied as desired, although 37°C is the usual choice 
since the goal is to maintain physiological conditions (Bylund & Toews, 1993).
Extraneuroal transport is the predominant pathway for terminating the actions of 
circulating adrenaline and noradrenaline (Eisenhofer et al, 1996). Although neuronal 
and extraneuronal uptakes compete for released catecholamines, these transport 
systems have distinct pharmacological profiles, that is, affinity for substrates and
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sensitivity to various drugs (Grundemann et al, 1998). Iversen & Salt discovered in 
1970 that corticosterone was a potent inhibitor o f Uptake2. When the transporter is 
blocked, the metabolism of noradrenaline is attenuated. To test the hypothesis that 
noradrenaline and other ligands may penetrate the cells via the EMT, binding 
experiments were performed in the presence o f corticosterone. The result was a 
biphasic binding curve where a high affinity component was followed by a small 
plateau phase before the low affinity component. This curve was evidently more 
biphasic than the binding curve where no corticosterone was present. The high 
affinity component may represent an initial displacement from cell membranes and 
the plateau phase may correspond to a difficulty o f the ligand to penetrate the cell.
The low affinity phase would therefore represent the ability o f ligands to displace the 
radiolabel from intracellular binding sites. Although corticosterone did not prevent 
total displacement, one could speculate that it caused greater difficulty in the cellular 
penetration process by the ligand, as represented by a more pronounced plateau phase 
on the binding curve.
Altering the incubation times in binding experiments using noradrenaline as the 
competitor reinforced the concept that the uptake o f a ligand into the cell may be time 
dependant. A 30-minute incubation achieved a greater displacement than a 15-minute 
incubation.
2.3.1.2 Antagonists
The binding affinities o f various antagonists were also determined in the present study 
in a series o f competition-binding experiments with prazosin as the radioligand. 
Similar to agonist experiments, the binding affinities were determined in membrane 
and whole cell preparations.
Prazosin displayed a similar binding profile in cells and membrane preparations. The 
binding curves were monophasic and suggest prazosin has no difficulty penetrating 
the cell. QAPB (BODIPY FL-prazosin) was expected to display a similar binding 
profile to prazosin as it is structurally related to prazosin. The binding curve for 
QAPB was monophasic and it shared similar affinity for bovine aia-AR membranes
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as prazosin. In whole cells, QAPB continued the trend of a high affinity component 
preceding a slow sustained plateau and low affinity component. The difficulty in 
cellular penetration by QAPB may be related to the size or chemical properties o f the 
fluorescent component of the compound. Light surroundings had no effect on the 
ability of QAPB to displace the radiolabel. QAPB is apparently a light-sensitive 
compound (McGrath et al, 1996) and a comparison o f binding curves for QAPB in 
dark and light surroundings were made. Both curves were almost identical; hence 
QAPB is fully operational under light conditions.
Consistent with its specificity for aia-ARs (Williams et al, 1999), R S I00329 
displayed the highest affinity binding values out o f all antagonists tested. In whole 
cells preparations, R S I00329 continued the trend o f a high affinity component 
(approx. 2 0 % of binding sites) followed by a slow sustained plateau phase before the 
low affinity component (approx. 80% of binding sites), which again raised the 
possibility of a difficulty o f cellular penetration. The selective a,b-AR antagonist L- 
765314 displayed a much lower affinity for the bovine a^-A R  than prazosin, QAPB 
and R S I00329, consistent with its specificity for aib-ARs (Patane et al, 1998). The 
curve was biphasic, which again suggests that this antagonist has difficulty with 
regards to cellular penetration.
The binding affinities for [^H]prazosin sites o f the subtype selective oCw-AR 
antagonist BMY7378 were assessed on membrane and whole-cell preparations 
harbouring the recombinant bovine aia-AR and also the recombinant human otta-AR 
BMY7378 displayed a lower affinity than prazosin, QAPB and R S I00329 at bovine 
aia-AR whole cells, but produced subnanomolar affinity for the displacement of 
[^HJprazosin at human ot^-AR whole cells. Both whole cell curves were monophasic 
suggesting BMY7378 has no difficulty penetrating cells. These results relate to work 
by Piascik and Perez (2001), who studied the cellular distribution o f the a rA R  
subtypes in stably transfected fibroblasts as well as cultured vascular smooth muscle 
cells. They detected veiy little cell surface expression o f the otm-AR. Most o f the 
a,D-AR immunoreactivity was detected intracellulariy in a perinuclear orientation. 
The groups also found, using a,-AR/GFP fusion proteins, that Œia-AR  fluorescence 
was detected on the cell surface and intracellulariy, whereas aio-AR fluorescence was
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detected intracellulariy. This lends weight to the theory that ai-ARs are expressed, to 
one degree or another, in intracellular compartments (Hrometz et al, 1999; Piascik & 
Perez, 2001).
There is an interesting observation in the present study when comparing membrane 
and whole-cell binding curves for agonists and antagonists. There is higher affinity 
for membrane preparations compared with whole cells for nearly all agonists and 
antagonist tested. The only notable exception is that o f prazosin. MacKenzie and 
colleagues (2000) reported similar results. The group foimd binding affinities were 
greater in membrane preparations than in cells, but also is greater in native prostatic 
tissues or cells compared with recombinant receptors. This supported, for native 
prostatic tissue, the theory of Ford (1998) who proposed that receptors expressed in 
cells displayed lower binding affinities than those in membrane preparations.
2.3.2 New radioligand binding protocol 1
A new displacement protocol was devised that would recreate a more ‘real’ context of 
visualisation experiments than in standard ligand-ligand competition. The “classical” 
RLB approach dealt more with the 30-minute competition between competitor and 
radiolabel. The timing and order o f addition o f competitive ligands were now very 
important. The time o f incubation has to be sufficient to ensure that equilibrium (or at 
least steady state) has been achieved. Most radioligands appear to reach steady state 
at room temperature within 20-60 minutes (Bylund & Toews, 1993). The new 
protocol therefore pre-equilibrated cells with [^HJprazosin for varying time periods, 
followed by the addition o f displacing ligand for a further time course. This meant 
that competitors had to displace [^Hjprazosin from its pre-equilibrated location(s).
A 60-minure pre-incubation between cells and radiolabel at room temperature resulted 
in the greatest displacement by noradrenaline. Noradrenaline was added for 60 
minutes at 37°C following pre-incubation between cells and prazosin. This was 
consistent with Bylund & Toews (1993) theory that radioligands appear to reach
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steady state at room temperature within 20-60 minutes. A 15- and 30-minute pre­
incubation between cells and radiolabel resulted in similar results. There was a lesser 
displacement o f radiolabel. A comparison o f noradrenaline binding curves using the 
‘classical’ and new RLB approaches revealed that noradrenaline was less effective at 
displacing [^HJprazosin after binding was pre-established (new RLB protocol).
2.3.3 New radioligand binding protocol 2
Imaging results from the present study had revealed that 60 minute was sufficient 
time for an analogue o f prazosin to reach and maintain steady state. These results 
coupled with results from the previous displacement RLB protocol helped establish 
that 60 minutes was indeed sufficient time for [^H]prazosin binding to reach 
equilibrium to bovine ai^-AR whole cells both on cell surface and at intracellular 
binding sites. An expanded version o f the aforementioned displacement protocol 
provides a more consistent comparison with visualisation studies. A fixed 60-minute 
pre-incubation between cells (or membranes) and [^HJprazosin at room temperature 
was followed by addition o f the displacing ligand for varying times.
Before any further investigations using the new displacement protocol, the initial aim 
was to determine if incubation temperature had any effect on ligands ability to 
displace [^HJprazosin following the pre-incubation period. A 30-minute incubation 
with R S I00329 at 37°C caused a slightly greater displacement o f [^Hjprazosin than 
the same time period at 22°C. The same result was confirmed using QAPB as 
displacing ligand. A comparison o f RSI 00329 and QAPB binding curves using the 
‘classical’ and new displacement approaches revealed that the antagonists were less 
effective at displacing [^HJprazosin after binding was pre-established (new 
displacement protoeol). This new displacement protocol would suggest that both 
antagonists find it much harder to penetrate cells, although both curves are less 
biphasic than their respective “classical” binding curves. Similar to its binding profile 
with the “classical” RLB approach, prazosin displayed no apparent difficulty 
penetrating the cell, but consistent with R S I00329 and QAPB, prazosin was less
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effective at displacing [^Hjprazosin using the new displacement protocol. Both L- 
765314 and BMY7378 displayed ease in cellular penetration. L-765314 had a higher 
binding affinity value using the displacement protocol than the “classical” RLB 
protocol. BMY7378 displayed exactly the same binding profile when comparing both 
protocols. These differences in cellular penetration by various antagonists may be 
structurally related.
As the equilibration between cells, [^H]prazosin and incubation temperature for 
maximum displacement had been resolved, a new series o f experiments determined 
whether displacement was time-dependant once the displacing ligand had been added. 
Following pre-incubation between radiolabel and membranes, a series o f adrenaline 
concentrations were added for 15, 30 and 60 minutes at 37°C. The thi'ee curves were 
almost superimposed and displayed similar one-site binding affinities, consistent with 
our thought that varying incubation times should have no effect on displacement from 
the cell surface. The same results were obtained on membrane preparations using 
noradrenaline as the displacing ligand. The same protocol In whole cell preparations 
produced an expected response with adrenaline as displacing ligand. The smallest 
displacement occurred after a 15-minute incubation and the 60-minute incubation 
produced the greatest displacement. Again, the same results were obtained with 
noradrenaline as the displacing ligand. Phenylephrine produced an unusual set of 
results in that a 15-minute incubation provided the greatest displacement. (i?)-A- 
61603 experienced obvious difficulty penetrating the cells as noted by the extremely 
biphasic binding curve. In a continuing trend, there were approximately 20-25% of 
binding sites being inaccessible to (7?)-A-61603. One common trend with agonists 
and antagonists when using the new displacement protocol was the lower affinity 
values than when used with the “classical” RLB approach.
Zhu and Toews (1995) proposed that the low affinity for agonists observed in assays 
with whole cells was a result o f receptor internalisation. Exposure o f cells to agonist 
for the time required to achieve “equilibrium” during competition binding assay 
would lead to receptor internalisation. As [^FI]prazosin is relatively lipophillic, it can 
cross cell membranes and label internalised receptors. In contrast, agonists such as 
adrenaline are quite hydrophilic and cross cell membranes poorly. Adrenaline would
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have limited accessibility to the internalised receptors and therefore inhibit binding to 
internalised receptors only at high concentrations. Zhu and Toews (1995) modified 
their hypothesis for whole cell low affinity binding to propose that either 
sequestration within the plasma membrane or endocytosis into intracellular vesicles 
resulted in low affinity binding.
Corticosterone was again used to investigate our proposal that ligands may penetrate 
cells and access intracellular binding sites via an EMT. Adrenaline was used as the 
displacing ligand rather than noradrenaline as adrenaline is believed to be a better 
substrate for the EMT (Grundemami et al, 1998). These results gave a more “real” 
displacement result than experiments carried out with corticosterone using the 
“classical” RLB protocol. With corticosterone present only after pre-equilibrium with 
[^H]prazosin, this would reveal whether corticosterone had any direct single effect on 
the ability of adrenaline to penetrate the eells. The only displacement curve that 
suggested corticosterone might be having some, if any effect, was following the 60- 
minute incubation with adrenaline, which produced a biphasic curve, although a full 
displacement was still achieved. With corticosterone present for the entire 
experiment, the only difference noted was again following the 60-minute incubation 
with adrenaline. When compared with the same control experiment, there was a 
lower affinity in the presence o f corticosterone and also a greater displacement in the 
control experiment. This is still not strong enough evidence to suggest that ligands 
are crossing the cell membrane and accessing intracellular binding sites via the EMT. 
One thing is definite from the displacement protocols and that is that agonists and 
antagonist can both cross the cell membrane by a certain mechanism and displace 
[^HJprazosin from intracellular binding sites throughout the cytosol.
To test the theory proposed by Zhu and Toews (1995) that ligands access intracellular 
compartments via an endocytotic mechanism, the present study investigated the 
effects o f the endocytotic blocker concanavalin A on displacement by agonists and 
antagonists. Using protocols identical to the corticosterone experiments, it was clear 
that concanavalin A was having no effect on the displacement o f radiolabel by 
adrenaline. There was still a near full displacement using both protocols suggesting 
that the endocytotic blocker was exerting no effect. QAPB, when used as the 
displacing ligand, produced a slightly more positive result in similar experiments
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using concanavalin A. When compared with the biphasic control displacement curve, 
the QAPB displacement curve in the presence o f  concanavalin A appeared 
monophasic which suggested a difficulty in cellular penetration. There seemed to be 
difficulty o f cellular penetration until lO'^M, where only approximately 15% of 
radio label had been displaced. There was then a sharp fall in the displacement curve 
and at the next QAPB concentration (3xlO'^M), approximately 75-80% o f radiolabel 
had been displaeed. It was apparent something crucial had occurred between the two 
concentrations. A possible explanation is that concanavalin A is blocking the 
endocytotic pathway until a certain high QAPB concentration is applied which can 
overcome this blockade and hence allow QAPB access to intracellular binding sites.
2.3.4 New radioligand binding protocol 3
If displacing ligands do penetrate cells and access intracellular binding sites by 
endocytosis, they should fail to penetrate cells at 4°C as a result o f the endocytotic 
mechanism being halted by cold temperatures. This proposal formed the basis of 
altering the displacement protocol to investigate the effects cold temperature has on 
displacement. It has been previously reported that endocytosis is temperature 
dependent and that the internalisation process is blocked at 4°C (Von Zastrow & 
Kobilka, 1994).
In the present study, using whole cells preparations, noradrenaline and QAPB 
displayed similar curves, with only approximately 25% of all sites displaced. There 
was a marginally greater displacement after 60 minutes using noradrenaline. This 
would suggest that the 25% of displaced sites might represent cell surface receptors. 
These whole cell results correlate with the theory that endocytosis is blocked at low 
temperature. Surprisingly, there were only 25% o f  sites displaced when the 
experiments were repeated in membrane preparations. A full displacement from the 
cell surface had been expected and these different results prove difficult to explain.
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3.0 Aims & objectives
To investigate whether quantitative agonist/antagonist pharmacology could be carried 
out at the single cell level on ai-adrenoceptors using a Rat-1 fibroblast cell line that 
stably expresses the recombinant aia-adrenoceptor. Using microspectrofluorimetry 
techniques, this would be determined by:
1. Defining the nature o f the [Ca^^]j signal for the bovine aia-AR
2. Evaluating functional Fura-2 Ca^^ responses to aia-AR activation that allows 
us to make a quantitative analysis for the interaction of agonists and 
antagonists.
Another aim was to use direct visualisation techniques to investigate:
1. The ability o f a fluorescent antagonist to enter cells and bind to intracellular 
compartments throughout the cytoplasm.
2. Can ligands penetrate cells and displace the fluorescent antagonist from such 
intracellular binding sites?
3. To determine the identity o f these intracellular compartments and hence 
comment on the process o f cellular penetration by ligands.
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3.1 METHODS
3.1.1 Cell Culture.
Rat-1 Fibroblasts stably expressing the bovine aia~AR were used. Cells were grown 
in monolayers in DMEM containing 10% (v/v) foetal bovine serum, 100 I.U./ml 
penicillin, lOOjig/ml streptomycin and ImM  L-glutamine in a 95% air and 5% CO2 
atmosphere at 37°C. Selection was maintained by adding geneticin (0418) 
(400pg/ml) to the growth media.
3.1.1.1 Freezing cells.
Cells are grown to confluence in 75cnf tissue culture flasks, growth media removed 
and replaced with fresh growth media containing 10% DMSO. Cells are removed 
from the base of the flask by gentle agitation and aliquoted into 1.5ml cryovials. The 
cryovials are stored at -70°C for 24 hours, then labelled in cryocanes and frozen down 
in liquid nitrogen.
3.1.1.2 Growing cells
Single cryovials containing the cells were removed from cryocanes and left in the 
incubator at 37°C for 5-7 minutes. Once defrosted, cells were carefully triturated 
twice and added to a 25cm^ tissue culture flask. lOmls o f DMEM was slowly added 
to the flask, the flask cap was loosened and the suspension left In the incubator for 40 
minutes to allow cells to adhere to the base o f the flask. The media was then 
removed, replaced with 5mis fresh media and flask placed in incubator to be 
maintained as normal.
131
3 .L I .3 Cell splitting
Cells were maintained using a “splitting” process. Once cells reached confluence, 
growth media was removed and cells washed with 2mls 0.25% trypsin/EDTA 
solution. The wash solution was removed, replaced with 2.5mis fresh trypsin/EDTA 
and 2.5mls fresh DMEM, then transfen'ed to a 13ml centrifuge tube and centrifuged at 
4000rpm for 3 minutes at 22°C. The solution was discarded, leaving a pellet. Using a 
Pasteur pipette, 1ml DMEM was added and carefully triturated 15-20 times before 
adding a further 9mls DMEM. After resuspending, 1ml o f the cell suspension was 
added to a 25cm^ tissue culture flask along with 4mis fresh DMEM. The cells were 
then placed in the incubator and maintained as normal.
3.1.2 Measurement o f [Ca^^Ji
3.1.2.1 Microspectrofluorimetry analysis
Rat-1 fibroblasts stably expressing the bovine a^ -A R  were removed from culture 
flasks using trypsin/EDTA and washed by centrifugation-resuspension in fresh 
DMEM. Aliquots o f this suspension were plated onto 22mm circular cover slips and 
grown overnight. Cells were then loaded (15 minutes at 37°C) with the dual 
excitation Ca^’^ -sensitive dye Fura-2 AM (IpM ). A rise or fall In [Ca^^Jj causes a 
corresponding effect in the Fura-2 fluorescence ratio recorded from cells loaded with 
this dye and this allows receptor/voltage-mediated changes in [Ca^’*']i to be 
microspectrofluorimetrically monitored (Grynkiewicz et al., 1985). Fura-2 
fluorescence ratios (excitation wavelengths, 340 and 380nm) were recorded at 4-Hz 
intervals from single cells at room temperature. Experimental set-up is shown in 
Figure 3.1. Data was digitised and recorded directly to computer disk using an 
interface and associated software (Version 5.2) obtained from Cairn Research Ltd 
(Faversham, Kent, UK).
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3,1.2.2 Calcium Imaging
After 15 minutes loading with Fura-2 at 37°C, the cells were mounted in a chamber 
attached to the stage o f a Nikon Diaphot inverted microscope where the cells were 
superfused with physiological saline solution (130mM NaCl, 5mM KCl, 20mM 
FIEPES, lOmM D-glucose, ImM  M gC f and ImM  CaCf, pH 7.4). An Optoscan 
monochromator (Cairn Research, Faversham, Kent, UK) positioned between a 70W 
Xenon lamp and the epifluorescence port o f the microscope was used to alternate the 
excitation wavelength between 340, 380 and 488nm (band pass lOnm) and to control 
the excitation frequency. Excitation light was reflected from a custom designed 
dichroic mirror thi’ough a Nikon 40x oil immersion FLUOR objective (NA==1.3). 
Fura-2 emitted fluorescence emitted light at 515nm was monitored either by a low 
noise COHU CCD camera or a photomultiplier tube with a bialkali photocathode. 
Using Meta Fluor imaging software (Universal Imaging Corp, West Chester, PA, 
USA), the images obtained using the CCD camera were stored and analysed digitally. 
Images obtained for each excitation wavelength were collected every 1 second; 
exposure to excitation light was always 80ms/image and the time interval between the 
acquisition of each image was approximately 2 milli seconds. Cells were delimited 
by producing a mask that contained pixel values above a thieshold applied to the 
380nm image and time dependant changes in [Ca^^j; were calculated from the ratio of 
two background subtracted images.
3.1.2.3 Response curves
A desired group o f cells was selected using cell autofluorescence and the focal plane 
fixed by locking the focus motor. The system was then set to acquire images at 30- 
second intervals. After a baseline had been established for 5-7 minutes in every 
experiment, a 30-second pulse o f agonist (IpM  phenylephrine in all experiments) was 
applied to determine the maximum Fura-2 Ca^^-signal in control solution alone. The 
initial experiments involved a test for cell photobleaching where 4nM QAPB was 
applied for approximately 4 hours. The subsequent experiments looked at the time to 
equilibrium between QAPB and the cells, along with the simultaneous recording of 
the antagonised fura-2 Ca^^ signals. In such experiments 0.5, 2, 4 or 6 nM QAPB was
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equilibrated with the cells for a period of 1.5 hours before construction o f 
concentration-Ca^’*’ response curves. The concentration-Ca^^ response curves to 
phenyleplnine were constructed by noncumulative addition ( 10 -minute pulses of 
increasing concentrations of phenylephiine applied at 15-minute intervals).
3.1.2,4 Data analysis
Agonist-evoked [Ca^^ji signals were quantified as the difference between the baseline 
resting ratio level and that attained at the peak response. The effect o f QAPB on the 
concentration-Ca^"^ response to phenylephiine was analysed by expressing the data as 
a fraction o f the maximal peak response elicited by phenylephrine in control solution 
alone.
3.1,3 Materials and Chemicals
Cell culture plastics were supplied by Falcon. DMEM with sodium pyruvate, foetal 
bovine serum, L-glutamine, penicillin, streptomycin and trypsin/EDTA were 
purchased from Gibco Life Technologies (Paisley, Scotland); Fura 2-AM, 
phenylephiine HCl, adrenaline, noradrenaline, HEPES and EDTA were purchased 
from Sigma (Dorset, UK); The (7?)-enantiomer o f A-61603 was a gift from Dr 
Michael Meyer (Abbott Laboratories, Abbott Park, IL); L-765314 was a gift from Dr 
Michael Patane (Merck & Co. Inc, NJ); R S I00329 (Dr. Michelson, Roche Bioscience, 
Palo Alto, CA); Phentolamine, QAPB, prazosin HCl, BMY7378 dihydrochloride 
from Research Biochemicals Inc. (Natick, MA); [^H]Prazosin (0.2nM; specific 
activity, 76 Ci/mmol) was ordered from Amersham Corp. (Arlington Fleights, IL).
Stock solutions for each chemical were prepared in distilled water or dimethyl 
sulfoxide and subsequently aliquoted and stored at -20°C. These stock solutions were 
diluted to working concentrations in the physiological salt solution on each 
experimental day.
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3.2 RESULTS
3.2.1 Microspectrofliiorimetry
The objective was to investigate whether quantitative agonist/antagonist 
pharmacology could be canied out at the single cell level on a rA R s  using a Rat-1 
fibroblast cell line that stably expresses the recombinant cxia-AR. Schwimi and 
colleagues (1995) reported that an ai-A R  cloned from bovine brain (e.g. bovine aia- 
AR) activates IP formation in R -lFs, suggesting that this receptor raises [Ca '^^ji in this 
cell-line by mobilising intracellular Ca^ '*' stores via the PLC-P/IP3 pathway. In the 
present study, microspectrofluorimetry analysis using the dual excitation Ca^^- 
sensitive fluorescent dye Fura-2 AM was used to monitor [Ca^^ji. Fura-2 (Fig. 3.2) is 
a fluorescent derivative o f the Ca^’^ -chelator BAPTA which itself is an aromatic 
analogue o f the Ca^^-selective chelator EOT A. The fluorescence excitation spectrum 
o f Fura-2 is shown in Figure 3.3. The excitation wavelengths for Fura-2 are 340 and 
380nm and its Ky value is 220, when 50% of Fura is bound to 50% of free calcium 
ions.
3.2.1.1 signalling mechanism
3.2.1.1.1 Effect o f phenylephrine on [Ca^^Ji
The first experiments determined the nature o f the [Ca^^j, signal for the bovine aia- 
AR. Figure 3.4A shows the rise in [Ca^ " ]^i in response to a 3 minute pulse o f the a r  
AR agonist, phenylephrine (IpM ). The response was transient, followed by a rapid 
decline and small plateau phase, despite the continued presence o f phenylephrine.
3.2.1.1.2 Role o f external Ca^  ^in [Ca^ J^i responses to phenylephrine
Phenylephrine (IqM ) evoked a transient rise in [Ca^^ji without the sustained phase 
when applied under Ca^^-free conditions (Fig. 3.4B). Subsequent elevation of
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external Ca^^ (ImM ), in the continued presence of phenylephrine, resulted in a 
maintained rise in [Ca^^],. Once the nature of the functional [Ca^’^ 'ji signal had been 
determined, we wanted to make a quantitative analysis o f agonist and antagonist 
pharmacology at this recombinant subtype in single R~lFs by evaluating functional 
Ca^^-responses to receptor-activation, which would allow us to predict a relationship 
for the interaction o f agonists and antagonists.
3.2.2 Functional pharmacology studies
3.2.2.1 Agonist response
Concentration-Ca^^ response curves (CRCs) were recorded to cells stimulated 
noncumulatively with 30-second exposures (applied at 5-minute intervals) to 
increasing concentrations (10'^ lO'^M) of phenylephrine (Fig. 3.5). Phenyl eplnine 
caused a concentration-dependant peak increase in [Ca^^Ji. Beyond the concentration 
o f phenylephiine that produced the maximum response (> 3xlO'^M), the 
concentration-respouse relationship displayed an inverse phase (i.e., smaller peak 
responses to increasing concentrations o f phenylephrine).
3.2.2.2 Photobleaching
Before studying any interaction between phenylephrine and the fluorescently labelled 
a i-A R  antagonist QAPB, the possibility o f a “photobleaching” effect by QAPB was 
tested. Initially, a 30 second pulse o f phenyleplirine was applied to evoke an increase 
in [Ca^^ji (Fig. 3.6). QAPB (4nM) was then applied for a 4 hour and 10 minute 
period. The trace in Figure 3.6 shows that no degradation/photobleaching o f QAPB 
intensity existed, hence a steady state equilibrium binding of QAPB could be 
maintained over a 4 hour time period. This had no effect on the Fura-2 Ca^^ signal.
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3.2.2.3 Antagonist response
3.2.2.3.1 4nMQAPB
Antagonism versus phenylephrine by QAPB was assessed across the concentration 
ranges indicated by its RLB affinities. Figure 3.7 shows the time to equilibrium 
between QAPB (4nM) and the recombinant a^ -A R  along with the simultaneous 
recording o f the antagonised Fura-2 Ca^ "^  signals.
The cells were loaded (15 minutes at 37°C) with Fura-2 (IqM ). A control 30 second 
pulse o f phenylephrine (IpM ) was applied to evoke an inerease in [Ca^^ji (not 
shown). This was followed by a 60-minute incubation at room temperature with 4nM 
QAPB. This is shown as the initial part o f the trace in Figure 3.7, representing the 
time for QAPB to reach equilibrium binding. A series o f phenylephrine 
concentrations (0.1 —> lOOOpM) were then applied, each for 3 minutes, followed by a 
6 -minute washout. The top trace in Figure 3.7 shows the QAPB signal, which has an 
excitation wavelength o f 490nm. The middle two traces show the two Fura-2 signals, 
one excited at 380nm and the other at 340mn. The bottom trace shows the ratio 
340/380nm Fura-2 Ca^^ signal. Subsequent traces show only the ratio Ca^ "^  signal.
The experiment shown in Figure 3.7 is reproduced in Figure 3.8A with only the 
QAPB signal and ratio Fura-2 Ca^^ signal shown. The first thi*ee concentrations of 
phenyleplirine (0.1 —> IqM ) produced no rise in [Ca^^]i, but as each subsequent 
concentration increased, so did the [Ca^ '*’]i until a maximum response was elicited by 
lOOOpM. Despite the first thi’ee concentrations producing no rise in [Ca^^ji, they did 
cause a decrease in QAPB fluorescent intensity. The intensity increased following 
each washout period. The Ca^^ signal associated with each increasing phenylephiine 
concentration (□ 3pM) reached a maximal response before the corresponding 
decrease in QAPB intensity had reached its maximum. Throughout the experiment, 
the intensity o f the QAPB signal remained constant.
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3.2.2.3.2 Removal o f QAPB
The graph shown in Figure 3,8B represents the end o f the experiment shown in Figure 
3.8A when QAPB was removed from the control saline solution and left for 60 
minutes until the QAPB intensity had maximally decreased. A 3-minute pulse of 
phenylephiine (lOOOtiM) was applied and the resulting rise in [Ca^^], was far greater 
than the corresponding phenylephrine concentration elicited in the presence of 4nM 
QAPB.
S.2.2.3.3 O.SnMQAPB
The following experiments studied the time to equilibrium between the recombinant 
aia-AR and varying concentrations o f QAPB, along with the simultaneous recording 
o f the antagonised Fura-2 Ca^^ signals.
The lowest concentration of QAPB studied was 0.5nM. After incubation with Fura-2, 
a control 30 second pulse o f phenylephrine (l|iM ) was applied to evoke an increase in 
[Ca^’^ Ji (not shown). Cells were then incubated with QAPB (0.5nM) until equilibrium 
binding was achieved (Fig. 3.9). A series o f phenylephrine concentrations (0.1 —> 
300qM) were then applied, each for 3 minutes, followed by a 5-minute washout. The 
first two concentrations of phenylephiine (0.1 —> 0.3|lM) produced no rise in [Ca^^ji, 
but as each subsequent concentration increased, so did the [Ca^^ji until a maximum 
response was achieved by 300p.M. Despite the initial two phenylephrine 
concentrations producing no rise in [Ca^^];, they did cause a small decrease in QAPB 
fluorescent intensity. For each phenylephrine concentration tested, the corresponding 
decrease in QAPB fluorescence intensity remained minimal. After phenylephrine 
concentrations above and including IpM , the Ca^^ responses were transient, followed 
by a rapid decline and small plateau phase that continued into each washout period. 
Throughout the experiment, the intensity o f the QAPB signal remained unaltered.
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3 .2.2J.4 2nMQAPB
The next concentration o f QAPB studied was 2nM. Following incubation with Fura- 
2, a control 30 second pulse o f phenylephrine (IpM ) was applied to evoke an increase 
in [Ca^’*']i (shown on left of Fig. 3.10). Once equilibrium binding had been achieved 
between the cells and QAPB, 10-minute phenylephrine concentrations (0.1 -> 
3000qM) were applied, each followed by a 15-minute washout (Fig. 3.10). Although 
the first two phenyleplirine coneentrations produced no Ca^^ response, there was a 
decrease in QAPB fluorescence intensity. The following Ca^^ responses were all 
transient, followed by small, sustained plateau phases. For each phenylephrine 
eoncentration, the maximum rise in [Ca^^]} had occurred before the corresponding 
decrease in QAPB fluorescent intensity had started. Throughout the experiment, the 
intensity o f the QAPB signal remained unaltered.
3.2.2.3,S ônMQAPB
The highest concentration o f QAPB studied was 6 nM. Following incubation with 
Fura-2, a control 30 second pulse o f phenylephiine (IpM ) was applied to evoke an 
increase in [Ca^^ji (shown on left o f Fig. 3.11). Cells were then incubated with QAPB 
(6 nM) for 75 minutes, until equilibrium binding was achieved. Phenylephiine 
concentrations (1 300|liM) were applied, each for 10 minutes, followed by a 15-
minute washout (Fig. 3.11). There was no Ca^ "^  response to IpM  phenyleplirine, but a 
decrease in QAPB intensity was observed. From 3 to 30pM phenylephrine, the 
response was transient, followed by a small, sustained plateau phase and then a rapid 
decline upon washout. The final two Ca^^ responses were transient followed by a 
rapid decline and then a small increase before declining upon washout. For each 
phenylephiine concentration, the maximum rise in [Ca^^ji had occurred before the 
con'esponding decrease in QAPB fluorescent intensity had started. Following every 
washout, the QAPB signal recovered, but its intensity diminished with every 
corresponding phenylephrine concentration.
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3.2.2.4 Insurmountable Antagonism
Phenylephrine-evoked signals were quantified as the difference between the
baseline resting ratio level and that attained at the peak response. The effect o f QAPB 
on the CRC to phenylephrine was analysed by expressing the data as a fraction o f the 
maximal peak response elicited by phenylephrine in eontrol solution alone.
QAPB produced concentration-dependant, nonparallel, rightward displacements in the 
control CRC to phenylephrine with a decrease in the maximal response (Fig. 3.12). 
This represents an example o f insurmountable antagonism, where the antagonist 
dissociates very slowly (or not at all) from the receptor. It is demonstrated by a 
rightward shift as the antagonist concentration increases and also by a decrease in 
maximal response.
3.2.3 Direct visualisation o f fluorescent binding
3.2.3.1 QAPB displacement by agonist
Using our knowledge from radioligand binding studies, competitive binding was 
visualised in cells using QAPB. Rat-1 fibroblasts were mounted in a chamber 
attached to the stage o f an inverted microscope and superfused with physiological 
saline containing 4nM QAPB for 60 minutes at room temperature until equilibrium 
binding was achieved. Cells were imaged by exciting at 490nm and 515mn and 
QAPB fluorescence was monitored by a CCD camera.
Pediani and colleagues had demonstrated, using HEK293T cells, that QAPB is 
specific for intracellular human a^ -A R  binding sites (results not published). 
HEK293T cells are very similar to Rat-1 fibroblasts in that they are secretory cells. 
Using non-transfected HEK293T cells, there was no evidence o f intracellular QAPB 
binding after cells had been stained with the nuclear dye Hoechst 33342 and 20nM 
QAPB. Using transiently transfected HEK293T cells, there was clear evidence of
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intracellular binding to human aia-AR binding sites around the perinuclear region 
when nuclear staining and QAPB images were merged.
Figure 3.13 shows 4nM QAPB equilibrium binding after 60 minutes at room 
temperature. Within minutes of QAPB application, diffuse low intensity fluorescent 
signals were observed in punctate intracellular sites that were scattered throughout the 
cell cytoplasm. After a period of 60 minutes, higher intensity fluorescent signals were 
observed in larger punctate structures. This suggests a pattern o f fluorescence evolves 
from a small particulate distribution towards larger structures with time.
Following 4nM QAPB equilibrium binding, three 15-minute applications o f the a j-  
AR agonist phenylephrine, were added cumulatively (Figs 3.14 & 3.15). The first 
concentration o f 0.1 p,M phenylephrine caused a large decrease in QAPB fluorescent 
intensity, but the following 1 |lM  caused only a small decrease. The application of 
lOqM produced a further decrease in QAPB intensity. Following the 15-minute 
application o f the 1 OpM concentration, phenylephrine was removed from the 
perfusion system and a reversal o f QAPB fluorescent intensity was observed (Figs 
3.14 & 3.16). This is an example o f reverse displacement. Figure 3.17 compares the 
fluorescent intensity o f QAPB in the absence and presence o f phenylephrine. 
Following thi'ee consecutive applications of phenylephrine, there was a clear, large 
decrease in fluorescent intensity. Phenyl eplnine can therefore penetrate the cells and 
cause displacement from these intracellular sites o f high fluorescent intensity.
3.2.3.2 QAPB displacement by antagonist
A  similar series o f experiments was performed to determine if  antagonists could 
penetrate cells and displace QAPB in a manner similar to that o f agonists.
Cells were incubated with 5nM QAPB at room temperature for 75 minutes. The cells 
exhibited fluorescence at punctate intracellular sites and more diffusely over the cell 
surface (Fig. 3 .ISA). All of the fluorescent sites could be totally displaced by 
phentolamine (O.lmM). Phentolamine was present for 150 minutes after equilibrium
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binding was established (Fig. 3.18B), thus establishing that the fluorescent receptor 
ligand complexes were accessible to competitive ligands.
3.2.3.3 Intracellular compartment localisation
It was now clear that QAPB entered the cell and could be detected within intracellular 
compartments tliroughout the cytoplasm. When reconstructed as a short movie, the 
motions of individual fluorescent signals observed in punctate structures were very 
characteristic of endocytosis. Some were inert and displayed short range, bi­
directional motion, whereas others appeared to move with great speed. To visualise 
and determine the identity o f these intracellular compartments, a fluorescently tagged 
agonist was used that could identify subcellular compartments. Transferrin Alexa 
Fluor^ '*® is an early and recycling endosomal marker for endocytosis via clathiin- 
coated pits (Anderson, 1998). This was used to identify the endocytotic recycling 
pathway. Transferrin Alexa Fluor^'’^  also binds to the constitutively active Transferrin 
receptor, which localises predominantly in the perinuclear-recycling compartment 
(PNRC). Hence, the red dye is ideal for labelling the PNRC. Constitutively active 
receptors can be transported to the PNRC and then recycled back to the cell surface 
independent o f agonist activation.
Unstimulated Rat-1 fibroblasts expressing the bovine aia-AR were labelled with the 
nuclei dye Hoechst 33342. This corresponds with the blue coloured panel in Figure 
3.19. Cells were then labelled with 4nM QAPB for 75 minutes at room temperature 
and the corresponding green image is shown in Figure 3.19. The image shows that 
QAPB fluorescence corresponding to intracellular binding sites was scattered 
throughout the cytoplasm. Cells were further labelled with Transferrin-Alexa Fluor^‘“^ 
for 75 minutes. This corresponds with the red panel shown in Figure 3.19. The 
merged images for all three labels are shown in Figure 3.20. Areas of yellow/orange 
colour represent overlapping sites o f co-localisation. The areas o f co-localisation 
appear to be found around the perinuclear region, thus implying that aia-AR ligand 
complexes follow the endocytotic recycling pathway, via early and recycling 
endosomes. A similai' experiment is shown with a larger field o f cells in Figure 3.21.
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Again, the areas o f overlap appear to be of a perinuclear nature. Although in both 
experiments a small proportion o f fluorescent sites overlapped with the Transferrin- 
Alexa F lu o f th e r e  was a large proportion o f the QAPB binding sites that were 
spatially distinct from the recycling endosomal marker. These sites can be clearly 
identified as single green “hotspots”.
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Figure 3.2 Chemical structure o f fura-2
145
Em = 5 1 0  nm
C/ÎC(D
C
o4—»m-w
’5XLU
43.5 free 
0.756
0.441
0 .2 8 4
0.189
0.126
0.081
0 .0 4 7
0.021
250 300 350 400 450
W a v e le n g th  (nm)
Figure 3.3 Excitation spectra o f fura-2 in increasing concentrations o f free calcium
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Figure 3.4 Trace showing changes in [Ca^ ]^j in response to phenylephrine in R-lFs 
stably expressing the bovine aia-AR. A, effects o f phenylephrine (IjlM; 3-minute 
pulse) on [Ca^ ]^i in the presence o f external Ca^  ^ (ImM). B, resolution o f the initial 
Ca^  ^release phase from the sustained Ca^  ^entry phase. Cells were superfused with 
Ca^^-free saline solution and exposed to phenylephrine ( 1 jiM) before external Ca^  ^
was restored to ImM for the indicated period.
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Figure 3.5 Concentration-dependant effects o f phenylephrine on [Ca^^ji release. 
Phenylephrine was applied for 30 seconds and delivered at 5-minute intervals. Trace
shows effects evoked by increasing concentration o f phenylephrine on [Ca^^]
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Figure 3.6 Maintenance o f steady state equilibrium binding o f QAPB (4nM) over a 
4-hour time period in R -lFs stably expressing the bovine ttia-AR. Cells were exposed 
to 30-second pulse o f phenylephrine ( I rM ) before QAPB was applied. Trace shows 
no degradation/photobleaching o f QAPB intensity existed.
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Figure 3.7 Trace showing simultaneous recording o f QAPB signal and antagonised 
fura-2 Ca^^ responses. Top trace shows 4nM QAPB signal, which has an excitation 
wavelength o f 490nm. Middle two traces show two Fura-2 signals, one excited at 
380nm and the other at 340nm. Bottom trace shows ratio 340/380nm Fura-2 Ca^^ 
signal.
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Figure 3.8 Trace represents same experiment shown in Figure 3.7, with only the 
QAPB signal and antagonised ratio 340/380 Fura-2 Ca^  ^signal shown. A, trace shows 
time to equilibrium between cells and 4nM QAPB and the subsequent effect of 
phenylephrine (0.1 -4  lOOOpM) applications (3-minutes at 6-minute intervals) on
[Ca ] i . B, trace shows removal o f 4nM QAPB from control saline solution, the 
subsequent decrease in QAPB intensity signal and rise in [Ca^ ]^i following a 3-minute 
pulse o f phenylephrine (1000|aM).
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Figure 3.9 Trace showing simultaneous recording of 0.5nM QAPB signal and 
antagonised fura-2 Ca^^ responses. Trace shows time to equilibrium between cells 
and O.SnM QAPB and the subsequent effect o f phenylephrine (0.1 -4  300|liM)
applications (3-minutes at 5-minute intervals) on [Ca^^ji.
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Figure 3.10 Trace showing simultaneous recording o f 2nM QAPB signal and 
antagonised fura-2 responses. Trace shows time to equilibrium between cells 
and 2nM QAPB and the subsequent effect o f  phenylephrine (0.1 -> 3000jiM) 
applications ( 10 -minutes at 15-minute intervals) on [Ca^^],.
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Figure 3.11 Trace showing simultaneous recording o f 6nM QAPB signal and 
antagonised fura-2 Ca^  ^responses. Trace shows time to equilibrium between cells 
and 6nM QAPB and the subsequent effect o f phenylephrine (1 300pM)
applications (10-minutes at 15-minute intervals) on [Ca ’^^ ji
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Figure 3.12 CRC to phenylephrine in the absence ( • )  and presence o f QAPB 
(0.5nM, aî=4, ■; 2nM, n=6, ; and 4nM, n=4, ). Pooled data (mean ± S.E. for each 
test concentration) presented as fraction o f maximal response evoked by 
phenylephrine in control saline solution alone.
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Figure 3.13 QAPB binding to Rat-1 Fibroblasts expressing the bovine ttia-AR. A, 
Transmission image o f a selected patch o f R-IPs. 4nM QAPB equilibrium binding 
after B, 15 minutes, C, 30 minutes, D, 45 minutes and E, 60 minutes. Red colour 
indicates areas of high QAPB fluorescent intensity.
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Figure 3.14 Effect o f reverse displacement. Trace shows three 15-minute cumulative 
applications o f phenylephrine (0.1 10|iM) following 60-minute incubation o f cells
with 4nM QAPB. Phenylephrine was removed from the perfusion system and the 
resultant QAPB fluorescent intensity returned.
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BFigure 3.15 Cells incubated with 4nM QAPB in the presence o f increasing 
concentrations o f phenylephrine. Three 15-minute applications o f phenylephrine 
were added cumulatively. A, shows 0 .l|iM  phenylephrine causing a large decrease in 
QAPB fluorescent intensity. B, shows l|iM  phenylephrine having little effect and C, 
shows lOjLlM phenylephrine producing a further decrease in QAPB intensity.
Changes in QAPB intensity represented above by a decrease in the red colour 
intensity.
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Figure 3.16 Binding o f QAPB was reversible. When phenylephrine was removed 
from the perfusion system, a reversal o f 4nM QAPB fluorescent intensity was 
observed. This is represented above by an increase in red colour intensity.
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Figure 3.17 QAPB displacement by phenylephrine. A (+), shows cells in the 
presence o f 4nM QAPB alone with fluorescence at optimal intensity and also (-) after 
3 cumulative applications o f phenylephrine and the resulting decrease in fluorescent 
intensity. B, shows the corresponding threshold images where green (+) represents 
QAPB binding before addition of phenylephrine and red (-) represents QAPB binding 
following 3 cumulative applications o f phenylephrine. C, shows the overlay (+) of 
both green and red images and also the inverse colour overlay (-) images.
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BFigure 3.18 QAPB displacement by phentolamine. A, shows a group o f Rat-1 
fibroblasts expressing the bovine aia-AR labelled with 5nM QAPB at equilibrium 
binding after 75 minutes. B, shows equilibrium displacement by lOjiM phentolamine 
after 150 minutes.
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BFigure 3.19 QAPB staining in unstimulated Rat-1 fibroblasts stably expressing the 
bovine aia-AR. A, (blue) shows a field o f cells stained with the nuclear dye Hoechst 
33342. B, (green) shows cells labelled with 4nM QAPB after 75 minutes and C, (red) 
shows cells labelled with the fluorescently tagged agonist Transferrin-Alexa Fluof^'^’ 
after 75 minutes.
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Figure 3.20 Merged image between internal QAPB-receptor complex and early 
endosomal marker in Rat-1 fibroblasts. Image o f a red (Transferrin-Alexa Fluof''^), 
green (4nM QAPB) and blue (Hoechst 33342) overlay. Areas o f yellow/orange 
colour represent co-localisation.
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Figure 3.21 Co-localisation between internal QAPB-receptor complex and early 
endosomal marker in Rat-1 fibroblasts. Image shows a greater field o f cells stained 
with Hoechst (blue), QAPB (green) and Transferrin-Alexa FluoP^^ (red). Areas o f co­
localisation represented by yellow/orange colour.
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3.3 DISCUSSION
3.3.1 Microspectrofliiorimetry
The development of molecular cloning o f the DNA encoding at-A Rs in tissue along 
with the expression these clones in null cell lines (e.g. R -lFs which lack 
endogenous ARs) enables the pharmacological properties o f a particular a i-A R  of 
defined amino acid sequence to be defined unambiguously.
In most cells, the primaiy fimctionai effect o f a i-A R  activation is an increase in 
intracellular Ca^^ ([Ca^^ji) (Harrison et al, 1991) and this is a result o f Ca^^ release 
from internal stores and/or the influx o f extracellular Ca^’*' into the cell (Mlnneman & 
Esbenshade, 1994). Extracellular Ca^^ can enter the cell via VOCCs (Putney Jnr & 
Bird, 1993; Berridge, 1995; Clapham, 1995) and via a subgroup o f  RACCs that have 
been o f interest in recent years called the SOCCs (capacitative Ca^^ channels) (Putney 
Jnr & Bird, 1993; Berridge, 1995; Clapham, 1995; Macrez-Lepretre et al, 1997; 
Barritt, 1999). These are defined as plasma-membrane Ca^^ channels that are opened 
in response to a decrease in the concentration o f Ca^^ in the lumen of the ER ([Ca^" ]^er) 
(Putney Jni* & Bird, 1993) (Fig. 3.22).
Han and colleagues (1987) worked with isolated smooth muscle and reported 
evidence for two types of ai-ARs. They proposed that the aiA-and otig-AR could 
raise intracellular Ca^^ levels by different mechanisms, with the Œi^-AR primarily 
elevating intracellular Ca^^ levels by gating Ca^^ influx through VOCCs, whereas 
the aiB-AR evoked this effect by mobilising stored Ca^^. There are now numerous 
exceptions to proposals such as Han’s. Putative «ia-A R  elevate IP3 formation and/or 
liberate stored Ca^^ in many primary tissues (Han et al, 1990; Macrez-Lepretre et al,
1997) which suggests that this subtype o f  receptor can regulate [Ca^^j; by mobilising 
intracellular Ca^’*’ stores via the PLC-p/IP] mechanism. Expressed receptors in COS-1 
cells demonstrate that all tliree aj-A R  subtypes can mobilise intracellular calcium and 
increase Ca^^ influx via voltage-operated Ca^^ channels (Perez et al, 1993; Lomansey 
et al, 1993).
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Figure 3.22 Types o f RACC: One o f the two main types o f RACC in animal cells is 
the store-operated Ca^^ channel (SOCC), shown above. These plasma-membrane 
Ca^^ channels open in response to a decrease in the [Ca^^] in the ER lumen (Barritt, 
1999).
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R -lFs expressing the bovine aia-AR have been previously used as a model system for 
evaluating homologous a p A R  mediated signalling events (Schwimi et al, 1995). 
Activation o f this receptor was shown to increase IP formation which strongly 
suggested that the receptor regulated [Ca^" ]^i by mobilising Ca^ "^  from internal stores.
The active uptake o f Ca^^ into intracellular stores was discovered during studies on 
the natur e o f muscle relaxing factor (Kumagai et al, 1955; Ebashi & Lipmann, 1962). 
The active principle is a Ca^^, Mg^^-activated ATPase in the sarco-endoplasmic 
reticulum (SR/ER) membrane and these enzymes are now referred to as SERCA 
pumps (sarco-endoplasmic reticulum Ca^’^ -ATPases) (Pozzan et al, 1994; Mogami et 
al, 1998). The principle o f operation is simple: when the [Ca^ "^ ]i rises due to release 
from intracellular stores, the SERCA pumps are activated and following the closure of 
SR/ER Ca^ "^  release channels, the net Ca^^ reuptake will occur. When [Ca^’^ Jj has 
been reduced to the resting (pre-stimulation) level, the activation o f the SERCA 
pumps stops (Mogami et al, 1998).
Since the idea of store-operated Ca^ "^  inflow was first proposed (Casteels & 
Droogmans, 1981; Putney Jm:, 1986), there have been further discoveries providing 
evidence for this phenomenon, including the discovery o f a SERCA inhibitor, 
thapsigargin (Putney Jnr & Bird, 1993). Thapsigargin-evoked depletion o f internal 
Ca^’*’ stores occurs in the absence o f agonist activation of membrane-bound 
receptors/generation o f related second messengers and activates the same Ca^ "^  entry 
pathway as that resulting from agonist activation (Putney Jm’ & Bird, 1993). These 
potent SERCA inhibitors can therefore be used to provide an important distinction 
between Ca^^ entering through SOCCs as opposed to RACCs or VOCCs.
In the present study, the dual excitation Ca^^-sensitive fluorescent dye Fura-2 AM 
was used to assess the mechanism o f Ca^ "^  signalling activated by the recombinant 
aia-AR. The first aim was to determine the nature of the [Ca^^Ji signal and it was 
initially established that phenylephrine could evoke a rapid rise in the [Ca^^ji that 
could be resolved into two functionally distinct phases. There was an initial transient 
phase, which was due to Ca^^ release from internal stores, followed by a small- 
sustained plateau, which was due to the influx o f extracellular Ca^^. In experiments
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using rat-tail arteries, Li and colleagues (1993) reported similar results. The group 
reported fast and transient increases in intracellular Ca^^ resulting from Ca^^ 
mobilization from intracellular stores and Ca^^ influx tlii'ough receptor-operated 
channels following ttj-AR stimulation.
Intracellular Ca^ "^  levels are held at a constant low level by Ca^^ buffering within the 
cell and by the balance between Ca^ "^  release/influx into the cytosol and the opposing 
actions o f the mechanisms that extrude Ca^ '*' from the cytosol (Pediani et al, 2000). 
This balance is temporarily overcome upon receptor activation. A rapid mobilisation 
o f stored Ca^’*' into the cytosol causes a rise in [Ca^’^ ji during a short exposui'e to 
phenylephrine. As the stores are limited, the release rate rapidly declines to a point 
where it is exceeded by removal processes and the [Ca^ "^ ]j declines. This explains the 
“faded” response during the 30-second phenyleplirine application. A 5-minute cycle 
was sufficient to replenish the stores if  extracellular Ca^ "^  was present. Any 
involvement o f VOCCs in the regulation o f [Ca^^Jj was discarded by Pediani and 
colleagues (2000) who found that a depolarising concentration of KCl failed to evoke 
any change in the resting [Ca^^]i. The lack o f VOCCs indicates Ca^^ entry must 
follow receptor occupation rather than a change in membrane potential.
At various phenylephrine concentrations, the time course o f the fade varied as 
described previously. At low phenyleplii'ine concentrations, the responses were slow 
to rise and did not reach a peak or fade, which is consistent with the Ca^^ stores not 
yet having emptied. The Ca^ "^  responses rose and peaked more quickly and faded 
earlier as the phenyleplirine concentrations increased. This would be expected, as the 
Ca^^ stores would have emptied more quickly. This pattern continued with each 
phenyleplii'ine application up to an optimal concentration. Beyond this concentration 
of phenylephrine that produced the maximum response (30pM), the concentration- 
response relationship displayed an inverse phase (i.e., smaller peak Ca^^ responses to 
increasing concentrations o f phenylephi'ine).
Although the peak responses decreased as the phenylephrine concentration increased, 
the initial rate of rise continued to increase. Pediani and colleagues (2000) found a 
similar trend and suggested the Ca^^ response had been limited by a reduced release
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from the internal stores before they had emptied. They observed that when the peak is 
reduced, the response takes longer to decline, as it might if  Ca^ "^  release continued at a 
lower level for a longer time. This could be attributed to a negative feedback 
mechanism. High levels o f [Ca^^]i can inliibit IP3 receptors found on the ER and also 
the activity o f its integral Ca^ '*’ release channel (Goldbeter et al, 1990; Atri et al,
1993). The main point regarding such a mechanism is that a very fast response 
achieves a lesser peak than a slightly lower one. This may explain a result o f the 
agonist-antagonist interaction discovered in the present study in that the presence of 
antagonist abolished the inverse phase of the concentration-response relationship.
This applied to all concentrations o f QAPB tested in the present study.
Prior to studying the interaction between phenylephrine and QAPB, a possible 
“photobleaching” effect by QAPB was addressed. Results showed that no 
degradation/photobleaching o f QAPB intensity existed, hence a steady state 
equilibrium binding o f QAPB could be maintained over a 4 hour time period and 
without having any effect on the antagonised fura-2  Ca^ '*' signal.
The equilibrium relationship between phenylephrine, QAPB, receptor pool, and the 
response depends on the fractional receptor occupancy required by the agonist to 
achieve a response, and the dissociation equilibrium constants for the aia-AR, the 
agonist and the antagonist. The ratio o f the association and dissociation rate constants 
determines the dissociation equilibrium constant for each drug/receptor. When the 
antagonist, QAPB, is present at equilibrium (at adequate concentration to occupy a 
high proportion o f the receptors) and the agonist, phenylephrine is added, the initial 
agonist association rate depends greatly on the QAPB dissociation rate as the agonist 
can only associate with free receptors (Pediani et al, 2000). The resulting rate of 
formation of agonist-receptor complexes will be slowed.
It was then possible to study antagonism versus phenylephrine by QAPB across the 
concentration ranges indicated by its RLB affinities. A period of 60 minutes was 
sufficient for QAPB to reach and maintain steady state equilibrium binding before a 
series o f 3-minute phenyleplirine pulses were applied. For each phenylephrine 
application, there was a gradual decline in the QAPB signal and this fall in intensity
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was reversed when phenylephrine was removed. This trend was similar for each 
concentration o f QAPB tested (0.5, 2, 4, 6nM) and only a small amount of the 
maximal QAPB signal detected was displaced.
It as also clear that in the presence o f QAPB, the initial rate o f [Ca '^^], is slower and 
that the magnitude o f  peak Ca^^ responses was reduced/ antagonised. For each QAPB 
concentration tested, the peak o f the Ca^ "^  response occurred prior to equilibrium 
displacement o f QAPB. The binding o f QAPB and its antagonistic action upon 
[Ca '^^Jj in response to phenylephrine was reversible. Following a 60-minute period 
after the removal o f QAPB, the fluorescent signal had maximally decreased. The 
magnitude and time course for the initial rise in [Ca^’*’]i was then faster when 
phenylephi'ine was applied.
By defining the nature o f the Ca^ "^  signal, it was possible to investigate the nature of 
the agonist-response relationship for the bovine aia-AR and to determine the 
relationship for the interaction o f agonists and antagonists. The peak [Ca '^^Ji signal 
elicited by phenyleplii'ine was short-lived and a result of the rapid movement o f stored 
Ca^^. The transient nature for the receptor-response coupling process therefore does 
not permit sufficient equilibrium time to produce a true thermodynamic equilibrium 
between the agonist/antagonist and receptor (Pediani et al, 2000). The Ca^^ responses 
in the present study could therefore be described as non-equilibrium functional 
responses.
The present study also predicts a consequence o f insurmountable antagonism for 
competitive antagonists as their concentration increases. During the short time period 
that the frinctional response occurs, only a very small amount of QAPB is actually 
displaced by phenylephrine. As the QAPB concentration increases, the dominant 
influence becomes the reduced number of available sites and hence the agonist 
fractional occupancy is reduced in proportion to the fraction of receptors that are not 
occupied by QAPB. This leads to insurmountable antagonism (Furchgott, 1972), 
where the concentration-Ca^^ response curves produced by QAPB display a rightward 
shift and fall in maximum.
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3.3.2 Direct visualisation o f fluorescent binding
Studies by Price and Schwinn (1998) reported that a green fluorescent protein-tagged 
aia-AR underwent constitutive cycling between the cell surface and nonlysosomal 
intracellular compartments suggesting a possible mechanism for continuous aia-AR 
signalling. These results were supported by earlier studies by Hirasawa and 
colleagues (1997) who found that transiently expressed, green fluorescent protein- or 
FLAG-tagged aia-AR and aib-AR subtypes displayed differential sensitivity to CEC 
as a result o f differences in siibcellular localisation and not differences in structural 
determinants. This different subcellular localisation o f the ai-A R  subtypes has been 
confirmed by other studies (Piascik & Perez, 2001; Sugawara, et al 2002), and the 
intracellular expression of the ai-A R s was observed not only in the cloned receptor 
transfected cells, but also in the endogenous oti-ARs expressed in native tissues 
including prostate smooth muscle cells and vascular smooth muscle cells (McGrath et 
al, 1999; Hrometz et al, 1999).
Visualisation of QAPB binding to a i a-ARs in Rat-1 fibroblasts was used in the 
present study to determine whether the ligand was internalised with the receptor and 
to identify subcellular compartments. The “hot spots” emitting the strongest 
fluorescent signal moved considerably around the cell. Some o f these “hot spots” 
appeared to move in a bi-directional motion over a short range, whereas others moved 
with great speed. This trafficking o f fluorescent “hot spots” suggests a possible 
endocytotic mechanism. Within minutes of QAPB application, diffuse low intensity 
fluorescent signals were observed in punctate intracellular sites that were scattered 
throughout the cell cytoplasm. After a period o f 60 minutes, higher intensity 
fluorescent signals were observed in larger punctate structures. This suggests that the 
basic units of transport were smaller structures, beyond the resolution o f the 
microscope, characteristic o f endocytotic vesicles. These endocytotic vesicles would 
most likely fuse reversibly with the “hot spots” and exchange a load o f plasmalemmal 
proteins including the ligand-receptor complex. These fluorescent “hot spots” will 
then move further into the cell towards the perinuclear region where they will fuse 
with larger structures, delivering ligand-receptor complexes.
171
The fate o f the small fluorescent structures can be decided be thr ee different pathways 
inside the cell (Fig. 3.23). They can simply traffic inwards via collection ti'ansit 
vesicle structures and fuse with early endosomes. Once fused with the endosomes, a 
bud forms and subsequently traffics the ligand-receptor complex back towards the cell 
surface where the ligand will then exit the cell by exocytosis. A second pathway for 
the ligand-receptor complex is to follow a degradation and synthesis pathway once 
fused with the early endosomes. A third pathway is for the ligand-receptor complex 
to traffic from the early endosome thi'ough to the late endosome, where a bud will 
subsequently form a delivery transit vesicle. This transit vesicle will carry the ligand- 
receptor complex back to the cell surface where it will leave via exocytosis. During 
all these intracellular transactions, the ligand and its binding site will be restricted to 
the internal face o f the endosomes, so that even if they dissociate, the ligand 
molecules will be restricted to the compartment and be likely to reassociate.
The present study also confirmed that an agonist could enter the cell and displace 
QAPB fi'om intracellular compartments. The fluorescent QAPB signal observed in 
these intracellular “hot spots” decreased in intensity after phenyleprine had been 
added cumulatively at 15-minute intervals. It would be assumed that phenylephrine 
would enter the cell and traffic to these “hot spots” in a manner similar to that of 
QAPB. The binding of QAPB is also reversible. The high fluorescent intensity signal 
was observed once phenylephrine was removed from the perfusion system.
Antagonists could compete with QAPB fluorescence at the cell surface level and at 
intracellular compartments. The present study confirmed that the a-A R  antagonist 
phentolamine could penetrate the cell and almost completely reduce all QAPB 
fluorescence. The aia-AR antagonist R S I00329 could also selectively compete at the 
cell surface. The use o f phentolamine is an advantageous tool for fluorescence 
binding as image subtraction removes the non-specific binding leaving only the image 
o f receptors that have been competitively antagonised by the competitor.
Daly and colleagues (1998) were the first to report the existence o f diffuse and 
clustered populations of ai-A R s binding sites in live cells using confocal microscopy
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Figure 3.23 Constitutive recycling o f the aia-AR in Rat-1 fibroblasts. A, shows 
intracellular compartments and movement o f ligand-receptor complexes. B, shows 
receptors on intracellular organelles with binding sites (yellow) facing inwards.
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and showed that the affinity o f both populations for the ligand were identical. This 
proved that the environment o f the clustered domain left the binding sites accessible 
to ligands. The group also predicted the relative distribution o f receptors between 
these two domains, stating that although the clusters were visually striking, they 
represented a relatively small proportion o f the receptor population accessible to 
ligands. This emphasised that subjective visual assessment can exaggerate the 
relative proportion o f receptors that appear to be present in the clusters (Daly et al,
1998).
The diffuse binding described by Daly was reduced when phentolamine was added in 
the present study. After a 75-minute period, QAPB binding had reached and 
maintained a steady state, showing both areas o f diffuse binding and areas of clustered 
“hot spots”. Phentolamine reduced all diffuse binding and a large proportion o f 
intracellular “hot spots” when added for over 2 hours. The ability o f antagonists, as 
well as agonists, to bind competitively to intracellular components in live cells 
suggests a possibility that they are involved in signal transduction. Al-Damluji and 
colleagues (1997) previously reported similar findings. Using hypothalamic peptideric 
neurones, they found QAPB accumulated in a granular distribution, compatible with 
storage in intracellular vesicles. Using fluorescence microscopy, the group also 
reported an antagonist, prazosin, could be internalised, possibly by clathrin-coated 
pits and could inhibit QAPB binding.
To visualise and determine the identity o f the intracellular compartments, a 
fluorescently tagged agonist was employed that would identify subcellular 
compartments. Many earlier studies using GPCR-GFP chimeras have used red 
fluorescent markers that label particular cellular organelles or membranes (Kallal & 
Benovic, 2000). By studying GPCR-GFP and the red fluorescent compound in the 
same cell, potential co-localisation can be readily ascertained. In addition to visual 
representations of red and green overlap, it is also possible to quantitate subcellular 
co-localisation digitally (Tarasova et al, 1997, 1998). The present study used 
Transferrin Alexa F l u o f T h i s  labels early endosomes and endocytotic recycling 
compartments and was used to identify the endocytotic recycling pathway.
Transferrin Alexa Fluor '^*  ^also binds to the constitutively active Transferrin receptor,
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which localises predominantly in the perinuclear-recycling compartment (PNRC), 
hence the red dye is ideal for labelling the PNRC. Co-localisation occurred to a small 
extent between QAPB and Transferrin Alexa Fluor^'’^ , suggesting a possible 
perinuclear site for the intracellular components that emit QAPB fluorescence. 
Although a small proportion o f fluorescent sites co-localised with the red dye, there 
was a large proportion o f QAPB binding sites that were spatially distinct from the 
recycling endosomal marker.
MacKenzie and colleagues (2000) reported similar findings to the present study using 
confocal microscopy. In Rat-1 fibroblasts expressing all three recombinant ai-A R  
subtypes, they discovered QAPB bound to cell membrane and intracellular 
perinuclear sites. The perinuclear binding was more obvious in the aib-AR subtype. 
There was no general rule, however, for the localisation o f particular subtypes. The 
group found stark similarities between the intracellular distribution o f binding sites in 
reeombinant and native systems. In prostatic SMCs, 40% of specific binding sites 
were intracellular, particularly around the perinuclear region, which could represent 
binding in the Golgi apparatus and may include both newly synthesised and recycling 
stores o f receptors (MacKenzie et al, 2000). This proves that the vast quantity of 
intracellular binding sites previously shown in recombinant cells is not an artefact of 
artificial systems, but a natural phenomenon.
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4.0 CONCLUSIONS
The present study used classical and updated radioligand binding tecliniques to 
compare binding to isolated cell membranes and whole cells In R at-1 fibroblasts 
expressing the recombinant bovine a ,  a-AR. The results indicate that both agonists 
and antagonists can displace a radiolabel (^H-prazosin) from cell surface binding sites 
and intracellular compartments. Displacement curves of biphasic nature displayed a 
high affinity component (approx. 20% of binding sites) followed by a slow sustained 
plateau phase before the low affinity component (approx. 80% of binding sites). The 
high affinity component suggests a displacement from cell surface receptors and the 
low affinity component may represent cellular penetration. The uptake of ligands into 
the cell was found to be time-dependant and temperature-independant. An early 
hypothesis that the uptake o f ligands occurred via an EMT was ruled out after 
displacement curves demonstrated near maximum displacement o f radio label by 
ligands in the presence o f a potent EMT blocker, corticosterone.
A more probable explanation of how ligands penetrate cells and access intracellular 
compartments is via an endocytotic pathway. The present study found that an 
endocytotic blocker, concanavalln A, exerted an inhibiting effect that could be 
overcome once a certain amount o f antagonist (QAPB) had been applied, A similar 
result could not be applied to agonists. Coneanavalin A displayed little, if  any, 
inhibiting effect on the ability o f adrenaline to displace radio label. Performing 
identical experiments at cold temperature (4°C) supports a possible endocytotic 
mechanism. The endocytotic process is not functional at cold temperatures. The 
results presented in this study coiTespond with this theory, as there was little 
displacement o f radiolabel (approx. 20% of binding sites) at cold temperatures. This 
would imply that due to the non-functioning endocytotic process, the ligands are 
unable to penetrate the cell and displace the radiolabel. This presents the question of 
how the radiolabel penetrates the cell. One could speculate that ^El-prazosin enters 
the cells via a separate mechanism, such as a carrier process.
The hypothesis that ligands penetrate cells and access intracellular compartments via 
an endocytotic mechanism was further tested in the present study by direct
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visualisation techniques. The fluorescent a i-A R  antagonist QAPB could be detected 
within intracellular compartments tlu'oughout the cytoplasm following a sufficient 
time period. Movement o f individual fluorescent signals observed on punctate 
structures were characteristic o f endocytosis. Unstimulated Rat-1 fibroblasts 
expressing the bovine aia-AR were labelled with QAPB, a nuclear dye (Hoechst 
33342) and an early/recycling endosomal marker for endocytosis via clathrin-coated 
pits (Transferrin Alexa Fluor '^' '^ )^. The latter is ideal for labelling the perinuclear- 
recycling compartment. When all three labels were merged, the overlapping areas of 
co-localisation appeared around the perinuclear region, suggesting that aia-AR ligand 
complexes follow the endocytotic recycling pathway, via early and recycling 
endosomes.
Microspectrofluorimetry techniques were also employed in the present study to 
investigate whether quantitative pharmacology could be carried out at the single cell 
level on ai-A R s using a Rat-1 fibroblast cell line that stably expresses the 
recombinant a i a-AR. The results demonstrate that the dominant Ca^^ entry pathway 
evoked by the bovine aia-AR is store-operated, in which the Ca^ '*' content o f agonist- 
sensitive intracellular Ca^^ stores governs influx.
Results from the study of antagonism versus phenylephrine by QAPB suggested a 
consequence o f insurmountable antagonism for competitive antagonists as their 
concentration increases. Although low phenyleplnine concentrations produced no rise 
in [Ca '^^Ji, there was still a small decrease in QAPB fluorescent intensity. As 
phenylephrine concentrations inereased, the Ca^^ responses were all transient, 
followed by small, sustained plateau phases. For each phenylephrine concentration, 
the maximum rise in [Ca^^]j had occurred before the corresponding decrease in QAPB 
intensity had started. The QAPB signal also recovered following each washout of 
phenylephrine.
There are a number o f experiments that would have been worth investigating had time 
not been a factor in the present study. Using direct visualisation studies, the 
experiments (from Chapter 2) carried out in the presence o f coneanavalin A could be 
repeated. Cells would be incubated with coneanavalin A for a sustained period of
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time, and following the addition o f QAPB, there would presumably be a small amount 
o f fluorescence observed in intracellular compartments. Similarly, if  cells were 
incubated with QAPB until steady state binding was achieved, visualisation 
techniques would reveal clusters o f fluorescent “hot spots” around the perinuclear 
region as shown in Chapter 3. If  eoncanavalin A was introduced following steady 
state QAPB binding, one could speculate that there would be a large decrease in these 
areas o f high fluorescent intensity.
Other experiments of interest would be to repeat all the updated displacement 
protocols (Chapter 2) using visualisation techniques to determine the ability o f 
various ligands to displace QAPB. The corticosterone experiments would certainly be 
worth investigating, firstly with QAPB alone, to determine whether it enters the cell 
via an EMT. If so, then a series o f other agonists and antagonists could be applied to 
determine their method of uptake.
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